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ABSTRACT

Yu, Hui. Ph.D., Purdue University, December 2013. Genes with Physiological Roles in
Callipyge Muscle Hypertrophy. Major Professor: Christopher A.Bidwell.

Callipyge sheep is an excellent model to study genes regulation in muscle growth
since the upregulation of DLK1 and/or RTL1 results in extreme postnatal muscle
hypertrophy in loin and hindquarters. DLK1 and/or RTL1 are the primary inducers of
muscle hypertrophy due to the inheritance model for the callipyge phenotype. The overall
aim of this dissertation is to study the physiological pathways responding to the up
regulation of DLK1 and / or RTL1 in the hypertrophied muscles. Microarray analysis of
gene expression identified 375 genes that were differentially expressed in callipyge
semimembranosus. Twentyfive transcripts were further verified by quantitative PCR in
two hypertrophied muscles (semimembranosus and longissimus dorsi) and one non
hypertrophied muscle (supraspinatus). In order to identify the genes that are consistently
coexpressed with DLK1/RTL1, the current study extends the gene expression analysis on
these 25 genes in 4 hypertrophied muscles (longissimus dorsi, semimembranosus,
semitendinosus and triceps brachii ) and 3 nonhypertrophied muscles (supraspinatus,
infraspinatus and heart). The quantitative PCR results showed that DLK1 expression was
significantly increased in the 4 hypertrophied muscles but not in the 3 nonhypertrophied
muscles. However, RTL1 was upregulated in both hypertrophied and nonhypertrophied
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muscles, which confirmed that RTL1 is not sufficient to induce muscle hypertrophy but it
may act in concert with DLK1 to increase muscle mass in callipyge lambs. Five other
genes, including PARK7, DNTTIP1, SLC22A3, METTL21E and PDE4D, were
consistently coexpressed with DLK1, herein they were the potential transcriptional target
genes responding to DLK1 signaling. Since the hypertrophied muscles have a fiber type
shift to a more fasttwitch, glycolytic muscle fibers and less oxidative fibers, DNTTIP1,
METTL21E and PARK7 were examined for their effects on MYH promoter activity using
luciferase assays. The results showed that both PARK7 and DNTTIP1 had an effect to
increase MYH4 and decrease MYH7 luciferase activity, similar to the effects of DLK1. In
contrast, METTL21E increase MYH7 and decreased MYH4 luciferase activity. In DLK1
treated myotubes, the mRNA expression of Myh4 and DNTTIP1 were both increased,
suggesting DLK1 may regulate Myh4 expression through elevated DNTTIP1 expression.
Though PARK7 was not upregulated in DLK1treated cells, its increased levels in
hypertrophied muscles still indicated its important role in callipyge muscle hypertrophy.
PARK7 has been shown to positively regulate PI3K/AKT pathway by suppressing the
phosphatase activity of PTEN in mouse fibroblasts. The aim of the second study is to
determine whether the elevation of PARK7 was part of the physiological mechanism for
muscle hypertrophy in callipyge lambs. Primary myoblasts isolated from Park7 (+/+) and
Park7 (/) mice were used to examine the effect of differential expression of Park7. The
Park7 (+/+) myotubes had significantly larger diameters and more total sacomeric
myosin expression than Park7 (/) myotubes. IGF1 treatment increased the mRNA
abundance of Myh4, Myh7 and Myh8 between 2040% in Park7 (+/+) myotubes relative
to Park7 (-/-). The activity of PI3K/AKT pathway was determined by examination the

xii
level of phosphorylation of AKT. The basal level of AKT phosphorylation (S473) was
increased in Park7 (+/+) myotubes and this increase was substantially elevated in Park7
(+/+) myotubes at all levels of IGF1 supplementation. The differential levels of AKT
phosphorylation were eliminated by the addition of a PTEN inhibitor, suggesting PARK7
inhibited PTEN activity in myotubes. After removal of IGF1, the Park7 (+/+) myotubes
could still maintain about 20% higher signal intensity through 12 hours. These combined
results suggested PARK7 can positively regulate the PI3K/AKT pathway by inhibition of
PTEN phosphatase activity. The elevated expression of PARK7 in the muscles of
callipyge lambs would be expected to lead to increased muscle growth in response to the
normal IGF1 signaling present in young growing lambs. The results presented in this
thesis unveiled the genes consistently coexpressing with DLK1 in callipyge lambs and
identified DNTTIP1 as a secondary transcriptional effector gene responding to DLK1
signaling. Furthermore, this thesis suggested a positive role of PARK7 in callipyge
muscle hypertrophy.
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CHAPTER 1. INTRODUCTION

1.1

Objective

In food animal industry, there is always a need to identify genes that can increase
meat production. Callipyge sheep is an excellent model for this study since the up
regulation of DLK1 and / or RTL1 results in the increased muscle mass. The overall aim
of this dissertation is to study the physiological pathways responding to the upregulation
of DLK1 and / or RTL1 in the hypertrophied muscles. The current study is based on the
results from the previous study, in which twentyfive transcripts were discovered and
validated with differential expression in hypertrophied muscles. Two projects were
included in this study. The objective of the first project was to identify the secondary
transcriptional targets for DLK1 and / or RTL1 signaling (primary effectors) from the 25
transcripts. The consistent upregulation of Parkinson Protein 7 (PARK7) expression in
hypertrophied muscles but not in nonhypertrophied muscles makes it a potential
secondary target. Therefore, the objective of the second project was to explore the
functional role of PARK7 in muscle growth and protein accretion. Based on the
objectives of the two projects, callipyge sheep, DLK1, RTL1, PARK7 and muscle
hypertrophy pathways will be reviewed in this section to provide a better understanding
in the followup experiments.
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1.2

Callipyge Phenotype

The first callipyge sheep was identified in a commercial Dorset flock in Oklahoma in
1983 when it was referred to as “Solid Gold”. The unexpected superior muscling in the
hindquarters makes it a unique model for researchers to study muscle development. Some
of the offspring from the “Solid Gold” inherited the same extrememuscling phenotype
and thus were termed callipyge from the Greek –calli for beautiful, and –pyge for
buttocks (Cockett et al. 1994).
The callipyge lambs are born normal and carry the same live weights as the normal
lambs throughout their entire life (Jackson et al. 1997a; Freking et al. 1998b; Duckett et
al. 2000; Lorenzen et al. 2000). However, depending on location, different degrees of
increased muscle mass are found when slaughtering (Koohmaraie et al. 1995; Jackson et
al. 1997b, c; Freking et al. 1998b; Duckett et al. 2000). Specifically, the increase of
muscle mass in the pelvic limb (42%) and the torso (50%) is much greater than in the
thoracic limbs (14%) (Jackson et al. 1997c), which is consistent with the visual
perception that callipyge sheep appear to be more muscular in the hind legs and also
appear to be wider and deeper through the rack and loin (Jackson et al. 1997c). Notably,
the supraspinatus and infraspinatus muscles located in thoracic limbs do not undergo
muscle hypertrophy (Koohmaraie et al. 1995; Jackson et al. 1997c; Lorenzen et al. 2000).
The “rostro–caudal gradient” is given to describe this special characteristic (Georges et al.
2003). Furthermore, the selective muscular hypertrophy of callipyge lambs develops
during the postnatal growth period between birth and weaning (Jackson et al. 1997a;
Carpenter & Cockett 2000; Duckett et al. 2000; Lorenzen et al. 2000), therefore the 30
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day old lambs are utilized in the present study when the increase of muscle mass is
statistically detectable.
As different from the “doublemuscling” cattle (Kambadur et al. 1997), whose
increased muscle mass is a results of the increase in the fiber number (hyperplasia), the
muscle hypertrophy in callipyge sheep is due to the increased diameter of muscle fibers
(hypertrophy). (Koohmaraie et al. 1995; Carpenter et al. 1996; Carpenter & Cockett 2000;
Lorenzen et al. 2000). In a study of the histology and composition of muscles from
callipyge lambs, a 34% increase in fiber size was determined in the longissimus, which
was sufficient to account for the observed 31% increase in the loin eye area (Carpenter et
al. 1996). A striking muscle fiber change is observed in the hypertrophyresponsive
muscles with an increase in the proportion and size of type IIB fasttwitch, glycolytic
muscle fibers (Carpenter et al. 1996; Carpenter & Cockett 2000). These fasttwitch fibers
increase in diameter by 35% to 75% depending on the age and muscle affected
(Carpenter et al. 1996; Carpenter & Cockett 2000; Kerth et al. 2003). The muscle fiber
switch reflects the metabolic change in callipyge muscles, and identifying of the
regulators in the muscle fiber switch will enrich our knowledge concerning the muscle
growth in callipyge sheep. The current study investigates the potential genes modulating
muscle fiber switch using a cell culture model.
A reduction in the rate of protein degradation, rather than increased protein synthetic
capacity, was first proposed to account for the higher protein accretion in callipyge sheep
(Koohmaraie et al. 1995; Lorenzen et al. 2000). Calpains are calciumdependent
proteases that degrade myofibers, whereas calpastatin inhibits calpain activity
maintaining the integrity of myofibers. Increased calpastatin activity was described in
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callipyge muscles suggesting a reduced protein degradation and increased protein
accretion (Koohmaraie et al. 1995; Lorenzen et al. 2000). Recently, a higher level of
PARK7, a positive regulator of the PI3K/AKT pathway (see section 1.5.5), has been
identified in hypertrophied muscles (FlemingWaddell et al. 2009). The upregulation of
PARK7 is assumed to enhance the downstream targets of AKT, such as p70S6 kinase
(p70S6K), to increase protein synthesis (see section 1.6.1)(FlemingWaddell et al. 2009).
One goal of the current study is to address whether the elevation of PARK7 is part of the
physiological mechanism for the induced muscle hypertrophy in callipyge lambs.
Other advantages of callipyge over normal sheep are the superior feed efficiency for
both male and female animals and the higher dressing percentage (Koohmaraie et al.
1995; Jackson et al. 1997a; Jackson et al. 1997b). Lambs with the callipyge mutation
have average daily gains which are similar to that of their halfsiblings with a normal
muscle phenotype but less feed per day (Jackson et al. 1997a). Dressing percentage is
influenced by the amount of muscle, fat, gutfill, and wool on the lamb (Jackson et al.
1997b). A total of 6 to 7% decrease in fat depot is constantly described in callipyge
animals, and this reduction is not limited to subcutaneous fat, but also is reported in
internal fat and intramuscular fat. (Koohmaraie et al. 1995; Jackson et al. 1997b; Freking
et al. 1998b; Goodson et al. 2001). The results of the comparison of internal organs vary.
The lighter lungs, liver, and kidneys were first demonstrated in callipyge animals,
(Koohmaraie et al. 1995) but a later comprehensive study showed no statistically
significant difference in the mean weights for liver, lungs, kidneys, rumen, reticulum,
omasum, abomasum, small intestine, spleen, and testicles (Jackson et al. 1997b). At the
same time, a lighter large intestine was indicated in this study. Two other studies
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confirmed the lighter liver weights in more animals (Freking et al. 1998b; Lorenzen et al.
2000). Furthermore, the carcasses of callipyge lambs are more compact with a
significantly shorter length and greater width at the shoulder and rump (Freking et al.
1998b). In addition, a reduction in fleece weight and staple length is observed for ewes
with the callipyge phenotype (Freking et al. 1998a). These unique characteristics together
contribute to the higher dressing percentage in callipyge sheep.
Despite the advantageous characteristics described above, the meat quality in
callipyge muscle is not as good as in normal muscle. The higher levels of calpastatin
activity are detrimental to meat tenderness. Several studies showed the increased Warner
Bratzler shear force value from callipyge loin chops (Duckett et al. 2000) as a result of
the reduced rate of calpainmediated postmortem proteolysis. One study indicated that the
postmortem proteolysis is delayed by as much as 20 days in callipyge lambs
(Koohmaraie et al. 1995). Notably, no difference in the tenderness of the SS (non
hypertrophied muscle) between callipyge and normal lambs was reported (Koohmaraie et
al. 1995; Shackelford et al. 1997; Duckett et al. 2000). Moreover, the lower marbling
score also affects the quality, making them less juicy and flavorful (Jackson et al. 1997b;
Freking et al. 1999; Abdulkhaliq et al. 2002).
Despite the low meat quality in callipyge lambs, the better feed efficiencies and
higher muscle yields allow researchers to use them as a model to study muscle growth. In
addition, the unique inheritance model also attracts attention from the Genetics experts.
1.3

Genetics in Callipyge Sheep

The mutation causing muscle hypertrophy in callipyge lambs was first mapped to the
distal end of ovine chromosome 18 (Cockett et al. 1994). Later, a nonMendelian mode
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of inheritance called polar overdominance was described based on the offspring
production from multiple mating combinations (Cockett et al. 1996). The Callipyge
sheep is the only animal model that demonstrates the polar overdominance phenomena.
Only the lambs inherit a paternal mutant allele and a normal maternal allele (+/C) exhibit
the callipyge phenotype, whereas the lambs inheriting a maternal mutant allele (C/+) or
both mutant alleles (C/C) possess the same phenotypes as the normal lamb (+/+) (Cockett
et al. 1996; Freking et al. 1998a). Although the underlying mechanism for polar
overdominance is complex (Georges et al. 2003) and is still under investigation, studies
suggests that it relates to the altered genes expression around the callipyge mutation.
The callipyge mutation was identified in 2002 as a single base change of an A (wild
type allele) to a G (callipyge allele) between the DLK1 (Delta-Like homolog 1) and
MEG3 (Maternal Expressed Gene 3) genes in the DLK1DIO3 (Deiodinase,
Iodothyronine, type III) imprinted gene cluster (Freking et al. 2002; Smit et al. 2003). No
evidence showed that the callipyge mutation disrupted protein coding. However, several
studies have suggested that it acts as a longrange control element to alter the
transcription of the nearby imprinted genes in cis (Freking et al. 1998a; Bidwell et al.
2001; Charlier et al. 2001a; Bidwell et al. 2004; Murphy et al. 2006; Takeda et al. 2006;
FlemingWaddell et al. 2007; Vuocolo et al. 2007; FlemingWaddell et al. 2009). These
imprinted genes include the paternally expressed genes: DLK1 and Retrotransposon-like
1 (RTL1), and the Maternal Expressed Gene 3 (MEG3), Maternal Expressed Gene 8
(MEG8) and RTL1 antisense (RTL1AS) (Fahrenkrug et al. 2000; Schmidt et al. 2000;
Charlier et al. 2001b; Shay et al. 2001; Bidwell et al. 2004). Telomeric to MEG8 is the
largest known cluster of mammalian miRNA, which are present in the introns of an

7
ncRNA transcript, called MicroRNA-containing Gene (MIRG) (Seitz et al. 2003a; Seitz et
al. 2004). The existence of these maternally expressed MIRG has been confirmed in the
skeletal muscle of sheep (Caiment et al. 2010)(see Figure 1.1). The imprinted status of
DIO3 in sheep has not been determined. Increased expressions of the paternally
expressed genes (DLK1 and RTL1) are detected in the lambs which inherited the mutation
from the sire (+/C), and upregulated levels of maternally expressed genes (MEG3,
MEG8 and RTL1AS) are identified in the animals which inherited the mutation from the
dam (C/+) (Bidwell et al. 2001; Charlier et al. 2001a; Bidwell et al. 2004; Perkins et al.
2006; Takeda et al. 2006; FlemingWaddell et al. 2007; FlemingWaddell et al. 2009).
Notably, only the paternally expressed genes are proteincoded (DLK1 and RTL1),
whereas all the maternally expressed genes are noncoding RNA. Unlike RTL1, whose
increased transcript abundance has been detected in all the muscles in callipyge animals,
the upregulation of DLK1 has been shown exclusively in the hypertrophyresponsive
muscles, suggesting DLK1 is the primary effector of muscle hypertrophy but a synergistic
effect of RTL1 cannot be ruled out (Bidwell et al. 2004). The following section will
demonstrate the function of DLK1 and RTL1 respectively.
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Figure 1.1 The DLK1-DIO3
DIO3 Imprinted Gene Cluster.
The relative positions of these imprinted genes are shown above. The protein coding
genes (DLK1 and RTL1; blue) are expressed from the paternal allele (Pat) and the non
non
coding RNA (MEG3, RTL1AS,
RTL1AS MEG8 and MIRG; pink)
k) are expressed from the maternal
allele (Mat). The genes are shaded with blue or pink on the parentoforigin
parent
origin chromosome
to indicate their allelespecific
specific expression. The causative mutation (A to G; CLPG) for
the callipyge phenotype lies in the intergenic
intergeni region between DLK1 and MEG3
MEG3.
1.4

Primary inducers in callipyge sheep

1.4.1 Delta-like Homolog 1
DLK1,, also known as FA1 (fetal antigen 1), Pref1 (preadipocyte factor 1), SCP1
(stromal cellderived
derived protein 1) and ZOG (zone glomerulosa specific factor) for its
multiple
tiple functions and different discoveries [for review see (Laborda
Laborda 2000
2000)], encodes a
protein that contains six extracellular epidermal growth factor (EGF)like
(EGF) like sequences, a
proteolytic cleavage reorganization site, and a short intracellular tail (Laborda
Laborda et al. 1993;
Laborda 2000).. The cleavage of the EGFlike
EGF like extracellular domain releases the soluble
form of DLK1 called FA1,
1, widely existing in the serum of pregnant females and in
amniotic fluid (Jensen et al. 1994b; Bachmann et al. 1996).. ADAM17 (tumor necrosis
factor alpha converting enzyme, TACE) is identified as an enzyme to catalyze the
production of FA1 (Wang
Wang & Sul 2006).
2006 An alternative
ative splicing form of DLK1 without
the proteolytic cleavage site is found to remain constitutively membrane
membranebound and this
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form of DLK1 predominates during later fetal and adult life (Davis et al. 2004; White et
al. 2008).
The function of DLK1 has been extensively explored in the context of adipogenesis.
DLK1 is proposed as a marker for preadipocytes where it strongly expressed, and its
expression level is immediately decreased during adipocyte differentiation. Constitutive
Dlk1 expression inhibits adipose differentiation (Smas & Sul 1993; Smas et al. 1997).
This result is further confirmed in Dlk1 knockout mice, whose fat deposition is highly
increased and serum lipid metabolites are altered (Moon et al. 2002). Thus, Dlk1 is
considered as a negative regulator of adipogenesis, and this antiadipogenic function of
Dlk1 could be an explanation for the lean muscle phenotype characteristic of callipyge
sheep.
Several studies have illustrated a role of Dlk1 in muscle growth. Transgenic mice
overexpressing Dlk1 results in a 10 to 15% increase in quadriceps femoris muscle mass
and a 9 to 10% increase in myofiber diameter (Davis et al. 2004). Conversely, muscle
specific gene ablation of Dlk1 in the mouse results in reduced body weight and skeletal
muscle mass due to reductions in myofiber numbers (Waddell et al. 2010). A
polymorphism in the DLK1 gene in pigs is associated with increased lean muscle mass
and decreased adiposity similar to callipyge sheep (Kim et al. 2004). Moreover, a marked
reduction in mRNA levels of myosin heavy chain 4 as well as compromised regenerative
capacity and elevated inflammatory response to injury are also detected in the Dlk1
knockout mice (Waddell et al. 2010). These combined transgenic models suggest the
important role of Dlk1 during postnatal muscle development and regeneration.
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The expression of Dlk1 is greater during embryonic development and gradually
decreases after birth. However, increased expression of Dlk1 is discovered in human
myopathies including Duchenne and Becker muscular dystrophies (Andersen et al. 2009).
The relationship between Dlk1 and muscle disorders could be explained by the
involvement of satellite cells. Muscle satellite cells have been characterized as a
population of musclespecific committed progenitors that are responsible for the postnatal
maintenance, growth, repair and regeneration of skeletal muscle [for review, see (Kuang
& Rudnicki 2008)]. The expression of transcriptional factor Pax7 has been defined as a
maker of muscle satellite cells (Kuang et al. 2006). A subpopulation of PAX7 positive
cells is found to be DLK1 positive in muscles of newborn sheep (White et al. 2008).
Substantial numbers of Dlk1 positive satellite cells were observed in Duchenne muscles.
Furthermore, myogenic Dlk1 positive cells were identified during muscle regeneration in
animal models in which the peak expression of Dlk1 mRNA and protein coincided with
that of myoblast differentiation (Andersen et al. 2009). These combined evidences
suggest that Dlk1 functions to regulate myogenic progenitor cells to modulate muscle
growth.
The mechanism on how Dlk1 regulates muscle growth has been explored and studies
have shown that Dlk1 acts as an inhibitor for Notch signaling. The structure of DLK1 has
high homology to the drosophila protein Delta except that DLK1 lacks the critical
Delta/Serrate/Lag2 (DSL) domain at its Nterminus (ArtavanisTsakonas et al. 1999;
Laborda 2000). However, DLK1 can still interact with Notch1 and downregulate its
activity in mammalian cell lines (Baladron et al. 2005; Bray et al. 2008). The Notch
signaling is a conserved cell fate regulator and is known to inhibit myogenic regulatory
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transcription factor MyoD expression and myogenic differentiation, but enhances satellite
cell proliferation and selfrenewal (Nofziger et al. 1999; Wen et al. 2012). Ablation of
Dlk1 inhibits the expression of MyoD, and facilitates the selfrenewal of activated
satellite cells. Conversely, overexpression of Dlk1 inhibits the proliferation and
enhanced differentiation of cultured myoblasts. This suggests a model in which Dlk1
facilitates muscle differentiation through dampening of Notch signaling (Waddell et al.
2010).
Extensive studies have shown that Dlk1 is involved in tumorgenesis. Dlk1 is proposed
as a marker for hepatoblastomas (Dezso et al. 2008) and adrenal gland tumors (Turanyi et
al. 2009). It is also detected frequently in colon adenocarcinomas, pancreatic islet
carcinoma, and small cell lung carcinoma (Yanai et al. 2010). The mechanism on how
Dlk1 regulates oncogenesis is complicated but studies have shown that Dlk1positive
fetal liver cells have higher proliferative potential compared to the Dlk1negative cell
population. The Dlk1positive fetal liver cells are able to differentiate into both the
hepatocyte and cholangiocyte lineages, which implies that Dlk1positive liver cells are
still hepatoblasts (Tanimizu et al. 2003; Xu et al. 2012). Interestingly, PARK7, the target
gene in the present study, is also associated with development of multiple cancers (see
section 1.5.5), indicating it may function together with Dlk1 to modulate cell fate
determination.
1.4.2

Retrotranposon-like 1

Retrotranposon-like 1 (RTL1), is the other upregulated gene in callipyge sheep.
RTL1 belongs to the Ty3Gypsy retrotransposons gene family and contains a gagpollike
structure common to retroviruses (Charlier et al. 2001b). This highly conserved gene only
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has one single exon open reading frame and encodes a full length 151 kD protein in
skeletal muscles (Byrne et al. 2010).
RTL1 is highly expressed at the latefetal stage in both the fetus and placenta.
Paternally knockout RTL1 in mice showed pre and postnatal growth retardation in the F1
and F2 generations, and after the F3 generation, most showed latefetal or neonatal
lethality (Sekita et al. 2008). A 40% decrease in passive permeability in placenta is also
reported in RTL1 deficient mice, indicating that the loss of RTL1 may damage the
placental physical barrier (Sekita et al. 2008). A 2.5 to 3 times overexpression of RTL1
leads to 15% retardation in growth after weaning in early generations, and predominant
neonatal lethality was found after the F6 generation (Sekita et al. 2008). The expansion of
the inner spaces of the fetal capillaries has also reported in this model. These combined
evidences indicate an essential function of RTL1 for the development of embryo and
growth of fetus and adult animals. Recently, RTL1 has been identified as a novel driver of
hepatocarcinogenesis (Riordan et al. 2013). Mutations resulting in the overexpression of
RTL1 are found in the mouse model of hepatocarcinogenesis. Overexpression of RTL1
results in highly penetrant (86%) tumor formation in vivo and the increased growth
ability of hepatocytes in vitro (Riordan et al. 2013).
A maternally expressed noncoding RNA transcribed from the opposite direction
(RTL1-antisense, RTL1AS), containing at least four microRNA, was identified for the
RISCmediated degradation of RTL1 transcripts (Seitz et al. 2003b; Bidwell et al. 2004;
Davis et al. 2005). The identification of RTL1AS provides a new insight into the polar
overdominance of the callipyge phenotype, in which only the paternal heterozygous (+/C)
have the increased level of RTL1. The miRNAmediated degradation of RTL1 transcripts
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in homozygous animals (C/C) reduces the mRNA abundance of RTL1 (Bidwell et al.
2004; Davis et al. 2005). However, the role of RTL1 in the callipyge muscle hypertrophy
is still unclear and needs further investigation.
1.5

Parkinson Disease 7

Parkinson Protein 7 (PARK7 / DJ-1) was first identified in 1997 as an oncogene that
transformed NTH3T3 cells in cooperation with activated Ras (Nagakubo et al. 1997).
PARK7 encodes a 20kDa protein comprising 189 amino acid residues ubiquitously
expressed in various human tissues (Nagakubo et al. 1997). Later, a mutation is found to
be responsible for a recessive earlyonset form of Parkinson’s disease (Bonifati et al.
2003). Substantial studies implicated that PARK7 plays important roles in male fertility,
cellular management of oxidative stress, mitochondrial homeostasis, and tumor
progression.
1.5.1

Genetics and Structure Biology of Park7

The PARK7 gene was located in human chromosome 1p36.2p36.3, in mouse
chromosome 4 and in sheep chromosome 12. PARK7 genomic DNA comprises seven
exons, in which the 27 exons encode for PARK7 protein. Human PARK7 homomers
comprise a structure with a sixstrand parallel βsheet sandwiched by αhelical
arrangements (flavodoxin fold) (Honbou et al. 2003a; Honbou et al. 2003b). The PARK7
protein is homologous to a number of bacterial enzyme families such as ThiJ, a protein
involved in thiamine biosynthesis, the Pfp1 protease (Bonifati et al. 2003) as well as the
YajL redoxsensitive chaperone (Martinat et al. 2004). The threedimensional structure is
given below (Figure 1.2.) [for review, see (Trempe & Fon 2013)]. Though the crystal
structure of PARK7 is similar to the Pfp1 protease, PARK7 does not exhibit protease
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activity due to the distorted catalytical triad that is essential for protease activity, and the
occupation of additional Cterminal helix at putative active site of PARK7 (Wilson et al.
2003; Martinat et al. 2004). PARK7 contains three cysteine residues, C46, C56, and
C106. Of the three cysteine residues, C106 is highly susceptible to oxidative stress and is
oxidized as SOH, SO2H, and SO3H. PARK7 at C106 with SO3H is thought to be an
inactive form of PARK7 (Figure 1.3.) and the mutation of C106 results in loss of PARK7
functions (Mitsumoto et al. 2001; Kinumi et al. 2004; Meulener et al. 2006; Hulleman et
al. 2007; Blackinton et al. 2009). So far, about 28 mutations are found in this gene
(Table1.1). The effects of most of these sequence alterations in PARK7 are not clear but
the L166P seems to be a dramatic point mutation, which affects PARK7 function
(Bonifati et al. 2003). L166 is located in the middle of αhelix 8 (α8) and the mutation
from leucine to proline seems to cause a break in the αhelix, which results in abrogation
of the dimer formation, unstable and degradation of the protein (Miller et al. 2003; Moore
et al. 2003; Gorner et al. 2004; Olzmann et al. 2004).
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Figure 1.2 Structure of PARK7 Protein
The crystal structure of human PARK7 (PDB 1P5F) was used to generate this dimer,
which represents the biologically active unit. The two subunits are colored in cyan and
magenta. Residues of the active site catalytic triad (Glu18, Cys106, His126) are shown as
sticks. The location of the PD mutation that disrupts dimerization (L166P) is indicated by
arrow (Trempe & Fon 2013).
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Table 1.1 Genetic Variation of PARK7
Mutation

Population

Effects

Reference

Ex15del

Dutch

Loss of protein

(Bonifati et al. 2003)

Ex15dup

Dutch

Unknown

(Macedo et al. 2009)

Ex2del

Chinese

Unknown

(Guo et al. 2010)

Ex5del

Serbian

Unknown

(Djarmati et al. 2004)

Ex57del

Northern Italian

Altered transcript

(Hedrich et al. 2004)

c.122_107del

South African

Promoter activity

(Keyser et al. 2009)

Leu10Pro

Chinese

Unknown

(Guo et al. 2010)

Met26Ile

Ashkenazi Jewish

Decreased stability

(AbouSleiman et al. 2003)

Ala39Ser

Chinese

Destabilized PINK1

(Tang et al. 2006)

Glu64Asp

Turkish

Unknown

(Hering et al. 2004)

IVS4+8_9insA

Southern Italy

polymorphism

(Tarantino et al. 2009)

Arg98Gln

Global

Polymorphism

(Hedrich et al. 2004)

Ala104Thr

Latino

Unknown

(Hague et al. 2003)

IVS5+2_12del

Russian

Altered transcript

(Hague et al. 2003)

Asp149Ala

Afro Caribbean

Unknown

(AbouSleiman et al. 2003)

Pro158del

Dutch

Unknown

(Macedo et al. 2009)

Thr160

American

Unknown

(Pankratz et al. 2006)

(g.33808C>A)
Glu163Lys

Italian

Altered activity

(Annesi et al. 2005)

Leu166Pro

Italian

Protein instability

(Bonifati et al. 2003)

Ala171Ser

Global

Unknown

(Clark et al. 2004)

Ala179Thr

Dutch

Unknown

(Macedo et al. 2009)
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Figure 1.3 Cysteinee Oxidation and Activation
A
of PARK7.
PARK7 contains three cysteine residues at amino acid numbers 46, 54, and 106 (C46,
C54, and C106). C106 is sequentially oxidized with SOH, SO2H, and SO3H, and then
C46 and C54 are oxidized. Graph modified from (Ariga et al. 2013).
1.5.2 Park7 and Male fertility
In rats, the contraceptive associated protein 1 (CAP1) is found in sperm
spermextracts from
fertile rats and epididymal fluid of ornidazole treated infertile rats. CAP1 is highly
expressed in rat testis, indicating its function in male fertility (Wagenfeld
Wagenfeld et al. 1998).
The further characterization of CAP1 showed that it shared high homology at the
nucleotide and amino acid level of human and mouse PARK7 (Wagenfeld
Wagenfeld et al. 1998). In
human and mouse, CAP1 is referred to DJ-1 or PARK7.. Ornidazole treatment reduces the
level of CAP1 expression in sperm, which leading to low fertilization both in rat and mice
(Wagenfeld et al. 1998; Okada et al. 2002). This decreased level of CAP1 is also
observed and quantified in rat serum extract treated with haloacids, which disrupts
spermiogenesis in rat (Kaydos
Kaydos et al. 2004; Klinefelter et al. 2004).. Furthermore, the
binding of sperm to the eggs is abrogated when treated with antiPARK7
anti PARK7 antiserum in
mice indicating PARK7 directly participates in the fertilization reaction ((Okada et al.
2002).. These results were further confirmed by another group using rats. In their study,
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the inhibition effect of antiPARK7 antiserum is decreased when using zonafree eggs,
which suggests that PARK7 works to enable binding of sperm to the egg surface and
penetrating of the egg surface (Klinefelter et al. 2002). Since its sensitivity and
correlation with fertility, PARK7 is proposed as a sperm fertility biomarker (Klinefelter
2008). In addition, a recent study unveils the expression and localization of PARK7 in
efferent ducts, which conduct sperm from the rete testis to the epididymis. The
epididymis is the place where the sperm acquire the mobility and ability to fertilize an
egg (TreposPouplard et al. 2010). In their study, they also found the promoter region of
PARK7 contains estrogen response elements, which together implicate its role in sperm
maturation and sex hormones regulation (TreposPouplard et al. 2010).
1.5.3

Park7 and Its RNA Binding Capacity

RNAbinding proteins play an important role in the posttranscriptional control of
gene expression. The activity of this family of proteins is mediated through specific
recognition of sequences and structural elements within the mRNA transcripts. In 1993, a
RNA binding complex includes a RNAbinding subunit (s), and a regulatory subunit(s)
(RS) were identified in FTO2B rat hepatoma cells (Nachaliel et al. 1993). Later, this RS
was cloned and characterized identical to human PARK7 gene (Hod et al. 1999). This
study also showed that the purified recombinant RS had the capacity to inhibit RNA
binding complex activity (Hod et al. 1999). However, the RNA binding capacity of
PARK7 has not been stated until recently (van der Brug et al. 2008). Though lacking of
classical RNA binding motifs, PARK7 can bind to GG/CCrich sequences and dissociate
under conditions of oxidative stress (van der Brug et al. 2008). The mRNA binding
partners of PARK7 were involved in but not limited to cell metabolism, mitochondrial
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transcripts and cell survival components both in vitro and in vivo (van der Brug et al.
2008). The RNA binding capacity provides an explanation of the multifunction of
PARK7.
1.5.4

Park7 and Parkinson ’s disease

Parkinson's disease (PD) is a progressive neurodegenerative disease affecting more
than 1 million individuals in the United States. Approximately 0.3% of the general
population and 3% of the population above 65 years have PD (Shaikh & Verma 2011).
Oxidative stress and mitochondrial dysfunction are implicated in the pathogenesis of PD.
Park7 had been investigated to exhibit the functions in maintaining mitochondrial
homeostasis and protecting neurons from oxidative stress.
1.5.4.1 Role of Park7 in Mitochondrial Homeostasis
PARK7 is located both in the cytoplasm and nucleus (Nagakubo et al. 1997) and a
portion of PARK7 has been shown to be located in the mitochondria (CanetAviles et al.
2004; Shendelman et al. 2004; Zhang et al. 2005; Hayashi et al. 2009). It has been
reported that some parts of PARK7 are translocated into mitochondria after cells has been
subjected to oxidative stress, to protect cells from oxidative stressinduced cell death (Li
et al. 2005; Junn et al. 2009). The oxidation of C106 with SO2H and the Nterminal 12
amino acids are necessary for the mitochondrial translocation of PARK7 (CanetAviles et
al. 2004; Maita et al. 2013). The localization of PARK7 in mitochondria is controversial.
Zhang et al. reported that PARK7 is located in the mitochondrial matrix and inner
membrane space (Zhang et al. 2005), while CanetAviles et al. reported that PARK7 is
located in the outer membrane but not inside of mitochondrial outer membrane (Canet

20
Aviles et al. 2004). Recently, the localization of PARK7 in outer mitochondrial
membrane is supported by the identification of a PARK7 binding partner BclXL, a
typical Bcl2 family protein that primarily localized in the outer mitochondrial membrane
(Ren et al. 2011). The Bcl2 family proteins are involved in PD pathogenesis and the Bcl
XL is required for mouse substantial nigra development. The BclXL inhibits
dopaminergic neuronal death induced by MPTP in the substantia nigra pars compacta
(Savitt et al. 2005; Dietz et al. 2008), thus it has a protective role in PD. In response to
ultraviolet B irradiation (an oxidative agent), the mitochondrial distribution of Park7
increases, which leads to the more binding capacity to BclXL and further to prevent Bcl
XL degradation (Ren et al. 2011).
Moreover, loss function of Park7 results in several mitochondrial abnormalities.
Significantly more fragmented mitochondria are reported in Park7 knockout mice and
cells (Irrcher et al. 2010). Loss of Park7 causes decreased mitochondrial transmembrane
potential and increased mitochondrial permeability transition pore opening, which can be
restored by treatment of antioxidant molecules (Giaime et al. 2012). Reduced activity
level and reduced amount of mitochondrial complex I have been reported in PD patients.
PARK7 is colocalized with mitochondrial complex I and directly bounded to NDUFA4
[NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4] and ND1 (NADH
dehydrogenase subunit 1), which are nuclear and mitochondrial DNAencoding subunits
of mitochondrial complex I respectively (Hayashi et al. 2009). Knockdown of Park7 in
vitro causes reduced activity of mitochondrial complex I and delivery of Park7 partially
restored its activity (Hayashi et al. 2009). Since the pathogenic Park7 mutants such as

21
L166P and M26I are localized in mitochondria as monomers, the dimer formation is
necessary for PARK7 to elicit its function in mitochondrial (Maita et al. 2013).
Since Park7 sequence contains no consensus mitochondrial targeting signals, the precise
mechanism by which Park7 is translocated into mitochondria is still not known. However,
the mitochondrial Hsp70 has the capacity to direct the import of nuclearencoded proteins
into mitochondria (Li et al. 2005; De Mena et al. 2009), therefore it has been proposed
that the binding of PARK7 to chaperones such as the Hsp70, CHIP, and mitochondrial
Hsp70 / Grp 75 may contribute to the translocation of PARK7 to mitochondria.
Regulation of autophagy and especially the autophagic degradation of mitochondria is
an essential tool to maintain mitochondrial function and cellular homeostasis. Autophagy
is a process that is involved in cell degradation of unnecessary or dysfunctional cellular
components to provide sufficient ATP to ensure the functionality of vital cellular
processes such as transcription and protein synthesis during periods of energy limitation
(Vasseur et al. 2009; Macintosh & Ryan 2013). Recent studies provide evidence for a
potential role of Park7 in regulation of autophagy. The association of Park7 with
autophagy varies. Park7 silencing results in both upregulation (Irrcher et al. 2010;
Thomas et al. 2011) and downregulation of autophagy (GonzalezPolo et al. 2009;
Vasseur et al. 2009; Krebiehl et al. 2010). It has been reported that Park7 acts in parallel
to the Pink1 / Parkin to control mitochondrial function and autophagy (Thomas et al.
2011). Future studies on the precise mechanism of autophagy induction by Park7 will be
needed to better understand the function of PARK7 in regulation of mitochondrial
homeostasis.
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1.5.4.2 Role of PARK7 in Antioxidative Stress
Park7 plays an important role in protecting neurons and somatic cells from oxidative
stress. Park7 has several isoforms with different isoelectric points (pI). It quenches
reactive oxygen species (ROS) by converting from pI 6.2 to the more acidic form pI 5.8
in mammalian cell lines. This pI shift is caused by the oxidation of cysteine residues in
PARK7 (Figure 1.3.) (Mitsumoto & Nakagawa 2001; Mitsumoto et al. 2001). Post
mortem studies of brain samples taken from sporadic Parkinson’s disease patients found
that the acidic isoforms of PARK7 are more abundant in PD brains as compared to
controls.
The antioxidative stress function of Park7 is confirmed both in vitro and in vivo. In
the presence of H2O2, the cell viability of Park7 knockout primary cortical neurons is
increased when transfected with wildtype Park7 and further improves upon over
expression of Park7, suggesting a gene dosage effect (Kim et al. 2005b). Transient
knockout Park7 in SHSY5Y neuroblastoma cells results in less resistant to 1methyl4
phenyl1,2,3,6tetrahydropyrindine (MPTP), a neurotoxin leading to the pathology most
similar to PD, and H2O2 treatment (Taira et al. 2004). Conversely, stable overexpression
of Park7 in H9C2 cardiomyocytes effectively attenuates ROS generation, enhances the
cellular antioxidant capacity and prevents ischemia/reperfusioninduced oxidative stress
(Yu et al. 2013). In addition to the in vitro studies, several Park7 knockout mice lines
were established to study the consequences of Park7 deficiency in vivo. Under basal
conditions, Park7 knockout mice are viable, fertile, and show no gross anatomical or
neuronal abnormalities (Kim et al. 2005b; Yamaguchi & Shen 2007). However, when
exposing to MPTP, Park7 deficient mice show increased striatal denervation and

23
dopaminergic neuron loss. Adenoviral vector delivery of Park7 restores all these
phenotypes (Kim et al. 2005b) and overexpression of Park7 resists the MPTP induced
striatal damage. Similar to Park7 knockout mice, Park7 knockdown zebrafish and
Drosophila melanogaster flies are specifically sensitized to lethal oxidative stress
(Menzies et al. 2005; Bretaud et al. 2007). Taken together, all these evidences suggested
the antioxidative stress and cell protective function of Park7.
The mechanism on how Park7 exerts its cell protective function has been extensively
studied. In addition to maintaining mitochondrial homeostasis and oxidizing itself to a
more acidic form, Park7 has chaperone activities and it can also regulate antioxidative
gene induction, and signaling pathways against oxidative stress.
1.5.4.3 Chaperone Activity of PARK7
Structural similarities to Hsp31 (heat shock proteins 31) suggests that PARK7 may
function as a chaperone, and the presence of a hydrophobic patch, which is a
characteristic of chaperone proteins, in the PARK7 dimer complex supports to this notion
(Lee et al. 2003). Subsequent evidence of its chaperone activity has been demonstrated
by quantification of the suppression of heatinduced aggregation of citrate synthase (CS)
and glutathione Stransferase (GST), two well characterized protein chaperone assays in
vitro (Shendelman et al. 2004). The chaperone activity of PARK7 is in a redox
dependent manner (Shendelman et al. 2004) and the oxidation of C106 to SO2H form is
required for this activity (Zhou et al. 2006). A recent study also showed that the
abrogation of chaperone activity of PARK7 by L166P mutation could be restored by
BAG1 (Bcl2 associated athanogene1), an antiapoptotic foldase stimulating co
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chaperone (Deeg et al. 2010). The aggregation of αsynuclein, a 140 residue presynaptic
protein, is believed to be a critical factor in the development of Parkinson’s disease and it
has been suggested that oligomeric forms of αsynuclein might be toxic (Zhou et al.
2006). Under an oxidative condition, the chaperone activity of PARK7 inhibits the
aggregation of αsynuclein, (Shendelman et al. 2004), suggesting an alternative
mechanism on how PARK7 is involved in PD pathogenesis.
1.5.4.4 Role of Park7 in Transcriptional Regulation
Park7 acts as a coactivator or a corepressor through binding to proteins to regulate
transcriptional activities. Several studies have reported the regulation of Park7 on
androgen receptor (AR) function. The androgen receptor is a member of the nuclear
receptor superfamily and plays a role as a liganddependent transcription factor. After a
ligand binds to the AR, the AR translocates into the nucleus and binds to the androgen
responsive element (ARE) and the androgenactivating genes. These AR binding partners
affect development, growth, and regulation of male reproductive functions (Heinlein &
Chang 2002). Park7 modulates androgen receptor activities in a highly celltypespecific
manner. The first identified PARK7 interacting protein is PIASxα (protein inhibitor of
activated STAT), also known as androgen receptorinteracting protein (Takahashi et al.
2001). PARK7 bounds to the ARbinding region of PIASxα to abolish the suppression of
AR transcription activity by PIASxα in CV1 monkey kidney cells and the TM4 mouse
testis sertoli cell line but not in human HepG2 hepatoma cells. In mouse Cos1 cells,
PARK7 is found to bind to DJBP (DJ1 binding protein) to reverse the suppression of
DJBP on AR transactivation activity in a testosteronedependent manner (Niki et al.
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2003). Surprisingly, in human neuroblastoma SKNBE(2)C, Park7 is reported to inhibit
ARdependent gene activation by approximately 50% (Jeong et al. 2006). In 2007, a
direct interaction between PARK7 and AR was reported in prostate cancer cells (LNCaP
and LAPC4 cell lines) and this study also showed PARK7 functions as a positive
regulator of AR signaling (Tillman et al. 2007).
The regulation of the transcriptional activity of the tyrosine hydroxylase (TH) gene by
androgen receptor leads to the studies on the modulation of Park7 on TH activity (Jeong
et al. 2006). The characteristics of Parkinson disease are the selective loss of
dopaminergic neurons and the decrease of striatal dopamine levels. Dopamine is
synthesized from tyrosine by two enzymes; tyrosine hydroxylase (TH) and LDOPA
decarboxylase (DDC). After synthesis, dopamine is transported into synaptic vesicles by
vesicular monoamine transporter 2 (VMAT2). Tyrosine hydroxylase catalyzes the first
and ratelimiting step of dopamine synthesis. Park7 positively regulates human TH gene
expression by sequestering the transcriptional repressor PSF (polypyrimidine tract
binding proteinassociated splicing factor) from the human TH gene promoter (Zhong et
al. 2006). Park7 suppresses PSF activity by inhibiting the sumoylation of PSF and
preventing its sumoylationdependent recruitment of histone deacetylase 1(Zhong et al.
2006). However, this upregulation of TH is only observed in human, the Park7 knockout
mice do not exhibit reduced TH expression or decreased dopamine production due to the
lacking of PSFrecognition sequence in the mouse TH gene (Ishikawa et al. 2010).
Recently, the nuclear receptor related protein 1 (NURR1) is reported to mediate Park7
induced TH activation via the ERK1 pathway (Lu et al. 2012). The TH upregulation by
Park7 can be abolished when NURR1 is silenced. Conversely, the upregulation of
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NURR1 as a result of overexpression of Park7 increases TH activity (Lu et al. 2012). In
addition, a recent study reported that Park7 regulates dopamine synthesis by stimulating
VMAT2 activity in the synapse through directly binding to VMAT2 and modulating the
transactivation of the VMAT2 gene. The cysteine 106 is necessary for the stimulating
activity of Park7 toward VMAT2 (Ishikawa et al. 2012).
Park7 is an important regulator of antioxidative gene induction. Park7 is reported to
stabilize Nrf2 (nuclear factor erythroid 2related factor) by preventing its association with
the inhibitor protein, Keap1 and further preventing the subsequent ubiquitination of Nrf2
(Clements et al. 2006). Upon exposure to oxidative stress, Nrf2 translocates to the
nucleus, which allows transcriptional activation of various antioxidant enzymes, such as
NQO1 [NAD(P)H quinone oxidoreductase 1], Hmox-1, and enzymes that generate
antioxidant molecules, such as glutathione. Therefore, Park7 acts as a positive regulator
of Nrf2driven antioxidant protection (Clements et al. 2006). Furthermore, Park7 protects
rat dopaminergic cells upon oxidative damage by mediating the induction of glutamate
cysteine ligase, the ratelimiting enzyme of glutathione biosynthesis (Zhou & Freed
2005). In addition, knockdown or L166P mutant of Park7 in NIH3T3 cells reduces the
expression of the extracellular superoxide dismutase (SOD3), leading to the increase of
ROS in cells (Nishinaga et al. 2005)
1.5.4.5 Role of Park7 on Signal Transduction
As introduced above (see section 1.5.4.2), Park7 quenches reactive oxygen species
(ROS) by converting itself to a more acidic form to protect cells from oxidative stress.
Notably, the ROS are not only cytotoxic molecules; they are produced in cells in minute
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amounts to facilitate signal transduction pathways (Hattori et al. 2009). The ASK1
signaling pathway is one of the pathways that can be activated by ROS (Hattori et al.
2009). Apoptosis signalregulating kinase 1 (ASK1) is mitogenactivated protein kinase
kinasekinase 5 (MAP3 K5) and it can activate cJun Nterminal kinase (JNK) and p38
mitogenactivated protein kinases (Hattori et al. 2009). Activation of these pathways
induces cellular responses such as apoptosis, differentiation, cell survival, and also
produces inflammatory cytokines (Hayakawa et al. 2012). PARK7 co
immunoprecipitates with ASK1 upon H2O2 exposure and this binding occurs after ASK1
dissociation with Trx1 (thioredoxin 1), an ASK1 inhibitor. Herein it has been proposed
that Park7 replaces Trx1 under acute oxidative stress, providing a second safeguard
suppressing ASK1mediated apoptosis (Gorner et al. 2007). This result is further
confirmed by another group, which demonstrated that after H2O2 treatment, Park7 is
incorporated into the ASK1 complexes and forms mixed disulfide bonds to suppress
ASK1 function (Waak et al. 2009). Furthermore, PARK7 has been identified to bind to
Daxx, a death domainassociated protein. Through this binding, PARK7 sequesters Daxx
in the nucleus, which prevents Daxx from binding to and activating its effector kinase
ASK1 (Junn et al. 2005). This process is reversed by the MPTP mediated down
regulation of Park7 (Karunakaran et al. 2007), which induces the translocation of Daxx
from nucleus to cytoplasm and results in the death of dopaminergic neurons. Through
suppression of ASK1 activity, Park7 negatively regulates the stressactivated p38 MAPK
and JNK pathways. In addition, Park7 has been shown to physically interacts with
MAPK/extracellular signalregulated kinase kinase kinase 1 (MEKK1) and inhibits
MEKK1 activation, resulting in the suppression of MEKK1mediated cell death (Mo et al.
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2008). Considering that MEKK1 is an MAP3K that participates in the JNK signaling
cascade, the inhibition of MEKK1 activation by Park7 may also be an important
mechanism in the progression of PD (Mo et al. 2008). Pathogenic mutants of PARK7 do
not have this activity.
Park7 has been identified to be involved in ERK pathway since 1997 when it was
first defined as a Raspathway interactor during oncogenic transformation (Nagakubo et
al. 1997). The ERK pathway is the main cellprogression pathway starting from Ras,
followed by Raf, Mek, and ERK. A recent study showed that dopamineexposure led to
the upregulation of Park7, which in turn to protect cells from dopamine toxicity and
reduce intracellular ROS (Lev et al. 2009). Inhibition of ERK 1, 2 phosphorylation
abolishes dopamine induced upregulation of Park7, suggesting the upregulation of
Park7 is mediated by the MAP kinases pathway through the activation of ERK 1, 2 (Lev
et al. 2009). Moreover, combined deletion of ERK and Park7 in Drosophila enhances the
developmental defects during eye and wing development caused by ERK deletion,
providing evidence for an important role for the interaction between Park7 and ERK
related signaling during evolution (Aron et al. 2010). In addition, it has been shown that
Park7 protects dopaminergic neurons against rotenoneinduced apoptosis by enhancing
ERKdependent mitophagy (Gao et al. 2012).
Since reactive oxygen species (ROS) has also been implicated to induce programmed
cell death or necrosis (Hancock et al. 2001), the involvement of JNK and ERK pathway
makes Park7 an important regulator in cancer development.
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1.5.5

Park7 and Cancer

Park7 has been shown to regulate a variety of cancers’ development. Both breast
cancer and pancreatic cancer patients have elevated levels of circulating Park7, and thus
Park7 is proposed as the biomarker for these two cancers (PucciMinafra et al. 2008; He
et al. 2011). Park7 stabilizes Nrf2 (nuclear factor erythroiddrived 2like2) to upregulate
the expression of antioxidant / protective enzymes, which confers a consequent survival
benefit to the lung carcinomas (Clements et al. 2006). PARK7 is associated with prostate
cancer by directly binding to androgen receptor to promote the progression of prostate
cancer to androgen independence (Tillman et al. 2007). In addition, elevated levels of
Park7 have been detected in astrocytomas (Miyajima et al. 2010), leukemias (Liu et al.
2008), and renal cell carcinomas (Eltoweissy et al. 2011). In addition to the involvement
of Park7 in JNK and ERK pathways, Park7 can also modulate cell survival through
regulation of p53, NFκB and the PI3K/AKT pathway.
p53 is a tumor suppressor and plays roles in induction of senescence and apoptosis of
cells (Smith et al. 2003). Park7 regulates p53 transcriptional activity in many ways.
Topors is a ring finger protein binding to both topoisomerase I and p53 in vitro and in
vivo. Transcription activity of p53 is found to be abrogated by Topors concomitant with
sumoylation of p53 in a dosedependent manner, and PARK7 restores the repressed
activity of p53 by releasing the sumoylated form of p53 (Shinbo et al. 2005).
Sumoylation of PARK7 itself is necessary for PARK7 to localize from the cytoplasm to
the nucleus (Shinbo et al. 2006), and PARK7 is a negative regulator for sumoylation (Fan
et al. 2008a). Interestingly, increased levels of p53 and Bax (a transcriptional target of
p53 and an inducer for apoptosis) are found in Park7 knockout zebrafish, suggesting
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Park7 may act as a negative regulator of p53 (Bretaud et al. 2007). This result is
supported by another group which demonstrated Park7 decreases Bax expression by
repressing p53 transcriptional activity (Fan et al. 2008b). A recent study showed that
PARK7 bounds to the DNAbinding region of p53 in a manner dependent on the
oxidation of C106. PARK7 suppresses the expression of p53 target genes through
preventing promoter recognition of p53 in a DNAbinding affinity dependent manner
(Kato et al. 2013).
The identification of Cezanne, a known deubiquitination enzyme that inhibits NFκB
activity, as a PARK7 binding partner leads to the investigation of Park7 in NFκB
signaling (McNally et al. 2011). The amino terminus of PARK7 is sufficient to mediate
this interaction, and this interaction between Cezanne and PARK7 is enhanced by
oxidation of the C106 residue of PARK7. (McNally et al. 2011). Park7 and Cezanne
shRNA are found to reciprocally regulate interleukin 8 (IL-8) and intercellular adhesion
molecule 1 (ICAM-1), whose transcription are mediated by NFκB, and both of them are
shown to be positively associated in human cancer (Dong et al. 2005; Rubie et al. 2007;
Chavey et al. 2008; Singh & Lokeshwar 2009). This result indicated the roles of Park7
and Cezanne in NFκB mediated transcription (McNally et al. 2011). The link between
Park7 and NFκB is confirmed with the discovery of decreased nuclear p65 expression in
the presence of Park7 shRNA, suggesting Park7 acts as a positive regulator of NFκB
signaling (McNally et al. 2011).
Park7 is shown to suppress the phosphatase activity of PTEN (Phosphatase with
tensin homology), one of the most frequently mutated tumor suppressor genes in human
cancers (Guldberg et al. 1997). PTEN is a negative regulator of the phosphatidylinositol
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3' kinase (PI3K)/AKT pathway (Kim et al. 2005a), which is an important pathway
regulating the signaling of multiple biological processes such as apoptosis, metabolism,
cell proliferation and cell growth (Morgensztern & McLeod 2005). The activation of
PI3K is initiated by the binding of the transmembrane tyrosine kinase linked receptors
(Hennessy et al. 2005). The activated PI3K phosphorylates phospholipid
phosphatidylinositol4, 5bisphosphate (PIP2) to phosphatidylinositol3, 4, 5
trisphosphate (PIP3), which creates a lipidbinding site on the cell membrane for the
recruitment of serine/threonine kinase AKT (protein kinase B). AKT is phosphorylated
and activated by 3’Phoshphoinositidedependent protein kinase 1(PDK1). PTEN
phosphatase activity catalyzes the reverse reaction of PIP3 back to PIP2, resulting in less
activated AKT (Maehama & Dixon 1998) (see Figure 1.4 in section 1.6.1).
The suppression of Pten phosphatase activity by Park7 is supported by several gain
offunction experiments. In Drosophila, Park7 rescues the reduced eye size caused by the
overexpression of Pten (Kim et al. 2005a). This result is further confirmed in
mammalian cells by observation of the increased cell survival in Park7 transfected Pten
(+/) cells, but not in Pten (/) cells. In NIH3T3 cells line, overexpression of Park7
reduces by 40 to 50% apoptosis in response to treatment with UV irradiation, sorbitol, or
TNFα. A decrease in phosphorylation of AKT is seen in Park7 siRNA treated Pten (+/−)
immortalized mouse embryonic fibroblasts, but not in Pten (/) cells, suggesting the
function of Park7 requires the presence of Pten (Kim et al. 2005a). In primary breast
cancer samples, Park7 expression correlates negatively with PTEN immunoreactivity and
positively with AKT hyperphosphorylation (Kim et al. 2005a). Since the
phosphorylation levels of PTEN at Ser380, Thr382, Thr383 and Ser385 are equal in
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Park7 transfected NIH3T3 cells (Kim et al. 2009), the inhibition of PTEN phosphatase
activity by Park7 is not affected by phosphorylation of PTEN. The detailed mechanism
on how PARK7 inhibits PTEN phosphatase activity is still remaining unclear. But studies
have proposed that PARK7 can directly bind to PTEN to change its conformation to form
a disulfide bond between C71 and C124 of PTEN upon oxidative stress and this form of
PTEN was considered to be inactive (Lee et al. 2002; Kwon et al. 2004; Kim et al. 2009).
It also has proposed that the interaction of PARK7 to PTEN may accelerate the oxidation
of PTEN, thus rendering the PTEN function inactive (Kim et al. 2009).
The inhibition of PTEN function by Park7 makes it as a positive regulator in the
PI3K/AKT pathway. AKT signaling inactivates several proapoptotic factors including the
proapoptotic protein (BAD) (Gu et al. 2004) , procaspase9 (Cheng et al. 2006) and
Forkhead (FKHR) transcription factors (Abid et al. 2004), and it also activates
transcription factors that upregulate antiapoptotic genes, including the cyclicAMP
response element binding protein (CREB) (Perkinton et al. 2002) and IκB kinase (IKK)
(Gustin et al. 2004). AKTmediated activation of mTOR (the mammalian target of
rapamycin, also known as FRAP1) is important in stimulating cell proliferation (Wendel
et al. 2004). mTOR is a serine/threonine kinase that serves as a molecular sensor
regulating protein synthesis on the basis of the availability of nutrients. It also has been
shown as an important mediator in regulating skeletal muscle hypertrophy (Glass 2003b)
(see section 1.6.1).
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1.6

Muscle Hypertrophy Pathways

The skeletal muscle growth during postnatal development reflects the balance
between overall rates of protein synthesis and rates of protein degradation. Two major
signaling pathways control the protein accretion: the PI3K/AKT pathway, acting as a
positive regulator; and the myostatinSmad2/3 pathway, acting as a negative regulator.
These two pathways are described in this section to provide the detailed mechanism on
how Park7 induced myotube hypertrophy.
1.6.1

PI3K/AKT Pathway

The PI3K/AKT pathway has been extensively studied and well characterized due to
its positive regulation on muscle growth (Bodine et al. 2001; Rommel et al. 2001; Glass
2003a; Stitt et al. 2004; Latres et al. 2005; Wilson & Rotwein 2007; Glass 2010;
Schiaffino et al. 2013). In live animals, the increases in muscle load stimulate the
expression of insulinlike growth factor 1(IGF1) (DeVol et al. 1990). The role of IGF1 on
muscle growth has been supported by a variety of evidences. Addition of the IGF1 into
culture medium induces hypertrophy in C2C12 myotubes through enhanced activation of
AKT (Rommel et al. 2001). Musclespecific overexpression of IGF1 causes muscle
hypertrophy (Musaro et al. 2001), and conversely, musclespecific inactivation of the
IGF1 receptors impair muscle growth due to the reduced muscle fiber number and size
(Mavalli et al. 2010). In mammals, IGF1 induces phosphorylation of the IGF1 receptor, a
tyrosine kinase that directly activates the insulin receptor substrate (IRS) (Bohni et al.
1999) and PI3K (Leevers et al. 1996). The detailed description on how PI3K activates
AKT was described in section 1.5.5. It has also been well demonstrated that the
activation of AKT is sufficient to induce hypertrophy. Overexpression of activated AKT
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in muscle fibers results in significantly larger fiber size (Bodine et al. 2001; Pallafacchina
et al. 2002). Transgenic mice expressing a constitutively active form of Akt in muscle
exhibits rapid skeletal muscle hypertrophy (Lai et al. 2004). Conversely, genetic
depletion of Akt in mice leads to smaller body size and shorter life span (Chen et al.
2001). AKT stimulates protein synthesis by activating mammalian target of rapamycin
(mTOR) and the downstream effectors of mTOR. The essential role of mTOR in muscle
growth has been well established. Loss of mTOR in skeletal muscle leads to premature
death and severe myopathy (Risson et al. 2009). Inhibition of mTOR by rapamycin
blocks the adaptive hypertrophy in adult animals (Bodine et al. 2001) and suppresses
muscle growth during postnatal development (Bodine 2006) and muscle regeneration
(Pallafacchina et al. 2002).
The activated mTOR further phosphorylates and activates p70S6 kinase (p70S6K) as
well as releases the inhibitory effects of phosphorylated, heat and acid stable (PHAS)
1⁄eukaryotic translation initiation factor 4Ebinding (eIF4Ebinding) protein 1 (4EBP1)
to promote protein synthesis. The activated p70S6K upregulates the translational rates of
mRNA in the ribosome and thus increases the total protein synthesis rates (Hornberger et
al. 2007). The 4EBP1, on the other hand, is a negative regulator of the protein initiation
factor eIF4E. The activation of mTOR leads to hyperphosphorylation of 4EBPs,
resulting in dissociation of the 4EBPs from eIF4E (Le Bacquer et al. 2007). Increased
phosphorylation of eIF4E as well as its overexpression is associated with the stimulation
of translation of mRNAs with highly structured 5’untranslated regions (Kimball et al.
1999).
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In addition to the mTOR pathway, the glycogen synthase kinase 3 beta (GSK3β) is a
distinct substrate of AKT that can also modulate hypertrophy [for reviews see (Glass
2005)]. GSK3β is a ubiquitously expressed constitutively active serine/threonine kinase
that phosphorylates cellular substrates, and thereby regulates a wide variety of cellular
functions, including development, metabolism, gene transcription, and protein translation
(Hardt & Sadoshima 2002). GSK3β is a negative regulator in myotube hypertrophy.
Phosphorylation of AKT inhibits GSK3β activity (Cross et al. 1995). Profound myotube
hypertrophy is observed in the dominant negative form of GSK3β expressed myotubes
(Rommel et al. 2001). GSK3β inhibits cardiac hypertrophy both in vivo and in vitro
through blockage of protein translation initiated by the eIF2B protein (Hardt &
Sadoshima 2002). Furthermore, deficiency of GSK3β protein results in enhanced
myotube formation and musclespecific gene expression in both mouse embryonic
fibroblasts and C2C12 myoblasts depending on the transcriptional regulator nuclear
factor of activated Tcells c3 (NFATc3) (van der Velden et al. 2008).
PTEN negatively regulates AKT activity (see section 1.5.5). Thus the inhibition of
PTEN phosphatase activity by PARK7 positively regulates PI3K/AKT pathway, and in
turn to modulate the activities of the downstream targets of AKT to enhance protein
synthesis (Figure 1.4.).
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Figure 1.4 Effects of PARK7 in PI3K/AKT Pathway.
P
Factors that are inhibitory of protein synthesis are indicated in red and stimulatory factors
are in blue. The activation of PI3K is initiated by the binding of IGF1 to its receptors.
The activated PI3K phosphorylates phospholipid phosphatidylinositol4,
phosphatidylinositol 4, 55bisphosphate
(PIP2) to phosphatidylinositol3,
phosphatidylinositol 4, 5trisphosphate
trisphosphate (PIP3), which creates a lipid
lipidbinding
site on the cell membrane for the recruitment of serine/threonine kinase AKT (prot
(protein
kinase B). AKT is phosphorylated and activated by 3’Phoshphoinositide
3’ Phoshphoinositidedependent
protein kinase 1(PDK1). PTEN catalyzes the reverse reaction of PIP3 back to PIP2,
resulting in less activated AKT. PARK7 inhibits PTEN phosphatase activity and
positively regulates AKT activity. Activated AKT phosphorylates mTOR and GSK3
GSK3β to
increase protein synthesis and thus leads to hypertrophy. Graph modified from (Glass
2005; FlemingWaddell et al. 2009; Russell 2010)

37
1.6.2 MyostatinSmad2/3 pathway
The myostatinSmad2/3 pathway is described here since the callipyge sheep share
several similar characteristics with myostatin mutant animals and the myostatinSmad2/3
pathway interferes with the AktmTOR pathway (Trendelenburg et al. 2009).
Understanding the myostatin pathway helps to build the whole picture on the regulation
of muscle growth.
Myostatin, also known as growth/differentiation factor 8 (GDF8), is a member of the
transforming growth factor β (TGFβ) super family. Myostatin is produced by skeletal
muscle and acts as a negative regulator of muscle growth (McPherron & Lee 1997b).
Several animal models, including mice, cattle, dogs and sheep, demonstrate the increased
muscle mass as a result of a variety of mutations in the myostatin gene (McPherron &
Lee 1997a; Girgenrath et al. 2005; McCroskery et al. 2005; Clop et al. 2006; Mosher et
al. 2007). Muscle growth due to a myostatin mutation results in both hyperplasia and
hypertrophy with 40% more fibers in each muscle as well as a 20 to 40% increase in fiber
diameters in cattle (Kambadur et al. 1997; McPherron & Lee 1997a; Lee 2004). In
addition to the hypertrophy, the myostatin knockout mice exhibit a larger proportion of
fast, glycolytic fibers as well as a decrease in adiposity. These characteristics are similar
to the callipyge phenotype (Pankratz et al. 2006). Purified myostatin inhibits protein
synthesis and reduces myotube size when added to differentiated myotubes in culture
further proves its negative effects in muscle growth (Taylor et al. 2001).
The myostatin signal initiates from the interaction and activation of a heterodimeric
receptor complex with serinethreonine kinase activity. These receptor complexes are
composed of a type II receptor, ACVR2 or ACVR2B, and a type I receptor, ALK4 or

38
ALK5 (Rebbapragada et al. 2003). The binding of myostatin to these receptor complexes
results in the phosphorylation and the activation of the transcriptional factors, Smad2 and
Smad3, which translocate to the nucleus upon phosphorylation to form heterodimers with
Smad4 [for reviews see (Lee 2004)]. The detailed mechanism on how these complexes
inhibit muscle growth is still unclear but many studies show that it interacts with the
AKT/mTOR pathway [for reviews see (Welle 2009)]. Myostatin reduces Akt
phosphorylation both in human and mouse C2C12 myotubes (Trendelenburg et al. 2009).
Blockage of mTOR increases myostatininduced phosphorylation of Smad2 and
facilitates myostatin’s inhibition of muscle differentiation (Trendelenburg et al. 2009).
The muscle fiber atrophy induced by Smad2/3 activation is prevented by the presence of
constitutively active Akt. Conversely, constitutively active Smad3 is also found to
suppress mTOR activation (Sartori et al. 2009). The addition of IGF1 does not block
Smad2/3 transcriptional activity but nevertheless it can promote myotube hypertrophy
when myostatin levels are high (Sartori et al. 2009). The precise crosstalk between these
two pathways is still under study.
In addition, transcriptomic and proteomic analyses in quadriceps muscles in
myostatinnull mice show elevated levels of PARK7 and phosphorylation of AKT (Chelh
et al. 2009). This result is further proved by the same group in doublemuscled cattle
showing higher PARK7 expression in doublemuscled fetuses compared to normal
controls (Chelh et al. 2011). Since upregulated PARK7 was reported in callipyge sheep
as well (FlemingWaddell et al. 2009), the combined results here suggest that PARK7
may be involved in the intersection of myostatin and PI3K/AKT pathway, and thus
deserves further investigation.
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1.7

Conclusion

Callipyge sheep is a unique model to study muscle growth since a small nucleotide
mutation leads to the profound muscle hypertrophy in live animals. Understanding the
genes network in callipyge muscle hypertrophy will enrich the notions on muscle
metabolism, muscle fiber type switch, and muscular protein synthesis. Since DLK1 and /
or RTL1 are examined as the primary causative genes, the identification of the secondary
transcriptional responses genes becomes the research goals in several studies including
the present one. In addition to the demonstration of callipyge phenotype and callipyge
genes regulation, this literature review detailed described the function of PARK7, which
is identified in previous study as a potential secondary response to DLK1 signaling , that
may stimulate protein synthesis in muscles. PARK7 is a multifunctional protein and is
involved in diverse biological processes. PARK7 occupies a pivotal position in cellular
biology with the loss of function leads to the Parkinson’s disease and the gain of function
results in the unregulated cell survival in human cancers. PARK7 acts through interaction
with RNA and partner proteins to modulate the transcriptional activities and signaling
pathways. The regulation of Park7 in muscle is explored in the present dissertation to
elucidate the molecular mechanisms behind muscle hypertrophy in callipyge sheep.

40

CHAPTER 2. ASSAY VALIDATION

2.1

Introduction

Callipyge sheep have extreme muscling in their loin and hindquarters as a result of a
genetic mutation located in the DLK1-DIO3 imprinted gene cluster (Freking et al. 2002;
Smit et al. 2003) This mutation upregulates the expression of nearby genes through cis
and these genes in turn to further alter the gene network in hypertrophied muscles
(Charlier et al. 2001a; Bidwell et al. 2004; Murphy et al. 2006; Perkins et al. 2006;
FlemingWaddell et al. 2007). Several recent studies have been conducted to profile gene
expression in callipyge sheep in order to understand the signals and pathways leading to
the increased muscle mass (FlemingWaddell et al. 2007; Vuocolo et al. 2007; Fleming
Waddell et al. 2009). The overall aim of this dissertation is to identify the downstream
genes that respond to DLK1 and / or RTL1 signaling and characterize their function in
muscle growth. In order to achieve this aim, several experiments including quantitative
PCR, western blots, ELISA, in situ ELISA, gene clone, gene transfection, and luciferase
assays have been conducted. This chapter covers the validation of assays used in this
thesis to provide reliable experimental methods as well as lab protocols to perform the
complete experiments.
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2.2
2.2.1

Material and Methods

PARK7 Plasmid Construct

Full length PARK7 cDNA was first synthesized by reverse transcriptional PCR from
total sheep RNA extraction using the following primers: F: 5’
CACCATGGCTTCAAAAAGAGCTCTAGT 3’ and R: 5’
ATCTTTAAGAACCAGCGG 3’. (CACC sequence was added into 5’ end of forward
primer to construct directional TOPO cloning vector). Primers were designed based on
the sequence from Bos taurus (GenBank accession number, NM_001015572). The PCR
product was cloned into pENTR/SD/DTOPO vector as instructed by manufacturer (Life
Technologies, Grand Island, NY USA). NotI and AscI enzymes were used to cut out the
whole vector in order to identify the insertion. The insertion was confirmed by
sequencing using T7_ZL primer (5’ GTAAAACGACGGCCAG 3’). To create an
expression clone construct, the LR Recombination Reaction (Life Technologies) was
performed to recombine pENTRPARK7/SD/DTOPO construct with pcDNA3.2/V5
DEST vector (Life Technologies). The pcDNA3.2/V5DEST vector contains V5 epitope
tag allowing detection of the recombination fusion protein by recognizing the V5 tag. To
confirm the insertion of PARK7, the expression construct was sequenced from both
directions using the following primers; T7_ZL F: 5’ GTAAAACGACGGCCAG 3’ and
V5 reverse: 5’ ACCGAGGAGAGGGTTAGGGAT 3’.
2.2.2

C2C12 Cell Culture and Cell Transfection

C2C12 cells were cultured in Dulbecco’s modified Eagle’s medium (Life Technology)
containing 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA USA), 100
units of penicillin, 100 µg of streptomycin, and 0. 292 mg/ml of Lglutamine. To valid
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the expression of pPARK7pcDNA3.2 /V5 construct, C2C12 cells were transfected using
FuGene 6 reagent (Roche Applied Science, Indianapolis, IN USA) according to the
manufacturer’s instructions. pPARK7pcDNA3.2 / V5 plasmids were transfected at a rate
of 1 μg of plasmid DNA in 3×105 cells and seeded in 24well plates with cover slides.
The transfected cells were cultured in growth medium without antibiotics on the first day
of transfection and the regular growth medium was changed to the culture afterwards.
2.2.3 Optimizing Electroporation Condition
In order to optimize the electroporation conditions, C2C12 cells were transfected
using Neon TM Transfection System (Life Technologies) according to the manufacturer’s
recommended protocol. C2C12 cells (2 × 105 for 10 µL tips and 2 × 106 for 100 µL tips)
were electroporated with green fluorescence protein (pGFP) (3 µg for 10 µL tips and 30
µg for 100 µL tips) construct at the indicated transfection condition (see Figure 2.3). The
transfected cells were plated in one well of 6well plate in the growth medium without
antibiotics and normal medium was changed into culture afterwards. Cells were
suspended in 2 days and count on BD Accuri™ C6 Flow Cytometry (BD Biosciences,
San Jose, CA USA). For each individual transfection, the total number of the cells
transfected was same. The gated cells reflect the population of cells in the restricted
gating area in the scatter plot. The same gating area was applied to every treatment. The
transfection efficiency was calculated by the percentage of GFP positive cells to total
gated cells.
2.2.4 Primary Myoblast Isolation and Culture
Primary myoblasts were isolated from hind limb skeletal muscles at 35 weeks of age.
Muscles were washed with Dulbecco’s PhosphateBuffered Saline (DPBS), minced and

43
digested in type I collagenase and dispase B mixture (Roche Applied Science,
Indianapolis, IN USA). The digested muscle pulp was then filtered through a 100 µm
filter (CellTrics®, Partec Inc., Swedesboro, NJ USA) to remove large muscle fiber debris
and then plated on culture dishes. In 3 days, the cells together with the small debris were
collected and digested with 0.025% trypsin for 10 minutes with agitation. Cells were
seeded in growth media (F10 Ham’s medium supplemented with 20 % fetal bovine
serum, 100 units of penicillin, 100 µg of streptomycin,0. 292 mg/ml of Lglutamine, , and
4 ng/mL basic fibroblast growth factor) on rattail collagen (Roche Applied Science)
coated dishes with preplating on noncoated plates for 45 minutes to deplete fibroblasts
as previous described (Waddell et al. 2010; Liu et al. 2012).
2.2.5

Luciferase Assay

Primary myoblast from Park7 (+/+) and Park7 (/) mice were transfected using Neon
TM

Transfection System (Life Technologies) according to the manufacturer’s

recommended protocol. Myoblasts (2 × 105 cells) were electroporated with 3 µg of
plasmid DNA consisting of 2.7 µg of pGL3IIB2.6 and 0.3 µg of pRLSV40 (control) at
three pulses of 1500 V for 10 ms. The transfected cells were plated into 96 well plate in
growth medium overnight and then fused into myotubes for 3 days with the indicated
concentration (50 ng/mL, 100 ng/mL and 200 ng/mL) of long®R3 IGF1. The reporter
assays were performed with DualLuciferase Reporter Assay System (Promega, Madison,
WI USA), according to the manufacturer’s recommendations. The samples were read at
Tecan Genios Pro (Tecan Group Ltd.) plate reader. Luciferase activity was adjusted for
transfection efficiency by multiplying the firefly luciferase activity of a given well by the
ratio of mean renilla luciferase activity for all wells divided by renilla luciferase activity
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of the given well to produce units of adjusted luciferase activity. The results were
analyzed for the genotype and IGF1 as the main effects by ANOVA using SAS 9.2
software.
2.2.6

Immunocytochemistry and Microscopy

C2C12 cells were transfected as described method and cultured in a 24well plate
with cover slides for 48 hours. Cells were fixed in 4 % formaldehyde and permeabilized
in 0.5 % Triton X100. Cells were blocked in 1 % bovine serum albumin (BSA) in PBS
for 1 hour at room temperature and stained with primary antibody with a dilution of
1:200 for 2 hours. The primary antibodies used in this experiment were goat antiPARK7
antibody (Santa Cruz Biotechnology) and mouse antiV5 antibody (Life Technology).
Cells were then washed with PBS, and incubated with secondary antibodies with a
dilution of 1:1000 for 1 hour. The secondary antibodies used in the experiments were
Alexa Fluor 488conjugated donkey antiGoat IgG secondary antibody (Life Technology)
and Alexa Fluor 594conjugated donkey antimouse IgG secondary antibody (Life
Technologies). Finally, cells were mounted with Prolong Gold antifade reagent with
DAPI (Life Technologies). The IP Lab software (Scanalytics Inc., Madison, WI USA)
and Leica DM6000 microscope were used to acquire pictures.
2.3
2.3.1

Results and Discussion

Validation of the pPARK7pcDNA3.2 Construct

Full length PARK7 cDNA was synthesis from total sheep RNA extraction using
primers designed from Bos taurus sequence (GenBank accession number,
NM_001015572) due to the unavailability of sheep PARK7 gene sequence. The forward
PCR primer contained the sequence, CACC, at the 5’end of the primer, matching the
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overhang sequence GTGG in pENTR™ TOPO® vector allowing directly cloning the
entire gene to the entry clone vector. The full length of PARK7 open reading frame is
570bp. In order to fuse PARK7 protein in frame with a Cterminal tag, the reverse PCR
primer was designed without the stop codon. The PARK7 cDNA was cloned into entry
vector first (pENTR™ TOPO®) and then subcloned into pcDNA3.2/V5DEST vector for
expression in mammalian cells. The illustration of PARK7 expression construct
(pPARK7pcDNA3.2 /V5) was shown in Figure 2.1. The human cytomegalovirus
immediateearly (CMV) promoter drove the highlevel expression of PARK7 and the
fusion of the V5 epitope tag allows the detection using antiV5 antibodies. The detailed
description of this vector can be found on the website
(http://www.lifetechnologies.com/us/en/home.html).
In order to examine the ectopic expression of PARK7 gene in mammalian cells,
C2C12 cells were transfected with pPARK7pcDNA3.2 /V5 construct and detected using
antiPARK7 and antiV5 antibodies (Figure 2.2). The cells stained with antiPARK7
antibody (green) can also be detected with antiV5 antibody (red), suggesting the
effectiveness of pPARK7pcDNA3.2 /V5 construct. PARK7 was mostly localized in
cytoplasm, however, the nucleus localization was also detected (Figure 2.2). This result
was in consistent with previous studies which also demonstrated the nucleus, cytoplasm
and mitochondrial localization of Park7 (Nagakubo et al. 1997; Junn et al. 2009). The
subcellular compartmentalization of Park7 is important to its cytoprotective activity. A
study reported that the oxidative stress drives the translocation of Park7 from cytoplasm
to mitochondrial and nucleus whereas under basal conditions Park7 is present mostly in
the cytoplasm and to a lesser extent in mitochondria and nucleus (Junn et al. 2009).
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2.3.2

Optimization of Electroporation Conditions

To accurately optimize the transfection conditions, the green fluorescence protein
(GFP) construct was transfected into cells and counted through the flowcytometry. The
start condition was based on the manufacture’s instruction. A combined consideration of
transfection efficiency and cell viability was taken to determine the best transfection
condition. The NeonTM transfection system provides two sizes of tips that fits two
volumes of cells, 10 µL for 2×105 (Figure 2.3) and 100 uL for 2×106 (Figure 2.4). The
nontransfected cells were used as controls to define the gated cells area and the non
fluorescence cells graphic area (Figure 2.3 A, B and Figure 2.4 A, B). The same gating
areas were applied to each treatment. The condition for the 10 µL tip was first examined.
The input pulse width and pulse number were maintained the same, however, an increase
of voltage results in higher transfection efficiency. There are 63.6 % of GFP positive cells
at the condition of 1800V, 10ms and 3 pulses (Figure 2.3 E and F); however, the cell
population that counted in this treatment and the observed cell viability is much lower
than at the condition of 1650V, 10ms and 3 pulses with 60.2 % GFP positive cells (Figure
2.3 C and D). Therefore, the optimized condition for transfection of 2×105 cells using 10
µL tips was at 1650 V, 10ms and 3 pulses. The conditions titrated in this study was given
in Table 2.1A. Based on the optimized condition for 10 µL tips, the starting voltage for
testing conditions using 100 µL tips was determined at 1500V and 1650V. Different
input pulse width and pulse number were examined in this assay. Interestingly, the
optimal transfection condition was still at 1650V, 10ms and 3 pulses, where 81.2 % cells
were GFP positive (Figure 2.4 C and D). The condition of 1650V, 20ms and 2 pulses
gave the worst transfection efficiency of 22.2% (Figure 2.4 E and F). The entire condition
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titrated in this study was given in Table 2.1B. These results suggested that over 50 % of
the cells can be transfected by NeonTM transfection system and the high transfection
efficiency supported the feasibility of luciferase assay.
2.3.3

Titration of IGF1 concentrations

One objective of current study was to investigate the effects of PARK7 in muscle
growth and protein accretion in response to IGF1 (see Chapter 4). Herein, the Long®R3
IGF1, whose effects was determined to induce myotube hypertrophy (Rommel et al.
2001), was introduced to this study. The effectiveness of IGF1 was also examined in the
current study by observation of the myotube size. C2C12 cells were fused into myotubes
for 6 days with the additional of indicated concentration of IGF1 for the last 4 days.
Additional of IGF1 led to observed more and larger sizes of myotubes (Figure 2.5B and
C) compared to no addition of IGF1 (Figure 2.5A). Here, we concluded that the
Long®R3 IGF1 enhanced myoblast differentiation.
PARK7 was identified as a secondary effector gene in DLK1 and RTL1 (primary
inducers) induced muscle hypertrophy in the current study (see Chapter 3). Since the
hypertrophied muscles in callipyge sheep have a greater proportion of fasttwitch,
glycolytic muscle fibers and a marked reduction in mRNA levels of Myh4 was detected
in the Dlk1knockout mice (Waddell et al. 2010), the effects of PARK7 on regulation of
myosin heavy chain 4 (Myh4) promoter luciferase activity was examined to determine
whether it is a component of DLK1 regulation of muscle fiber type switch. Different
concentrations of IGF1 were titrated here to determine the optimal treatment that can
induce significant differences between Park7 wildtype (+/+) and knockout (/) cells
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(Figure 2.6). The statistical analysis suggested that in the presence of PARK7, Myh4
luciferase activity was significantly elevated by 7% (P<0.0001). IGF1 treatments also
increased Myh4 luciferase activity by 30 % (P<0.0001). A significant interaction effects
was also detected (P=0.0122). Specifically, a 36 % increase was detected in the Park7
(+/+) myotubes at IGF1 concentration of 100 ng/mL and further increase of IGF1
concentration to 200 ng/mL does not change this magnitude. No significant differences
were observed in other lower IGF1 concentrations (12.5, 25 and 50 ng/mL). Therefore, a
higher concentration of IGF1 (100 ng/mL or 200 ng / mL) was used in the future
luciferase assays to explore the effects of overexpression of Park7 on the Myh4
luciferase activity (see chapter 3).
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Figure 2.1 Illustration of pPARK7pcDNA3.2 Construct.
Full length PARK7 cDNA was amplified by reverse transcriptional PCR from total sheep
RNA extraction, first cloned to pENTR/SD/DTOPO vector and subcloned to pcDNA3.2
/V5DEST vector. The CMV promoter drives the expression of PARK7 gene. The V5
epitope tag was fused with PARK7 and coexpressed with PARK7.
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A
Condition

Transfection Efficiency Gated Cells

Non-Transfection

0%

67.2%

1500V 10ms 3 pulse

49.5%

64.4%

1650V 10ms 3 pulse

60.2 %

48.8%

1800V 10ms 3pulse

63.6%

15.9%

1950V 10ms 3pulse

52.9%

14.3%

B
Condition

Transfection Efficiency Gated Cells

Non-Transfection

0%

72.3%

1500V 10ms 3pulse

66.3%

67.7%

1500V 30ms 1 pulse

62.3%

69.0%

1500V 20ms 2pulse

69.4%

42.4%

1650V 10ms 3pulse

81.2%

69.2%

1650V 30ms 1 pulse

65.9%

42.2%

1650V 20ms 2pulse

22.1%

17.8%

Table 2.1 Summary of the Transfection Efficiency.
C2C12 cells were transfected with GFP and counted through BD Accuri™ C6 Flow
Cytometry. The total number of the cells transfected was same. The gated cells reflect the
population of cells in the restricted gating area in the scatter plot. The same gating area
was applied to every treatment. The transfection efficiency was calculated by the
percentage of GFP positive cells to total gated cells. A: C2C12 cells were transfected
with 10 µL Neon tips with 3 µg plasmids in 2 × 105 cells per tip and B: C2C12 cells were
transfected with 100 µL Neon tips with 30 µg plasmids in 2 × 106 cells per tip.
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CHAPTER 3. IDENTIFICATION OF GENES DIRECTLY RESPOND TO DLK1
SIGNALING IN CALLIPYGE SHEEP

3.1

Abstract

Callipyge sheep are an excellent model to study genes regulation in muscle growth
since the up-regulation of DLK1 and RTL1 results in extreme postnatal muscle
hypertrophy. Gene expression analysis was conducted in four hypertrophied and three
non-hypertrophied muscles to distinguish the genes that directly respond to DLK1
signaling from the muscle specific effects of hypertrophy. The quantitative PCR results
suggested that DLK1 expression was significantly increased in the 4 hypertrophied
muscles but not in the 3 non-hypertrophied muscles. However, RTL1 was up-regulated in
both hypertrophied and non-hypertrophied muscles, which reinforced DLK1 as the
primary inducer for callipyge phenotype and also indicated that RTL1 alone is not
sufficient to induce muscle hypertrophy. Five genes, including PARK7, DNTTIP1,
SLC22A3, METTL21E and PDE4D, were consistently co-expressed with DLK1, and
therefore have the potential to be the transcriptional target genes responding to DLK1
signaling. The expression of DNTTIP1, METTL21E and PARK7 were examined for their
effects on Myosin Heavy Chain (MYH) promoter activity using luciferase assays. The
results showed that both PARK7 and DNTTIP1 increased MYH4 and decreased MYH7
promoter activity, similar to the effects of DLK1. In contrast, expression of METTL21E
increased MYH7 and decreased MYH4 luciferase activity. Treatment of myoblast and
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myotubes with DLK1 induced a 1.6-fold and a 2-fold increase in DNTTIP1 expression.
The expression of MYH4 also increased in DLK1-treated myotubes, however, no
significant difference was found in PARK7 expression. This suggests that DNTTIP1 was
a secondary effector gene responding to DLK1 signaling.
Keywords: DLK1, RTL1, skeletal muscle, hypertrophy, callipyge sheep
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3.2

Introduction

Callipyge sheep are well known for their postnatal muscle hypertrophy that is
prominent in loin and hind quarters (Koohmaraie et al. 1995; Jackson et al. 1997c;
Duckett et al. 2000). The muscle mass in callipyge sheep is increased 35-40 % and
carcass fat is decreased 6-7 % but the live weights were the same relative to normal
lambs (Jackson et al. 1997a; Jackson et al. 1997b, c; Freking et al. 1998b). Callipyge
lambs are born with normal muscling and hypertrophy becomes detectable at 4-6 weeks
of age (Jackson et al. 1997a; Carpenter & Cockett 2000; Duckett et al. 2000; Lorenzen et
al. 2000). After 5 weeks of age, an increased proportion and larger size of fast-twitch,
glycolytic muscle fibers were found in callipyge muscles (Carpenter et al. 1996;
Carpenter & Cockett 2000). Not all the skeletal muscles in callipyge sheep develop
hypertrophy, the supraspinatus and infraspinatus muscles in thoracic limb are two
muscles that do not undergo hypertrophy (Koohmaraie et al. 1995; Jackson et al. 1997b;
Freking et al. 1998b).
The callipyge mutation is a single base change of an A (wild-type allele) to a G
(callipyge allele) between DLK1 (Delta-Like homolog 1) and MEG3 (Maternal Expressed
Gene 3) genes in the DLK1-DIO3 (Deiodinase, Iodothyronine, type III) imprinted gene
cluster (Freking et al. 2002; Smit et al. 2003). The callipyge mutation did not disrupt any
protein coding sequence. However, several studies have shown that the highly conserved
12 bp sequence including the mutation acts as a long-range control element to alter the
transcription of the surrounding imprinted genes in cis. Specifically, the inheritance of a
callipyge allele from the sire up-regulates the transcription of paternal protein-coding
genes DLK1 and RTL1 (Retrotransposon-like 1), while the inheritance of a maternal
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callipyge allele enhances the expression of maternal non-coding RNA including MEG3,
MEG8 (Maternal Expressed Gene 8) and RTL1AS (RTL1 antisense)(Bidwell et al. 2001;
Charlier et al. 2001a; Bidwell et al. 2004; Perkins et al. 2006).
Dlk1 encodes a transmembrane protein belonging to the epidermal growth factor
(EGF)-like repeat containing family. This family includes proteins such as the Notch
receptors and their ligands including Delta-like (Dll1, Dll3 and Dll4) and Serrate
(Jagged)-like (Jagged1 and Jagged2) ligands (Laborda et al. 1993; Smas 1993; Jensen et
al. 1994a; Okamoto et al. 1998). Unlike Delta and Serrate, Dlk1 lacks the critical
Delta/Serrate/Lag-2 (DSL) domain at its N-terminus. Therefore, Dlk1 is thought to
interact with the Notch receptors through its EGF repeats as an antagonist and downregulates Notch signaling (Baladron et al. 2005; Bray et al. 2008). The Notch signaling is
a conserved cell fate regulator and is known to inhibit myogenic regulatory transcription
factor MyoD expression and myogenic differentiation, but enhances satellite cell
proliferation and self-renewal (Nofziger et al. 1999; Wen et al. 2012). Several studies
indicate that DLK1 expression can influence postnatal muscle growth. Transgenic mice
over-expressing Dlk1 caused increased muscle mass and myofiber diameter (Davis et al.
2004). Muscle-specific gene ablation of Dlk1 in the mouse resulted in reduced body
weight and skeletal muscle mass due to reductions in myofiber numbers (Waddell et al.
2010). Conversely, over-expression of Dlk1 in cell culture was shown to inhibit myoblast
proliferation and enhanced differentiation (Waddell et al. 2010). DLK1 mRNA was upregulated in longissimus dorsi, gluteus medius and semimembranosus, the hypertrophied
muscles in callipyge lambs but not up-regulated in supraspinatus, the non-hypertrophied
muscle (Bidwell et al. 2004; Perkins et al. 2006; Fleming-Waddell et al. 2007; Fleming-
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Waddell et al. 2009). The DLK1 protein was expressed at high levels observed in the
myofibers of callipyge longissimus dorsi and semimembranosus but was not detected in
normal muscles (White et al. 2008).
Similar to DLK1, the mRNA abundance of RTL1 is also increased in the calipyge
muscles. RTL1 belongs to Ty3-Gypsy retrotransposons gene family and contains gag-pollike structure common to retroviruses (Charlier et al. 2001b). This highly conserved gene
only has one single exon and encodes a full length 151 kDa protein in skeletal muscles
(Byrne et al. 2010). In the mouse, Rtl1 is highly expressed at the late-fetal stage in both
the fetus and placenta and the loss or over-expression of Rtl1 cause late-fetal and / or
neonatal lethality (Sekita et al. 2008). In callipyge sheep, the up-regulation of RTL1 is not
specific to hypertrophied muscles, a lower magnitude of induction of RTL1 in the nonhypertrophied muscle (supraspinatus) was detected (Bidwell et al. 2004), suggesting
RTL1 alone is not sufficient to induce muscle hypertrophy. These combined studies
suggest that elevated DLK1 expression is the primary cause of callipyge muscle
hypertrophy. Since the biological activity of RTL1 in muscles is not well understood, a
synergistic effect with DLK1 has not been ruled out.
MEG3, MEG8, and RTL1AS are all non-coding RNA that are transcribed from the
maternal chromosome. MEG3 was recently proposed to possess tumor suppressor
properties (Zhou et al. 2012; Balik et al. 2013). MEG8 was located in embryonic brain
and muscles (Gu et al. 2012) but the function of MEG8 is still unclear. RTL1AS contains
at least four microRNA that was identified for RISC-mediated degradation of RTL1
transcripts (Seitz et al. 2003b; Davis et al. 2005).
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Several studies were conducted to identify the downstream target genes responding to
the over-expression of DLK1 and RTL1 in callipyge animals (Fleming-Waddell et al.
2007; Vuocolo et al. 2007; Fleming-Waddell et al. 2009). Microarray analysis of gene
expression in the semimembranosus identified 375 genes that were differentially
expressed in callipyge versus normal lambs (Fleming-Waddell et al. 2009). Twenty-five
transcripts were further verified by quantitative PCR in 2 hypertrophied muscles
(semimembranosus and longissimus dorsi) and one non-hypertrophied muscle
(supraspinatus). It has been assumed that among these 25 transcripts, there are direct
targets of DLK1 signalings and tertiary responses to hypertrophy. Therefore, gene
expression analysis using 4 hypertrophied muscles longissimus dorsi, semimembranosus,
semitendinosus and triceps brachii and 3 non-hypertrophied muscles supraspinatus,
infraspinatus and heart was conducted in the current study to distinguish the genes that
directly respond to DLK1 signaling from tertiary effects of hypertrophy. These direct
targets are defined as the physiological directly respond to DLK1 signaling rather than a
direct binding partner of DLK1, and these genes would expect to have a similar mRNA
expression pattern as DLK1 in all the muscles examined. Whereas the tertiary response
genes are assumed as the genes that indirectly respond to DLK1 signaling and thus could
have different expression levels in one or several muscles. These tertiary response genes
could be associated with many bioactivities such as protein accretion, myofiber type and
metabolic changes. Since the hypertrophied muscles have a fiber type proportions shift to
a greater number of fast-twitch, glycolytic muscle fibers expressing MYH4, the MYH4 is
an appropriate indicator of the tertiary responses. Therefore, the MYH4 luciferase reporter
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assay was conducted to explore the potential components on DLK1 regulation of MYH4
expression.
3.3
3.3.1

Materials and Methods

Sample Collection

Matings between a ram that was heterozygous for the callipyge allele and a group of
normal ewes were used to generate a cohort of callipyge and normal lambs. The lambs
were genotyped to detect the callipyge SNP and sampled at 30-35 days of age following
protocols approved by Purdue University Animal Care and Use Committee. Seven
muscles including (longissimus dorsi, semimembranosus, semitendinosus, triceps brachi,
supraspinatus, infraspinatus, and heart) were weighed and sampled as described
(Fleming-Waddell et al. 2007; Fleming-Waddell et al. 2009) . Muscle RNA was isolated
according to the methods described previously (Fleming-Waddell et al. 2007).
3.3.2

Primary Myoblast Isolation and Culture

Primary myoblasts were isolated from hind limb skeletal muscles of mice at 3-5
weeks of age. Muscles were washed with Dulbecco’s Phosphate-Buffered Saline (DPBS),
minced and digested in type I collagenase and dispase B mixture (Roche Applied Science,
Indianapolis, IN USA). The digested muscle pulp was then filtered through a 100 µm
filter (CellTrics®, Partec Inc., Swedesboro, NJ USA) to remove large muscle fiber debris
and then plated on collagen-coated dishes. After 3 days, the cells together with the small
debris were collected and digested with 0.025% trypsin for 10 mins with agitation. Cells
were seeded in growth media (F-10 Ham’s medium supplemented with 20 % fetal bovine
serum, 100 units/mL of penicillin, 100 µg/mL of streptomycin,0. 292 mg/ml of Lglutamine, and 4 ng/mL basic fibroblast growth factor) on non-coated plates for 45 mins
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to deplete fibroblasts as previous described (Waddell et al. 2010; Liu et al. 2012) and
then transferred to collagen (Roche Applied Science)-coated dishes. Myoblasts were
differentiated into myotubes after plating cells at approximately 80% confluency on
Matrigel (BD Biosciences, San Jose, CA USA) coated plates and the addition of fusion
media consisting of DMEM supplemented with 5 % horse serum, 100 units/mL of
penicillin, 100 µg/mL of streptomycin, and 0. 292 mg/ml of L-glutamine. Myoblast
cultures testing the effects of DLK1 ligand were plated on a bed of 1 mg/mL BD Matrigel
containing 500 ng/mL of recombinant DLK1 protein [DLK1 (mouse): Fc(human),
Adipogen International Inc., San Diego CA USA]. Cells were induced to differentiate the
next day and fused for 2 days before mRNA isolation.
3.3.3

Quantitative PCR Analysis

Complimentary DNA (cDNA) synthesis for measuring RTL1 transcript abundance
used gene-specific priming of 5 µg total RNA and Superscript III reverse transcriptase at
50 ℃ (Life Technology). The cDNA synthesis for other transcripts used random hexamer
priming from 5 µg RNA and MMLV reverse transcriptase. The first strand cDNA
synthesis reaction was diluted 25-fold so that there was an equivalent of 20 ng of input
RNA per microliter. Quantitative PCR assays were carried out in 15-µL reaction volumes
of iQ SYBR Green Supermix with cDNA equivalent to 100 ng of input RNA. All cDNA
samples were assayed in duplicate. Absolute quantification was used to measure gene
expression in sheep muscle RNA. The quantitative PCR primers and the plasmid
standards were designed and tested according to the methods described previously
(Fleming-Waddell et al. 2009). Primer sequences were listed in Supplement Table 1.
Cloned amplicons were used as standards to calculate a regression of threshold cycle on
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molecule copy number to determine a log value of starting abundance for each of the
cDNA samples based on their threshold cycle (Bidwell et al. 2004). All plasmid
standards were diluted from either 108 to 102 or 107 to 101 molecules. Quantitative PCR
reactions for standards were performed in triplicate. The variance analysis was performed
using SAS 9.2 software and the MIXED procedure was used to analyze the log value of
gene expression. Genotype was the main effect in the model and each muscle was
analyzed individually. The random effect was defined as animal nested within genotype.
The least squares means; standard error and difference between least squares means were
calculated for the variance analysis.
Relative quantification was used to measure gene expression in DLK-treated
myoblast experiments. RNA from cultured myotubes was extracted and purified using
Nucleo Spin RNA II columns (Machery-Nagel Inc., Easton, PA USA) with DNase I
treatment. First strand cDNA was synthesized from RNA using random hexamer and
oligo dT priming and MMLV (Life Technologies). Quantitative PCR measurements were
performed using the SA Bioscience SYBR Green Supermix (QIAGEN, Valencia, CA
USA) reagents on an iCycler Real-Time PCR Detection System (Bio-Rad Inc.). Each
reaction was carried out in 15 µl reaction volumes of SA Bioscience SYBR Green
Supermix with 5 pM of each primer and diluted first-strand cDNA. Primer sequences
were listed in Supplement Table S1. Ribosomal protein large protein 38 (Rplp38) was
used as the housekeeping gene control for ΔCT calculation [ΔCT = (CT of the target gene)
– (average CT of housekeeping genes)]. Fold expression values were calculated using 2ΔΔCT

methods (Livak & Schmittgen 2001), where ΔΔCT = (ΔCT of the treatment sample)

– (ΔCT of control treatment samples) with no added DLK1 as control treatment and
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normalized to 1. Statistical significance was determined by Analysis of Variance
(ANOVA) method.
3.3.4

Plasmid Construction

Full length DNTTIP1, METTL21E and PARK7 cDNA were amplified by reverse
transcription PCR from total sheep RNA and directionally cloned into pENTR/SD/DTOPO vector (Life Technologies, Grand Island, NY USA) and then subcloned by
recombination into the pcDNA3.2/V5-DEST expression vector (Life Technologies)
according to the manufacturer’s recommendations. The mouse pDLK1-pCMV-SPORT
6.1 plasmid was commercial available (cat#: MMM1013-9201636, Thermo Fisher
Scientific Inc., PA USA). To confirm the insertion of the target genes with an intact open
reading frame, all plasmids were sequenced from both directions. The pGWCATpcDNA3.2 /V5 control plasmid was obtained from Life Technologies.
The mouse Myh4 luciferase construct (pGL3IIB2.6) containing 2.56 kb of the promoter
region of Myh4 was kindly provided by Dr. Swoap (Swoap 1998). The rat Myh7
luciferase construct (p-3542β-MHCluc), containing 3.5 kb of the promoter of Myh7, was
obtained from Dr.Hasegawa (Hasegawa et al. 1997). The pRL-SV40 plasmid expressing
renilla luciferase was commercial available at Promega Corporation. Plasmids for
electroporation were purified using EndoFree Plasmid Maxi Kit (QIAGEN) and
quantified by Nanodrop spectrophotometry (Thermo Fisher Scientific Inc, Rockford, IL
USA).
3.3.5

Luciferase Reporter Assay

Neon TM Transfection System (Life Technologies) was used according to the
manufacturer’s recommended protocol. Myoblasts (2 × 105 cells) were electroporated
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with 3 µg of plasmid DNA with three pulses 10 msec pulses of 1500V. To determine if
these target genes could have effects on myosin gene expression, the effector experiments
were done by co-transfection of protein coding sequence of the target genes along with
the myosin luciferase reporter construct. The myosin luciferase reporter construct and the
transfection control (renilla) were kept constant first, and the two different amounts of
effector cDNA were titrated. In order to keep a constant amount of the total plasmid
DNA, the GW-CAT was added and also used as the null control vector. A detailed
description of the plasmid combinations were given in Supplementary Table A4. The
electroporated cells were put into 96-well plates in growth media overnight and
subsequently fused into myotubes for 3 days. In PARK7 luciferase experiments, the
indicated concentrations of IGF1 (50, 100, and 200 ng / mL) (long®R3 IGF1, SigmaAldrich Co, St Louis, MO USA) were added to the fusion medium 24 hours after
differentiation and cultured for another 48 hours. The reporter assays were performed
with Dual-Luciferase Reporter Assay System (Promega, Madison, WI USA), according
to the manufacturer’s recommendations. The samples were read with a Tecan Genios Pro
(Tecan Group Ltd.) plate reader. Luciferase activity was adjusted for transfection
efficiency by multiplying the firefly luciferase activity of a given well by the ratio of
mean renilla luciferase activity for all wells divided by renilla luciferase activity of the
given well to produce units of adjusted luciferase activity. The results were analyzed for
the addition of target construct as the main effect by ANOVA using SAS 9.2 software.
The IGF1 treatment was also considered as a main effect when analyzing PARK7
luciferase assay.
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3.4
3.4.1

Results

Phenotypic Data Analysis

Animal birth weights and live weights were collected and statistical analysis (Figure
3.1) showed that there were no significant differences in birth weight and live weight
between callipyge (+/C) and normal lambs (+/+). The callipyge lambs have significantly
heavier longissimus dorsi, semimembranosus, semitendinosus and triceps brachi, ranging
from 23 % to 17 % more relative to normal muscles (Figure 3.1), thus these 4 muscles are
referred to “hypertrophied muscles” in this study. No significant differences were
detected in supraspinatus, infraspinatus, and heart; herein these are “non-hypertrophied
muscles”. These results verified the muscle specific hypertrophy in the experimental
samples.
3.4.2

Muscle Specific Gene Expression

The mRNA abundance of the 25 differentially expressed transcripts from the previous
study (Fleming-Waddell et al. 2009) were assayed by quantitative PCR. To investigate
the shift of myosin heavy chain isoforms in callipyge animals, the four myosin heavy
chain genes [MYOSIN HEAVY CHAIN 4 (MYH4), MYOSIN HEAVY CHAIN 7 (MYH7),
MYOSIN HEAVY CHAIN 2 (MYH2) and MYOSIN HEAVY CHAIN 1 (MYH1)] were also
examined in this study. The complete set of primers for all genes analyzed by quantitative
PCR and PCR conditions was given in supplementary Table A1 and the least square
mean with standard errors was given in supplementary Table A2. The differential
expression of these genes with corresponding p-values was given in supplementary Table
A3.
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The expression of Ribosomal protein, large P0 (RPLP0) was used as a control gene.
RPLP0 expression was not significantly different in the two genotypes in all the 7
muscles (Figure 3.2), which is an indication that equivalent amounts of RNA were used
for cDNA synthesis and for quantitative PCR. The callipyge mutation affected the genes
expression at DLK1-DIO3 locus (Figure 3.3). Compared to normal lambs, the expression
of DLK1 was significantly elevated in hypertrophied muscles with semimembranosus
having the largest magnitude of increase; and triceps brachi had the smallest increase.
There were no significant differences in supraspinatus, infraspinatus and heart (Figure
3.3A). The expression pattern of RTL1 was different from DLK1. Normal lambs had
extremely low RTL1 expression in longissimus dorsi , semitendinosus, triceps brachi and
supraspinatus with average log value is 1.14, and its expression level was barely
detectable in semimembranosus, infraspinatus and heart with average log value is less
than 1 (Figure 3.3B). The expression of RTL1 was significantly increased in callipyge
lambs in all the assayed muscles with an average log value for RTL1 was 4.6. The
expression patterns of MEG3 and MEG8 were quite similar. Both of their expression
levels were significantly elevated in the hypertrophied muscles (Figure 3.3D). The
callipyge lambs also had a significantly elevated MEG3 expression (4-fold, P=0.0323) in
supraspinatus. There was a trend (P=0.0678) for MEG8 to express differentially in
supraspinatus (Figure 3.3C). The expression patterns of these imprinted genes in DLK1DIO3 locus were consistent with the previous reports (Bidwell et al. 2004; Perkins et al.
2006).
The expression of several myosin isoforms were examined as markers of the muscle
hypertrophy response. The differential expression of myosin isoforms show the

68
established fiber type changes in callipyge muscle. Previous studies reported significant
and strong up-regulation of muscle genes characteristic of type IIb (MYH4) and downregulation of genes characteristic of type IIa fibers (fast oxidative/glycolytic) (MYH2)
and type 1 fibers (slow oxidative) (MYH7) in hypertrophied muscles (Vuocolo et al.
2007). The present study confirmed this phenotype by examination of a 60-fold increase
in MYH4 expression in the hypertrophied muscles (Figure 3.4A). MYH1 is the most
abundant myosin isoform measured in the skeletal muscles and its mRNA abundance was
significantly elevated in semimembranosus by 2.5-fold (Figure 3.4B). MYH2, which is
characteristic of an intermediate fiber type between fast and slow fibers, was relatively
unchanged in triceps brachi (2.5-fold) but down-regulated in other hypertrophied
muscles with longissimus dorsi has the largest magnitude at 0.125-fold (Figure 3.4C).
The mRNA abundance of MYH7 was only down-regulated in semimembranosus with
0.27-fold, which is different from the previous report indicating a decreased level of
MYH7 in longissimus dorsi (Figure 3.4D). The myosin heavy chain gene expression
results confirmed the reported callipyge phenotype with increased fast-glycolytic and
decreased slow-oxidative myofibers (Carpenter et al. 1996; Vuocolo et al. 2007).
The gene expression pattern of these 25 transcripts was given in Figure 3.5. The
variable gene expression pattern reflected the differences in response to the DLK1
signaling. Five genes including Parkinson Protein 7 (PARK7, also known as DJ-1)
(Figure 3.6A), Deoxynucleotidyltransferase, terminal, interacting protin 1 (DNTTIP1)
(Figure 3.6B), Solute carrier family 22 member 3 (SLC22A3) (Figure 3.6C), proteinlysine methyltransferase METTL21E (METTL21E) (Figure 3.6D), and cAMP specific
phophodiesterase 4D (PDE4D) (Figure 3.6E) were specifically up-regulated in the
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hypertrophied muscles, but not in the non-hypertrophied muscles, resembling the DLK1
expression pattern. The change in gene expression of PARK7 in hypertrophied muscles is
small relative to other four genes, but significantly different from normal muscles with
semimembranosus having the biggest magnitude of 6.1-fold (Figure 3.6A). DNTTIP1 had
the biggest magnitude of increase in longissimus dorsi with 6.8-fold and smallest increase
in semimembranosus with 5.6-fold (Figure 3.6B). There was a substantial up-regulation
of SLC22A3 in hypertrophied muscles with the magnitude ranging from 6.5-fold to 17.8fold (Figure 3.6C). The average mRNA abundance for METTL21E (Figure 3.6D) and
PDE4D (Figure 3.6E) in hypertrophied muscles were 8.4-fold and 5-fold greater relative
to normal lambs. In addition to these 5 transcripts, there is a muscle specific expression
pattern for all the other assayed genes. Since these transcripts were identified from the
microarray and quantitative PCR using longissimus dorsi and semimembranosus, the
majority of these genes were differentially expressed in both of these two muscles. Many
of these genes are metabolic in nature; for example, PFKM was up-regulated in 3 of the 4
hypertrophied muscles and LPL was down-regulated in 2 of the 4 hypertrophied muscles,
therefore they were likely to be involved in the response to the changes of MYH isoforms
and metabolic demands in callipyge lambs.
3.4.3

Effects of Candidate Target Genes on Myh4 and Myh7
Promoter Activity

The muscle specific gene expression analysis identified 5 genes, DNTTIP1, PARK7,
METTL21E, SLC22A3 and PDE4D, whose muscle specific expression pattern is the same
as DLK1. In order to determine if PARK7, DNTTIP1, and METTL21E could influence
myosin isoform expression similar to what occurs in callipyge muscle, a series of
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luciferase assays were conducted to test the effects of these candidate genes on MYH4
and MYH7 promoter activity. The luciferase assays were conducted by co-transfection of
the candidate gene cDNA constructs as effector plasmids together with Myh4
(pGL3IIB2.6) or Myh7 (p-3542β-MHCluc) luciferase reporter plasmids in primary
myoblasts. The amount of effector plasmid that was co-transfected was titrated for each
plasmid with the addition of the null vector (pGWCAT) to maintain equal amounts of
input DNA. After tranfection, the myoblasts were differentiated into myotubes for 3 days.
To validate the expression of the effector protein in cells, the cells were stained with
corresponding antibodies after transfection (DNTTIP1 in Supplementary Figure A1,
PARK7 in Supplementary Figure A2 and METTL21E in Supplementary Figure A3).
These results validated the expression of these constructs and also illustrated the nuclear
localization of DNTTIP1, and the nuclear and cytoplasmic localizations of PARK7,
METTL21E and GWCAT.
There was a dose effect for DLK1 induced MYH4 luciferase activity. Adding DLK1
significantly increased Myh4 luciferase activity at the high concentration (48%) (P=
0.0012) (Figure 3.7A). The same effect was also observed in DNTTIP1 treatment with the
high concentration (24%) of DNTTIP1 resulting in significantly elevation of MYH4
luciferase activity (P< 0.0001) (Figure 3.7C). In this experiment, less DNA was used for
DNTTIP1 because it was a nuclear factor. Conversely, adding METTL21E (60%)
significantly decreased MYH4 luciferase activity (P=0.0126) by 16.5 % (Figure 3.7E). An
opposite dose response was observed in MYH7 luciferase assay for DLK1 and DNTTIP1
treatments. A 35 % decrease in MYH7 luciferase activity was examined by adding a high
concentration of either DLK1 (48%) (Figure 3.7B) or DNTTIP1 (24%) (Figure 3.7C)
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treatment. Adding METTL21E, on the other hand, significantly increased MYH7
luciferase activity even at a low concentration (30%, P=0.0135 relative to control)
(Figure 3.7F).
Since PARK7 was assumed as a positive regulator in PI3K/AKT pathway which was
initiated by the binding of IGF1 to its receptor (Kim et al. 2005a; Fleming-Waddell et al.
2009), different concentrations of IGF1 were applied to the myotubes in order to induce a
differential response in PARK7 treatment. Statistical analysis indicated the overall effect
of PARK7 was significant in both MYH4 (P=0.0004) (Figure 3.8A) and MYH7 (P<0.0001)
(Figure 3.8B) luciferase assays (P=0.0471). Specifically, with a higher concentration of
IGF1 (100 ng/mL) treatment, adding PARK7 even at a low concentration (30%)
significantly increased MYH4 luciferase activity (P=0.0007). There is a similar trend at
IGF1 concentration of 200 ng/mL with 30% input of PARK7 significantly increasing
MYH4 luciferase activity by 20% (Figure 3.8A). No significant difference was found at
low IGF1 concentration (50 ng / mL) and no added IGF1 treatment. There is a dose effect
for IGF1 treatment in MYH4 luciferase assay, however, the MYH7 luciferase activity was
not affected by IGF1 treatment. A dose response for PARK7 was observed in PARK7
induced MYH7 luciferase activity. Adding PARK7 (60%) significantly reduced MYH7
luciferase activity regardless of IGF1 concentrations (Figure 3.8B).
3.4.4

Effects of DLK1 on DNTTIP1 and PARK7 Expression

The luciferase assay indicated both DNTTIP1 and PARK7 are capable of altering
MYH4 and MYH7 gene expression, similar to DLK1. Therefore treatment of myoblast and
myotube with DLK1 was tested to determine its effects on DNTTIP1 and PARK7
expression. Since it had been reported that C2C12 cells over-expressing DLK1 failed to
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proliferate (Waddell et al. 2010), the primary myoblasts were plated onto Matrigel
containing recombinant DLK1 protein to enable DLK1 to act as a ligand for cell surface
receptors. The mRNA abundance of DNTTIP1 was significantly increased by DLK1
treatment in both myoblast and myotubes (Figure 3.9A). Specifically, the DLK1-treated
myoblasts had 1.6-fold increase in DNTTIP1 expression and the DLK1-treated myotubes
had 2-fold increase. The expression of Myh4 was very low in myoblasts and there were
no significant differences between the control and DLK1 treatments (Figure 3.9B).
However, the mRNA abundance of Myh4 was significantly elevated after differentiation
with the DLK1 treated myotubes having 1.8-fold (P<0.0001) higher expression compared
to the control myotubes. The mRNA abundance of Park7 was not significantly changed
in the presence of DLK1 (Figure 3.9C).
3.5

Discussion

In food animal agriculture, there is a need to identify the mechanisms that can
improve the efficiency of muscle growth and protein accretion. Callipyge sheep have
improved feed efficiency with greater than 35% more muscle mass, which proves that
much higher production efficiency is biologically possible. Therefore callipyge muscle
hypertrophy provides a unique model for investigating the genes that are potentially rate
limiting for muscle growth. The 25 transcripts examined in the current study were
initially identified and validated from previous study by which their expressions were
explored at extensive postnatal developmental series (10, 20, 30 days and 80 days)
(Fleming-Waddell et al. 2009). Changes in gene expression during muscle hypertrophy
can be categorized as the primary causative genes, DLK1 and RTL1, which were known
due to the co-localization with the causative mutation and up-regulation with the
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inheritance of the mutation in cis. The secondary effector genes have a directly
physiological response to DLK1 and RTL1 activities, and the tertiary response genes that
indirectly respond to DLK1 signaling or hypertrophy. This study extended the
investigation to several muscles (longissimus dorsi, semimembranosus, semitendinosus,
triceps brachi, supraspinatus, infraspinatus and heart). The muscle specific patterns of
gene expression provide a comprehensive analysis to discern the secondary effectors
response to DLK1 and RTL1 from the tertiary changes in expression due to the muscle
hypertrophy.
The phenotypic data analysis supported the reported callipyge phenotype that the
callipyge lambs share the same body weight as normal lambs (Jackson et al. 1997a;
Freking et al. 1998b), and also confirmed the well-recognized pattern of muscle
hypertrophy that the increase of muscle mass in the pelvic limb and the torso is much
greater than in the thoracic limbs (Jackson et al. 1997c). The gene expression analysis in
DLK1-DIO3 locus showed the established pattern for induction of muscle hypertrophy in
callipyge lambs. There was high level of expression of DLK1 and RTL1 in the callipyge
lambs. DLK1 was only up-regulated in hypertrophied muscles but the up-regulation of
RTL1 was also detected in the 3 non-hypertrophied muscles. The expression levels of
MEG3 and MEG8 were increased in supraspinatus. These combined evidence together
suggested that RTL1 alone is insufficient to induce muscle hypertrophy and reinforce that
DLK1 is the primary inducer of muscle hypertrophy. However, since the biological
activity of RTL1 is not well understood, it is still possible that RTL1 acts in concert with
DLK1 to co-regulate the callipyge phenotype.
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Analysis of several myosin isoforms showed the up-regulation of the fast twitch
glycolytic myosin isoform (MYH4) in all hypertrophied muscles and the down-regulation
of the fast twitch mixed oxidative and glycolytic myosin isoform (MYH2) in
hypertrophied musclses except triceps brachi. The changes in muscle fiber type are
indicative for metabolism, which have been directly associated with elevated postnatal
expression of the DLK1 protein in muscle fibers (White et al. 2008). A decrease in slow
twitch oxidative MYH7 was only detected in the semimembranosus but not in other
hypertrophied muscles, which is inconsistent with previous observation of decreases in
MYH7 expression and smaller oxidative myofibers in longissimus dorsi (bCarpenter et al.
1996; Carpenter & Cockett 2000; Vuocolo et al. 2007; White et al. 2008). The
discrepancy is possibly due to the younger animals used in the current study. The
decreased level of MYH7 may not be evident in these animals.
Among the 25 examined transcripts, five genes, DNTTIP1, PARK7, PDE4D,
SLC22A3, and METTL21E, were up-regulated specifically in hypertrophied muscles,
resembling DLK1 expression pattern in 7 assayed muscles and thus these genes were
considered as the secondary targets in response to DLK1 and RTL1 signaling. Further
luciferase experiments demonstrated Park7 and DNTTIP1 positively regulate MYH4 and
negatively influence MYH7 luciferase activity similar to the effects of DLK1. However,
only the expression of DNTTIP1 was increased in DLK1 treated cells. These combined
results indicated that DNTTIP1 is a direct transcriptional response to DLK1 signaling.
DNTTIP1 (deoxynucleotidyl transferase interacting protein 1), is a transcriptional
factor that negatively regulates the activity of terminal deoxynucleotidyltransferase (TdT),
which is a DNA polymerase that synthesized the N-region of B and T-cell receptor genes,
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independent of a DNA template. (Yamashita et al. 2001). DNTTIP1 is ubiquitously
expressed and exclusively localized in the nucleus and it has a helix-turn-helix and AThook-like motif and preferentially binds to AT-rich regions of double-stranded DNA
(Yamashita et al. 2001; Kubota et al. 2007). Notably, the promoter region of Myh4 gene
contains two AT-rich motifs (Takeda et al. 1992) which suggested that DNTTIP1 may
bind to Myh4 promoter region to active its transcription. Moreover, DNTTIP1 is reported
to interact with HDAC1 and HDAC2 during M phase (Bantscheff et al. 2011). The
HDACs usually down-regulate transcriptional activity by deacetylating histones (Segre &
Chiocca 2011). The interaction with HDACs may facilitate DNTTIP1 to regulate gene
expression in muscles. The function of DNTTIP1 in muscle growth is unclear. But the upregulation of DNTTIP1 was reported in longissimus dorsi and semimembranosus in
callipyge lamb from two previous studies (Fleming-Waddell et al. 2007; FlemingWaddell et al. 2009). The current study confirmed its up-regulation in longissimus dorsi
and semimembranosus, and also revealed its increased levels in semitendinosus and
triceps brachi, along with the regulation of myosin gene expression and the response to
the DLK1 treatment. Taken together, DNTTIP1 could be a seconday effector in response
to DLK1 and it may involve in the differential expression of MYH genes and regulation
of other genes in callipyge lambs.
Since PARK7 was not up-regulated in DLK1-treated cells, it may not act as a direct
transcriptional response to DLK1 signaling. However, due to its increased expression in
hypertrophied muscles and the regulation of MYH4 and MYH7 luciferase activity, it may
have a physiological role in response to the DLK1-induced muscle hypertrophy. PARK7
encodes a ubiquitously expressed, highly conserved protein that was originally identified
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as an oncogene that transforms NIH3T3 cells in cooperation with the activated ras gene
(Nagakubo et al. 1997). PARK7 has been associated with diverse biological processes
including oxidative stress response, transcriptional regulation and cell survival
(Takahashi et al. 2001; Tillman et al. 2007; McNally et al. 2011). The PI3K/AKT
pathway is known for its positive regulation on muscle growth, and the binding of IGF1
to its receptor initiates this pathway. PARK7 was identified to positively regulate
PI3K/AKT pathway by suppressing the phosphatase activity of PTEN in mouse
fibroblasts (Kim et al. 2005a). Thus the up-regulation of PARK7 may lead to the
enhanced activity and prolonged sustained activity of PI3K/AKT pathway and in turn to
elevate the response of the downstream elements in PI3K/AKT pathway to increase
protein synthesis and muscle mass. Moreover, a recent study demonstrated that overexpression of constitutively active AKT resulted in the hypertrophy of glycolytic
myofibers not oxidative myobfiers (Izumiya et al. 2008). This study was supported by
identification a regulatory cascade that regulate AKT activation to drive the metabolic
and contractile specification of fast-twitch muscle fibers (Meng et al. 2013). Therefore,
the significantly higher Myh4 luciferase activity induced by adding PARK7 could be
expected as enhanced activation of AKT. Interestingly, in addition to callipyge animals,
double muscle cattle, in which the expression of Park7 gene was also elevated, had an
increased proportion of white fast-twitch glycolytic fibers as well (Chelh et al. 2011).
Although different from DLK1, METTL21E up-regulated MYH7 and downregulated MYH4 luciferase activity, it may still have a physiological role in callipyge
muscle hypertrophy since it consistently up-regulated in hypertrophied muscles similar to
DLK1. METTL21E has nuclear localization, but it mostly accumulated in perinuclear
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cytoplasm (Supplementary Figure S3). Herein, it may not act as a direct transcriptional
response to DLK1. The results from luciferase assay suggested METTL21E may not
regulate the myosin heavy chain gene expression, but it may be involved in other
biological activities since its multiple function. The METTL21E, known as protein-lysine
methyltransferase METTL21E in Bos taurus, encodes a methyltransferase domain similar
to members of the S-adenosylmethionine (SAM) -dependent methyltransferase family
(Marchler-Bauer et al. 2007). This family of methyltransferases catalyzes the transfer of a
methyl group (CH3) from a donor, generally S-adenosyl-L-methionine (AdoMet), to
various acceptor molecules (Martin & McMillan 2002; Schubert et al. 2003). In human,
there is no METTL21E, but the bovine METTL21E gene shares 51 % similarity to human
METTL21C. Due to the species specificity, the function of METTL21E is not well
defined. However, thousands substrates of SAM-dependent methyltransferases has been
identified. These substrates included nucleic acids for regulation of gene expression,
DNA repair or protection against restriction enzymes, proteins for repair or control of
signal transduction pathways, hormones and neurotransmitters, and biosynthetic
intermediates to produce secondary metabolites (Schubert et al. 2003). These
bioactivities of the substrates may indicate the diverse functional role of METTL21E in
the metabolic changes during the callipyge muscle development.
Both PDE4D and SLC22A3 have increased expression only in hypertrophied
muscles, which implied they may play roles in DLK1-induced muscle hypertrophy. The
luciferase analysis was not done for PDE4D in this study due to the expression of
numerous alternatively spliced transcripts that dictate subcellular localization and the
specific cAMP pools that are affected (Richter et al. 2005). PDE4D is a member of
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Phosphodiesterases (PDEs), which catalyze the hydrolysis of cyclic nucleotides cAMP
into the inactive substrate 5’-AMP. The cAMP signaling is important for muscle
hypertrophy and metabolism (Berdeaux & Stewart 2012). The β2-adrenergic receptors
(β2-ARs) as cAMP inducers in skeletal muscle draw the majority of attention since its
main target are β-agonists. The phenotype observed in callipyge hypertrophy is very
similar to muscle growth induced by the β-agonists agent, which includes increased
muscle mass and decreased adiposity (Kretchmar et al. 1990; Pringle et al. 1993). It has
shown that the activation of PDE4D is an important feedback regulation contributing to
the transient nature of the β2-ARs response and represents a major adaptive mechanism
required for physiological β2-ARs signaling (Liu et al. 2000). Though the callipyge lambs
do not respond to β-agonist supplementation with additional muscle hypertrophy
(Koohmaraie et al. 1996), the up-regulation of PDE4D in hypertrophied muscles may be
associated with a stronger response to the physiological levels of adrenaline in young
growing lambs. The nature of SLC22A3 is an organic cation transporter and SLC22A3
knockout mice did not show overt phenotypic abnormalities indicating it was not
essential for physiological functions (Zwart et al. 2001). Therefore, it is unlikely a direct
transcriptional response to DLK1. Herein, it was also excluded from the luciferase study.
SLC22A3 / OCT3 (Solute carrier 22A3 / Organic cation transporter 3) mediates the
uptake of many important endogenous amines and basic drugs in a variety of tissues
(Chen et al. 2013). Studies have shown that in excretory organs, such as kidney and liver,
SLC22A3 facilitated the uptake of organic cations across the basolateral membrane into
the cell (Ahmadimoghaddam et al. 2012; Ahmadimoghaddam et al. 2013). Though it had
been already reported that SLC22A3 expressed in skeletal muscle (Lee et al. 2009), the
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up-regulation of SLC22A3 in hypertrophied muscles was firstly discovered in our lab. It
is assumed that the high-levels of SLC22A3 may enhance the up-take of amines including
amino acids and biogenic amines to stimulate muscle growth in callipyge lambs. Further
studies will be needed to explore its function in muscle development.
In summary, the present study extended the knowledge on the genes regulation in
callipyge lamb. This study provided additional support that RTL1 alone was not sufficient
to induce muscle hypertrophy, examined the up-regulation of DNTTIP1, PARK7,
SLC22A3, PDE4D and METTL21E in hypertrophied muscles, proposed the regulation of
DNTTIP1 and PARK7 on myosin gene expression and identified DNTTIP1 as a
secondary effector gene responding to DLK1 signaling. The present study also assumed
the possible mechanisms on how these genes influence muscle mass in callipyge lambs.
The callipyge sheep is a valuable model in livestock since its increased muscle growth
and higher feed efficiency. Identification of the genes and the signaling that cause the
callipyge phenotype will enrich the understanding of the postnatal muscle growth in all
meat animal species, and will help to solve the world’s poverty problem by producing
higher protein accretion.
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Figure 3.1 Muscle Hypertrophy in Callipyge Lambs.
There were no differences in the birth weights (BW) and live weights (LW) between
callipyge (+/C) and normal lambs (+/+). Callipyge lambs had significantly heavier
longissimus dorsi (LD), semimembranosus (SM), semitendinosus (ST) and triceps
brachii (TB) muscles. There were no differences in muscle weights for the supraspinatus
(SS), infraspinatus (IS) and heart (HT). Significant differences are indicated by (*; P <
0.05, or **; P < 0.01) between callipyge and normal lambs within each muscle.
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Figure 3.2 Transcript Abundance of RPLP0 in 7 Muscles.
Least square means and standard errors for log transcript abundance in 100 ng of total
RNA are shown for each muscle and genotype. Callipyge animals indicated by +/C, and
normal animals are represented by +/+. LD, SM, ST, and TB are hypertrophied muscles,
SS, IS and HT are non-hypertrophied muscles. RPLP0 was used as a control to confirm
equivalent RNA input into cDNA synthesis and qPCR assays, and no significant
difference was detected between the two genotypes in all the muscles analyzed.
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Figure 3.3 mRNA Abundance of Genes From the DLK1-DIO3 Locus.
Least square means and standard errors for log transcript abundance in 100 ng of total
RNA are shown for each muscle and genotype. Callipyge animals indicated by +/C, and
normal animals are represented by +/+. LD, SM, ST, and TB are hypertrophied muscles,
SS, IS and HT are non-hypertrophied muscles. Samples are from 30 – 35 days of age
lamb. DLK1 shown in (A), RTL1 in (B), MEG8 in (C) and MEG3 in (D). Significant
differences are indicated by (*; P < 0.05, or **; P < 0.01) between callipyge and normal
lambs within each muscle.
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Figure 3.4 mRNA Abundance of Myosin Heavy Chain Genes.
Least square means and standard errors for log transcript abundance in 100 ng of total
RNA are shown for each muscle and genotype. Callipyge animals indicated by +/C, and
normal animals are represented by +/+. LD, SM, ST, and TB are hypertrophied muscles,
SS, IS and HT are non-hypertrophied muscles. Samples are from 30 – 35 days of age
lamb. MYH4 shown in (A), MYH1 in (B), MYH2 in (C) and MYH7 in (D). Significant
differences are indicated by (*; P < 0.05, or **; P < 0.01) between callipyge and normal
lambs within each muscle.
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Figure 3.5 Hierarchal Clustering of Candidate Gene Expression Pattern in 7 Muscles.
Columns for the seven muscles were fixed and rows representing gene expression were
subject to clustering. The fold change of transcript abundance for the ratio of callipyge to
normal was transformed to log2 . The magnitude of the fold change is represented by red
if gene expression was higher in callipyge than normal or blue if expression was lower in
callipyge than normal muscle. Significant differences are indicated by (*; P < 0.05, or **;
P < 0.01) between callipyge and normal lambs within each muscle.
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Figure 3.6 Transcript Abundance of the Candidate Target Genes in 7 Muscles.
Least square means and standard errors for log transcript abundance in 100 ng of total
RNA are shown for each muscle and genotype. Callipyge animals indicated by +/C, and
normal animals are represented by +/+. LD, SM, ST, and TB are hypertrophied muscles,
SS, IS and HT are non-hypertrophied muscles. PAKR7 (A), DNTTIP1 (B), SLC22A3 (C),
METTL21E (D), and PDE4D in (E) are up-regulated in hypertrophied muscles but not in
non-hypertrophied muscles. Significant differences are indicated by (*; P < 0.05, or **; P
< 0.01) between callipyge and normal lambs within each muscle.
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Figure 3.7 Effects of DLK1, DNTTIP1 and METTL21E on Myosin Promoter Activity.
Increased Myh4 and decreased Myh7 luciferase activity was examined in DLK1 (A:
Myh4; B: Myh7) and DNTTIP1 (C: Myh4; D:Myh7) over-expressed myotubes. Overexpression of METTL21E decreased Myh4 (E) and increased Myh7 (F) luciferase activity.
Primary myoblasts were transfected with different compositions (indicated by percentage
in graph) of effector constructs together with Myh4 or Myh7 luciferase plasmids. The
pRL-SV40 plasmid was constantly transfected into cells as a transfection efficiency
control. The transfected cells were put into 96-well plates in growth media overnight and
fused into myotubes for 3 days. Luciferase activity was adjusted for transfection
efficiency by multiplying the firefly luciferase activity of a given well by the ratio of
mean renilla luciferase activity for all wells divided by renilla luciferase activity of the
given well to produce units of adjusted luciferase activity. Differing lower case letters
indicate significance (P < 0.05) within each test.
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Figure 3.8 Effect of Park7 on Myosin Promoter Activity.
(A) Increased PARK7 input (30 % and 60 %) significantly elevated Myh4 luciferase
activity at high concentrations of IGF1 (100 ng / mL and 200 ng / mL). (B) Adding
PARK7 (30% and 60%) significantly decreased Myh7 luciferase activity regardless of
IGF1 concentration. Primary myoblasts were transfected with different compositions of
effector constructs pPARK7-pcDNA3.2 and pGWCAT- pcDNA3.2 (control) plasmids
together with Myh4 or Myh7 luciferase plasmids.The pRL-SV40 plasmid was constantly
transfected into cells as a transfection efficiency control. The transfected cells were put
into 96-well plates in growth media overnight and fused into myotubes for 3 days. IGF1
was added to the culture 24h after differentiation at the indicated concentration. Different
composition of the effector gene in the transfected plasmid complex was indicated as
percentage. Luciferase activity was adjusted for transfection efficiency by multiplying
the firefly luciferase activity of a given well by the ratio of mean renilla luciferase
activity for all wells divided by renilla luciferase activity of the given well to produce
units of adjusted luciferase activity. Differing lower case letters indicate significance (P <
0.05) within each IGF1 treatment.
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Figure 3.9 Transcript Abundance of DNTTIP 1, Myh4 and Park7 in DLK1 Treated
Myoblast and Myotubes.
Primary myoblasts cultured on Matrigel (Control) or Matrigel plus recombinant DLK1
protein (Dlk1) for 24 hours and induced to differentiation for 48 hours. (A) DNTTIP 1
expression was increased in DLK1 treatment in both myoblast and myotubes. (B) The
mRNA abundance of Myh4 was highly elevated in DLK1-treated myotubes but not in
myoblast. (C) No significant difference was observed in the expression of Park7.
Differing lower case letters indicate significance (P<0.05) between control and Dlk1
treatment within myoblast or myotubes.
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CHAPTER 4. PARK7 EXPRESSION INFLUENCES MYOTUBE SIZE AND
MYOSIN EXPRESSION IN MUSCLE

4.1

Summary

Callipyge sheep exhibit postnatal muscle hypertrophy due to the up-regulation of
DLK1 and/or RTL1. The up-regulation of PARK7 was identified in hypertrophied muscles
by microarray analysis and further validated by quantitative PCR. The expression of
PARK7 in hypertrophied muscle of callipyge lambs was confirmed to be up-regulated at
the protein level. PARK7 was identified to positively regulate PI3K/AKT pathway by
suppressing the phosphatase activity of PTEN in mouse fibroblasts. The purpose of this
study was to investigate the effects of PARK7 in muscle growth and protein accretion in
response to IGF1. Primary myoblasts isolated from Park7 (+/+) and Park7 (-/-) mice
were used to examine the effect of differential expression of Park7. The Park7 (+/+)
myotubes had significantly larger diameters and more total sacomeric myosin expression
than Park7 (-/-) myotubes. IGF1 treatment increased the mRNA abundance of Myh4,
Myh7 and Myh8 between 20-40% in Park7 (+/+) myotubes relative to Park7 (-/-). The
level of AKT phosphorylation was increased in Park7 (+/+) myotubes and this increase
was substantially elevated in Park7 (+/+) myotubes at all levels of IGF1 supplementation.
After removal of IGF1, the Park7 (+/+) myotubes maintained about higher signal
intensity through 3 hours. PARK7 positively regulates the PI3K/AKT pathway by
inhibition of PTEN phosphatase activity in skeletal muscle. The activity of PARK7 in
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muscle can increase protein synthesis and result in myotube hypertrophy. These results
support the hypothesis that elevated expression of PARK7 in callipyge muscle would
increase levels of AKT activity to cause hypertrophy in response to the normal IGF1
signaling in rapidly growing lambs and PARK7 could be a key regulator in protein
accretion and muscle growth.
Keywords
PARK7, skeletal muscle AKT, hypertrophy, callipyge sheep
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4.2

Background

Callipyge sheep exhibit postnatal muscle hypertrophy, with higher rates of protein
accretion and lower rates of fat deposition compared to wild type sheep (Jackson et al.
1997b; Freking et al. 1998a). The muscle hypertrophy phenotype is most prominent in
the loin and hind-quarters at 4-6 weeks of age due to increased muscle fiber diameter,
while the muscle fiber number remains unchanged (Carpenter et al. 1996; Jackson et al.
1997c; Duckett et al. 2000).After 5 weeks of age, fiber type proportions shift to a greater
number of fast-twitch, glycolytic muscle fibers at the expense of oxidative fibers in
callipyge muscles (Carpenter et al. 1996; Carpenter & Cockett 2000). The callipyge
mutation is a single nucleotide polymorphism in the DLK1-DIO3 imprinted gene cluster
(Freking et al. 2002; Smit et al. 2003) that causes up-regulation of Delta-like 1 (DLK1)
and Retrotransposon-like 1 (RTL1) in hypertrophied muscles (Charlier et al. 2001a;
Bidwell et al. 2004; Murphy et al. 2006; Perkins et al. 2006; Fleming-Waddell et al.
2007). Transgenic mice over-expressing Dlk1 exhibited increased muscle mass and
myofiber diameter (Davis et al. 2004). Muscle-specific gene ablation of Dlk1 in the
mouse resulted in reduced body weight and skeletal muscle mass due to reductions in
myofiber numbers (Waddell et al. 2010). Conversely, over-expression of Dlk1 in culture
was shown to inhibit myoblast proliferation and enhance myotube differentiation
(Waddell et al. 2010). The expression of DLK1 has a clear role for inducing muscle
hypertrophy although the biological activity of RTL1 is not well understood and a
synergistic effect with DLK1 has not been ruled out in the callipyge phenotype.
Microarray analysis of gene expression identified 199 genes that were differentially
expressed in semimembranosus muscle of callipyge and normal lambs (Fleming-Waddell

93
et al. 2009). Twenty-five transcripts were further verified by quantitative PCR in two
hypertrophied muscles (semimembranosus and longissimus dorsi) and one nonhypertrophied muscle (supraspinatus). Parkinson Protein 7 (PARK7; also known as DJ-1)
expression was consistently up-regulated in hypertrophied muscles.
PARK7 encodes a ubiquitously expressed, highly conserved protein that has been
shown to be involved in diverse biological processes including oxidative stress response,
transcriptional regulation and cell survival modulation. A mutation causing a loss of
function of PARK7 was found to be responsible for a recessive early-onset form of
Parkinson’s disease (Bonifati et al. 2003). PARK7 protects neurons and somatic cells
from oxidative stress by oxidizing itself to a more acidic form (Mitsumoto & Nakagawa
2001). PARK7 could modulate transcription through interaction with proteins. PARK7
enhances the NF-κB pathway by binding to Cezanne (McNally et al. 2011), restores
androgen receptor transcription activity by bound to PIAS1 (protein inhibitor of activated
STAT,1) (Takahashi et al. 2001), and up-regulates human tyrosine hydroxylase gene
expression by interaction and inhibition of PSF (Splicing factor proline/glutamine-rich;
also known as Polypyrimidine tract-binding protein-associated splicing factor) (Zhong et
al. 2006). In addition, PARK7 could mediate cell survival signaling pathways. Park7 was
originally identified as an oncogene that transforms NIH3T3 cells in cooperation with the
activated Ras gene (Nagakubo et al. 1997). Later, substantial studies have shown that
PARK7 is involved in the progression of many cancers including lung cancer (Clements
et al. 2006), breast cancer (Pucci-Minafra et al. 2008), pancreatic cancer (He et al. 2011),
astrocytomas (Miyajima et al. 2010), leukemias (Liu et al. 2008), and renal cell
carcinomas (Eltoweissy et al. 2011). The mechanism of how PARK7 is involved in
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cancer development is complex and studies have shown that PARK7 could bind to
Topors/p53BP3, p53 (Shinbo et al. 2005; Fan et al. 2008b), DAXX (death domainassociated protein), ASK1 (Apoptosis signal-regulating kinase 1) (Junn et al. 2005;
Karunakaran et al. 2007) and PTEN (Phosphatase with tensin homology) (Kim et al.
2005a) to regulate cell cycle progression.
PARK7 was shown to suppress the phosphatase activity of PTEN which is a negative
regulator of the phosphatidylinositol 3' kinase (PI3K)/AKT pathway (Kim et al. 2005a).
The activated PI3K phosphorylates phospholipid phosphatidylinositol-4, 5-bisphosphate
(PIP2) to phosphatidylinositol-3, 4, 5-trisphosphate (PIP3), which creates a lipid-binding
site on the cell membrane for the serine/threonine kinase AKT (v-akt murine thymoma
viral oncogene homolog 1 /protein kinase B). AKT is activated by phosphorylation of 3’Phoshphoinositide-dependent protein kinase 1(PDK1) (Latres et al. 2005). PTEN
phosphatase activity catalyzes the reverse reaction of PIP3 back to PIP2 resulting in less
activated AKT (Maehama & Dixon 1998). PARK7 acts to suppress PTEN phosphatase
activity and, therefore, can modulate levels of AKT activity (Kim et al. 2005a). The
phosphorylation of AKT activates several pathways to regulate cell proliferation
(Sandirasegarane & Kester 2001), cell survival (Lawlor & Rotwein 2000) and protein
synthesis (Rommel et al. 1999).
The PI3K/AKT pathway is known for its positive regulation on muscle growth
(Bodine et al. 2001; Rommel et al. 2001). The binding of insulin-like growth factor 1
(IGF1) to its receptor initiates this pathway and activates AKT. The role of IGF1 for
stimulating muscle growth had been well established. Addition of IGF1 into culture
medium induced hypertrophy in C2C12 myotubes through enhanced activation of AKT

95
(Rommel et al. 2001). Muscle-specific over-expression of Igf1caused muscle
hypertrophy in mice (Musaro et al. 2001) and conversely muscle-specific inactivation of
the Igf1 receptor impaired muscle growth due to reduced muscle fiber number and size
(Mavalli et al. 2010). It also had been well demonstrated that the activation of AKT is
sufficient to induce hypertrophy. Over-expression of activated Akt in muscle fibers results
in significantly larger fiber size (Bodine et al. 2001; Pallafacchina et al. 2002).
Transgenic mice expressing a constitutively active form of Akt in muscle exhibit rapid
skeletal muscle hypertrophy (Lai et al. 2004). Conversely, genetic depletion of Akt in
mice leads to a smaller body size and shorter life span (Chen et al. 2001).
Though extensively studied, the role of PARK7 in muscle growth had not been
reported until recently. Transcriptomic and proteomic analyses in quadriceps muscles in
myostatin-null mice, which exhibit a muscle hyperplasia phenotype, found elevated
levels of PARK7 and phosphorylation of AKT (Chelh et al. 2009). Further work by the
same group in double-muscled cattle also showed higher PARK7 expression in doublemuscled fetuses compared to normal controls (Chelh et al. 2011). In food animal
agriculture, there is a need to identify genes that can increase muscle growth and protein
accretion. The identification of elevated expression of PARK7 in hypermuscular animals
suggests PARK7 could play a functional role in muscle growth and could be a ratelimiting gene in protein accretion. Differential expression of PARK7 was examined in
this study using Park7 (+/+) and Park7 (-/-) mouse models to investigate the effects of
Park7 in muscle growth and protein accretion in response to IGF1. Here the elevation of
PARK7 was proposed as part of the physiological mechanism for the induced muscle
hypertrophy in callipyge lambs.
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4.3
4.3.1

Materials and Methods

Mice and Animal Care

Mice with the Park7 locus inactivated by gene targeting [Park (-/-)] are available
from JAX mice® (Strain 006577, Jackson Laboratories, Bar Harbor, ME). The initial
Park7 (-/-) mouse was back crossed with C57BL6 to produce Park7 (+/+) (+/-) and (-/-)
mice. Twenty females with 4 Park7 (+/+), 12 (+/-) and 4 (-/-) animals and twenty-five
males with 4 Park7 (+/+), 11 (+/-) and 10 (-/-) were examined to analyze the live animal
growth. The carcass and internal organ weights were measured on a total of 18 males (4
Park7 (+/+), 6 (+/-) and 8 (-/-) animals) and 16 females (4 Park7 (+/+), 8 (+/-) and 4 (-/-)
animals). Mice maintenance and experimental use were performed according to protocols
approved by the Purdue Animal Care and Use Committee.
4.3.2

RNA Isolation and Quantitative PCR Analysis

RNA from cultured cells was extracted and purified using Nucleo Spin RNA II
columns (Machery-Nagel Inc., Easton, PA USA). First strand cDNA was synthesized
from RNA using random hexamer and oligo dT priming and moloney murine leukemia
virus reverse transcriptase (MMLV, Life Technologies) were used to produce random
primed cDNA. Quantitative PCR measurements were performed using the SA Bioscience
SYBR Green Supermix (QIAGEN, Valencia, CA USA) reagents on an iCycler RealTime PCR Detection System (Bio-Rad Inc., Hercules, CA USA). Each reaction was
carried out in 15 µl reaction volumes of SA Bioscience SYBR Green Supermix with 5
pM of each primer and diluted first-strand cDNA. All cDNA samples were measured in
duplicate. Ribosomal protein large protein 38 (Rplp38) was used as the housekeeping
gene control for ΔCT calculation [ΔCT = (CT of the target gene) – (average CT of
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housekeeping genes)]. Primer sequences were listed in Additional file 3. Fold expression
values were calculated using 2-ΔΔCT methods(Livak & Schmittgen 2001), where ΔΔCT =
(ΔCT of the treatment sample) – (ΔCT of control treatment samples) with no added IGF1
as control treatment and normalized to 1. Statistical significance was determined by
ANOVA.
4.3.3

Primary Myoblast Isolation and Culture

Primary myoblasts were isolated from hind limb skeletal muscles at 3-5 weeks of age.
Muscles were washed with Dulbecco’s Phosphate-Buffered Saline (DPBS), minced and
digested in type I collagenase and dispase B mixture (Roche Applied Science,
Indianapolis, IN USA). The digested muscle pulp was then filtered through a 100 µm
filter (CellTrics®, Partec Inc., Swedesboro, NJ USA) to remove large muscle fiber debris
and then plated on culture dishes. In 3 days, the cells together with the small debris were
collected and digested with 0.025% trypsin for 10 minutes with agitation. Cells were
seeded in growth media (F-10 Ham’s medium supplemented with 20 % fetal bovine
serum, 100 units of penicillin, 100 µg of streptomycin,0. 292 mg/ml of L-glutamine, , and
4 ng/mL basic fibroblast growth factor) on rat-tail collagen (Roche Applied Science)coated dishes with preplating on non-coated plates for 45 minutes to deplete fibroblasts
as previous described (Waddell et al. 2010; Liu et al. 2012). Myoblasts were
differentiated into myotubes after plating cells at approximately 80% confluency on
Matrigel (BD Biosciences, San Jose, CA USA) coated plates and the addition of fusion
media consisting of DMEM supplemented with 5 % horse serum, 100 units of penicillin,
100 µg of streptomycin, and 0. 292 mg/ml of L-glutamine. Long®R3 IGF1 (Sigma-
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Aldrich Co, St Louis, MO USA) was added to the fusion medium for 15 minutes at 3
days after differentiation. Cells were collected for analysis of protein expression.
4.3.4

Protein Extraction and Western Blots Analysis

Semimembranosus and supraspinatus muscles were extracted from 4 callipyge and 4
normal lambs at 30-35 days. Samples were frozen immediately after dissection and
homogenized in RIPA buffer [50 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA, 10 %
TritonX100, 0.5 % Deoxycholate, 0.1 % SDS and 1 × complete protease inhibitor (Roche
Applied Science)]. Samples were centrifuged at 10,000 × g for 10 minutes at 4 ℃. The
supernatant was transferred into ultracentrifuge tubes and centrifuged at 50,000 × g for 15
minutes at 4 ℃.
Proteins were quantified by BCA assay (Thermo Fisher Scientific Inc, Rockford, IL
USA) per manufacturer’s recommendation. A total of 60 µg of protein from each muscle
sample was diluted in SDS loading buffer, denatured by heating for 5 minutes in boiling
water and loaded in the 6 %-18 % gradient SDS-PAGE gel. The gel was transferred to
PVDF membrane by semi-dry transfer using 20 % methanol, 40 mM glycine, 0.15 %
ethanolamine, 0.2% SDS at 180 mA for 1h 45 min. PVDF membrane was blocked
overnight with agitation in 5% sodium caseinate in PBS with 0.1 % Tween 20.
Antibodies used for blotting were goat polyclonal anti-Park7 (sc-27006, Santa Cruz
Biotechnology, Santa Cruz, CA USA), anti-DLK1 (provided by Dr. Ross L. Tellam,
CSIRO), and secondary antibodies were rabbit anti-goat antibody conjugated HRP or
goat anti-rabbit conjugated HRP respectively. The blots were incubated in primary
antibody 2 hours at room temperature with a dilution of 1:1000. After washing 3 times
with DPBS, the blots were incubated with secondary antibody with dilution of 1:20000.
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Super Signal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific) was used
to detect HRP on immunoblots. The blots were visualized using Gel Logic 2200 PRO
(Carestream Molecular Imaging System) with exposure times of 2-6 minutes. Carestream
Molecular Imaging Software was used to quantify the chemiluminescent signal intensity.
4.3.5

Analysis of Myotube Differentiation and Size

Primary myotubes were fixed in 4 % formaldehyde and permeabilized in 0.5 % Triton
X-100. Cells were blocked in 1 % bovine serum albumin (BSA) in PBS for 1 hour at
room temperature and stained with 1:1000 anti-myosin heavy chain antibody (MF20,
Developmental Studies Hybridoma Bank, Iowa City, Iowa USA) for 2 hours. Cells were
washed in PBS, and then incubated in 1:1000 Alexa Fluor 594-conjugated donkey antimouse IgG secondary antibody (Life Technologies) for 1 hour. Finally, cells were
mounted with Prolong Gold antifade reagent with DAPI (Life Technologies). The IP Lab
software (Scanalytics Inc., Madison, WI USA) and Leica DM6000 microscope were used
to acquire pictures.
The fusion index was defined as the ratio of nuclei within the myotubes (>2 nuclei) to
the total number of nuclei. The average number of nuclei per myotube was determined by
counting over 500 nuclei from randomly chosen MHC-positive cells. Myotube diameters
were measured at 5 points along the entire tube. A total of 150 counts were examined for
each genotype in the experiment.
4.3.6

In situ ELISA Quantification of Myosin Expression

Primary myoblasts were put into Matrigel coated-96-well plate at a high density. The
myoblasts were fused into myotubes for 3 days in fusion media with different
concentration (12.5, 25, 50, 100 and 200 ng / mL) of IGF1. The mature myotubes were
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fixed in 4 % formaldehyde in PBS for 5 minutes at room temperature, washed 3 times
with PBS and permeabilized with 0.5 % Triton×100 for 5 minutes. After washing 3 times
with PBS, the cells were blocked for 1 hour in 1 % BSA in PBS. Cells were incubated
with anti-myosin heavy chain antibody (MF20, Developmental Studies Hybridoma Bank)
diluted in 0.1 % BSA overnight at 4 ℃, and washed 5 times in PBS. Secondary antibody
(Donkey anti-mouse IgG, Life Technologies) were diluted in 0.1 % BSA and filtered
through 0.2 µM filters. Cells were incubated in secondary antibody for 1 hour and
washed 5 times with PBS.
The fluorescence signals were read on Tecan Genios Pro (Tecan Group Ltd.,
Morrisville, NC USA) plate reader and results were analyzed using SAS 9.2 software and
ANOVA procedure with IGF1 and genotype as main effects.
4.3.7

AKT Phosphorylation in Primary Myotubes

Cultured primary myoblasts or myotubes were used to examine AKT phosphorylation.
Different concentrations of IGF1 were added into culture for 15 minutes to induce
phosphorylation of AKT. For the PTEN inhibitor experiment, different concentrations (0,
100 nM and 800 nM) of VO-OHpic trihydrate (Sigma-Aldrich) were added into culture
and incubated with myotubes for 15 minutes after removal of IGF1. For testing sustained
activity of phosphorylation of AKT, IGF1 was removed 15 minutes after incubation with
myotubes. The cells were incubated in normal differentiation conditions and cell lysis
was collected at the indicated time points (0, 45, 90, 180, 360, 720 minutes). Cells
attached to plates were rinsed with ice-cold DPBS, and scraped on ice in cell lysis buffer
(50 mM Tris, pH 7.5, 150 mM NaCl, 20 mM sodium fluoride, 1 % Triton 100, 1 X phosstop (Roche Applied Science) and 1 × complete protease inhibitor cocktail ). Cells were
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collected in 1.5 mL microcentrifuge tubes, rotated for 45 minutes, and centrifuged at
12,000 × g for 10 minutes at 4 ℃ to remove insoluble debris.
A total of 45 µg protein from each cell sample was diluted in SDS loading buffer, and
loaded in the 6 %-18 % gradient SDS-PAGE gel. The gel electrophoresis and transfer to
PVDF membranes were the same as described above. The PVDF membranes were
blocked in 5 % non-fat milk in Tris-Buffered Saline (TBS) with 0.1 % Tween 20 for 3
hours. Antibodies used for blotting were rabbit polyclonal anti-AKT (Cat #: 4685, Cell
Signaling Technology, Danvers, MA USA), anti-phospho-AKT (Ser473) (Cat #: 4695
Cell Signaling Technology), anti-PTEN (Cat #: 9188 Cell Signaling Technology). The
primary antibody was incubated at 4 ℃ overnight at a dilution of 1:1000. The goat antirabbit conjugated HRP was used as secondary antibody and was incubated for 1 hour at
4 ℃ at a dilution of 1:20000. The visualization of blots was the same as described above.
4.4
4.4.1

Results

Up-regulation of PARK7 in Hypertrophied Muscle of
Callipyge Lambs

Semimembranosus and supraspinatus muscle samples were collected from 4
callipyge and 4 normal lambs at 30-35 days of age when muscle hypertrophy is
detectable by muscle mass. The semimembranosus from the pelvic limb undergoes the
largest magnitude of hypertrophy and supraspinatus from the thoracic limb does not
become hypertrophied (Koohmaraie et al. 1995; Jackson et al. 1997b). Western blots
(Figure 4.1A) showed that PARK7 protein expression was elevated about 3-fold
(P=0.027; Figure 4.1B) in the semimembranosus of callipyge animals (+/C) but not in
supraspinatus. Elevated levels of DLK1 protein were also confirmed in the callipyge
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semimembranosus. No detectable DLK1 expression was found in the muscles of normal
animals and non-hypertrophied muscles, along with a reduced PARK7 expression in
these same animals and tissues.
4.4.2

Effects of Park7 Genotype on Myosin Heavy Chain
Gene Expression

The initial Park7 (-/-) mouse was obtained from Jackson Laboratory and back crossed
with C57BL6 mice to generate Park7 (+/+), (+/-) and (-/-) littermate mice. Live animal
body weights were monitored and collected from 3 – 6 weeks of age. Mice were
euthanized at 6 weeks and carcass (muscle and skeleton) weight and internal organs
weights were collected. The phenotypic data from male and female mice was analyzed
separately to account for gender differences. No significant differences were found
between genotypes for analysis of live weight by age, carcass weight by live weight, or
organ weight by live weight analysis in males or females (Figure B.1 and Table B1).
The expression of PARK7 protein in the vastus lateralis muscle was examined to
verify the loss of expression in Park7 (-/-) mice (Figure 4.2). The results showed that the
expression of PARK7 was easily detectable in the muscles in Park7 (+/+) and Park7 (+/-)
animals, with lower expression in heterozygotes (+/-). No PARK7 protein was detectable
in Park7 (-/-) muscles.
Primary myoblasts were isolated from Park7 (+/+) and Park7 (-/-) animals and fused
into myotubes in order to model the effect of Park7 levels on growth and myosin
expression. The relative sizes of myotubes were determined after 72hours of
differentiation in fusion media (Figure 4.3A). The fusion index was calculated to
determine the proportion of myoblasts that fused into myotubes, and myotube diameters
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were measured to estimate relative myotube size. There were no differences (p=0.4103)
in the fusion index between the Park7 (-/-) and (+/+) cultures (Figure 4.3B). Park7 (+/+)
myotubes were significantly larger (1.6-fold; p<0.0001) than Park7 (-/-) myotubes
(Figure 4.3C). These results indicated that Park7 activity can influence myotube growth
through a hypertrophy mechanism. An in vitro ELISA assay was performed to detect
total sarcomeric myosin protein accretion to test the hypertrophy mechanism. IGF1
treatments were included due to its well-established role in regulating muscle
hypertrophy (Bodine et al. 2001; Rommel et al. 2001). Statistical analysis (Figure 4.4)
indicated the overall effect of genotype was significant (p=0.0471) with the Park7 (+/+)
myotubes having about 10% higher myosin expression than Park7 (-/-) myotubes,
regardless of IGF1 treatment. All IGF1 treatments had a significant effect compared to no
added IGF1 (p=0.0015), with 34 % higher myosin expression in IGF1 treated myotubes.
However, the genotype by IGF1 interaction effect was not significant (p=0.5208).
Quantitative PCR was used to detect the effect of Park7 genotype on Myh4, Myh7,
Myh8 and Myh3 expression in IGF1 treated mature myotubes (Figure 4.5). The mRNA
abundance of Myh4 was 40 % greater (p=0.0032) in Park7 (+/+) myotubes, relative to
Park7 (-/-) myotubes. The addition of IGF1 in culture induced significantly higher Myh4
expression with 1.6-fold increase at 10 ng / mL, 1.9-fold increase at 25 ng / mL and 1.3fold increase at 50 ng / mL of IGF1 respectively. The Myh7 and Myh8 genes had similar
expression patterns as Myh4. The mRNA abundance of Myh7 and Myh8 were increased
20 % (p=0.0018) and 30 % (p=0.0001) respectively in Park7 (+/+) myotubes. IGF1 also
stimulated Myh7 and Myh8 mRNA expression, but only at the lower concentration (10 ng
/ mL) with 23 % increase in Myh7 and 10 % increase in Myh8 respectively, relative to the
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treatment without IGF1. At the high concentration of IGF1 (50 ng / mL), Myh7
expression dropped 12 % and Myh8 expression dropped 16 % compared to the treatment
without IGF1. Myh3 was the only isoform measured that showed no genotype effect or
IGF1 effect. There was no significant genotype by IGF1 interactions for the four myosin
isoforms.
4.4.3

Effect of Park7 Genotype on Phosphorylation Level of
AKT (S473)

In order to explore the mechanism of Park7 regulation on myotube size and myosin
gene expression, a series of experiments were conducted to assess the activation of AKT
by phosphorylation at S473 in presence or absence of Park7. It has been demonstrated
that PARK7 can suppress PTEN phosphatase activity, which would have the effect of
increasing receptor tyrosine kinase signaling through AKT (Kim et al. 2005a). IGF1 was
used to test the effect of Park7 genotype on the phosphorylation of AKT. The level of
phosphorylation of AKT was elevated in Park7 (+/+) myotubes relative to Park7 (-/-) in
5% horse serum differentiation media without added IGF1 (Figure 4.6). The
phosphorylation of AKT was substantially elevated in Park7 (+/+) myotubes at all levels
of added IGF1. To investigate if the activity of PARK7 could be mimicked by inhibition
of PTEN function, VO-OHpic trihydrate, a known effective PTEN inhibitor (Rosivatz et
al. 2006) was introduced into this study. Myotubes were first treated with IGF1 (5 ng /
mL) for 15 minutes to induce increased phosphorylation of AKT. Different
concentrations of VO-OHpic trihydrate was then added for an additional 15 minutes
after removing IGF1. The addition of VO-OHpic trihydrate at 800 nM increased the level
of AKT phosphorylation in Park7 (-/-) myotubes and eliminated the differences between
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the two Park7 genotypes (Figure 4.7A). There were no detectable differences in PTEN
protein levels (Figure 4.7A) or RNA expression (Figure 4.7B, p= 0.6057). This indicates
that PARK7 inhibits the activity of PTEN but not its expression levels.
Since increased phosphorylation of AKT was found in Park7 (+/+) myotubes, the
timing and duration of the elevated phospho-AKT was tested. Myotubes were treated
with IGF1 for 15 minutes and protein was collected at several time points up to 12 hours.
Western blots showed increased phosphorylation of AKT in Park7 (+/+) myotubes
(Figure 4.8A). Quantitative analysis of relative signal intensity based on the ratio of
phospho-AKT to total AKT indicated a 2-fold higher level of P-AKT in Park7 (+/+)
myotubes relative to Park7 (-/-) myotubes with no added IGF1 (Figure 4.8B). The level
of AKT phosphorylation in Park7 (+/+) myotubes reached its maximum at 45 minutes at
3.4-fold higher signal intensity than Park7 (-/-) myotubes after removal of IGF1. Park7 (/-) myotubes had maximum phosphorylation at 90 minutes and the decreases in
phosphorylation over time were similar with Park7 (+/+) myotubes, generally
maintaining approximately 20% higher signal intensity through 12 hours.
4.5

Discussion

Overall, the present results indicate that differential expression of Park7 altered the
response to IGF1 signaling through inhibition of PTEN, and further affected myotube
growth and protein accretion. A previous study showed elevated PARK7 expression in
callipyge sheep at the transcriptional level (Fleming-Waddell et al. 2009). These western
blot results confirmed the increased expression of PARK7 in hypertrophied muscles at
the protein level.
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The Park7 (-/-) mice lack obvious developmental abnormalities and no significant
difference was found between Park7 (+/+) and (-/-) animals in vivo when we compared
body weight, carcass weight and internal organ weight. These results were consistent
with others findings, which indicated no significant differences in body weights between
the two genotypes from birth to 12 months (Chandran et al. 2008). Skeletal muscle
growth in live animals is stimulated by different hormones such as IGF1, androgens and
β-adrenergic agonists to initiate multiple signaling pathways to regulate growth.
Therefore, the loss of Park7 functions in Park7 (-/-) mice may be compensated by other
hormones and signaling pathways in vivo. Furthermore, the viability of Park7 (-/-) mice
suggests that Park7 is not essential for animal growth. An in vitro cell culture model was
introduced to this study to investigate the effects of differential expression of Park7 in
myogenesis. The in vitro comparison of myotube size showed Park7 (+/+) myotubes had
a bigger size and higher myosin expression, but no significant change in the fusion index,
which indicates Park7 causes myotube hypertrophy (increased myofiber diameter), not
hyperplasia (increased myofiber number). This result also supports the idea that PARK7
is part of the physiological mechanism for the induced muscle hypertrophy in callipyge
lambs.
The PI3K/ AKT pathway is one of the primary targets of IGF1 signaling and has been
well characterized for its positive regulation on muscle growth (Bodine et al. 2001;
Rommel et al. 2001). The postnatal muscle mass and myofiber size generally reflects
protein accretion. AKT stimulates protein synthesis by activating mammalian target of
rapamycin (mTOR) and its downstream effectors. This study showed that the Park7 (+/+)
myotubes had a higher increase of phosphorylation of AKT compared to Park7 (-/-) after
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IGF1 stimulation, which induced significantly more total sarcomeric protein accretion.
Notably, this increase of protein accretion reached saturation at IGF1 concentrations of
25 ng / mL and above. Higher levels of Myh4, Myh7 and Myh8 mRNA expression were
also observed in Park7 (-/-) myotubes. Myosin transcription as well as translation was
elevated. Myh3, also known as embryonic myosin heavy chain 3, was the only myosin
gene assayed that was not affected by the Park7 genotype. Muscle contractile
characteristics partially depend on the expression of myosin heavy chain isoforms. The
hypertrophied muscles in callipyge sheep have an increased size of fast twitch glycolytic
myofibers along with increased MYH4 expression and a decreased frequency of oxidative
fibers (Carpenter et al. 1996; Carpenter & Cockett 2000). Over-expression of
constitutively active Akt had been reported to promote myofiber growth with no effect on
fiber specification in regenerating skeletal muscle (Pallafacchina et al. 2002). The use of
a doxycycline-inducible Akt transgene in mice resulted in the hypertrophy of glycolytic
myofibers, but not oxidative myofibers (Izumiya et al. 2008). A recent study supported
this result by identifying a regulatory cascade of AKT activation to drive the metabolic
and contractile specification of fast-twitch muscle fibers (Meng et al. 2013). Similarly,
the results presented here are congruent with the up-regulation of Myh4 and the enhanced
activation of AKT in the presence of Park7. Interestingly, double-muscled cattle, in
which the expression of Park7 gene is also elevated, have an increased proportion of fasttwitch glycolytic fibers as well (Stavaux et al. 1994).
The difference of phosphorylation of AKT in Park7 (+/+) and Park7 (-/-) myotubes
was eliminated when treated with higher concentrations of PTEN inhibitor, but the total
amount of PTEN had not been changed, suggesting PARK7 acts through inhibition of
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PTEN phosphatase activity, not total PTEN expression. This result was consistent with
the findings of Kim et al. (Kim et al. 2005a; Kim et al. 2009). In their studies, they also
examined the phosphorylation level of PTEN at Ser380, Thr382, Thr383 and Ser385 in
Park7 transfected NIH3T3 cells, but no change was detected; indicating the inhibition of
PTEN phosphatase activity by PARK7 is not affected by phosphorylation of PTEN. The
detailed mechanism on how PARK7 inhibits PTEN phosphatase activity remains unclear.
Some studies have proposed that PARK7 can directly bind to PTEN to confer an inactive
conformation by forming a disulfide bond between cys71and cys124 of PTEN upon
oxidative stress (Lee et al. 2002; Kwon et al. 2004; Kim et al. 2009). It has also been
speculated that the interaction of PARK7 to PTEN may accelerate the oxidation of PTEN,
thus inactivating the PTEN function (Kim et al. 2009). Further analysis will be necessary
to determine how PARK7 inhibits PTEN function in muscle.
In live animals, skeletal muscle responds to the natural IGF1 stimulation to grow.
With the increased level of PARK7, the AKT phosphorylation in callipyge animals
would be expected to be higher relative to normal lambs with natural IGF1 stimulation,
thus causing increased muscle mass. However, the steady state level of AKT
phosphorylation would be difficult to determine in the live lambs since IGF1 stimulation
of individual in animals would be variable. Stress responses associated with
transportation and slaughter could rapidly alter levels of AKT phosphorylation. However,
this cell culture study provides evidence that PARK7 activity in muscle may be part of
the physiological mechanism for the DLK1-induced muscle hypertrophy in callipyge
lambs.
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4.6

Conclusions

In summary, the present study provided a novel insight into the function of PARK7 in
the regulation of skeletal muscle growth. The effect of PARK7 in muscle growth can
contribute to increased protein synthesis and result in myotube hypertrophy. Since
PARK7 can positively regulate the PI3K/AKT pathway by inhibition of PTEN
phosphatase activity, elevated expression of PARK7 in the muscles of callipyge lambs
would lead to increased muscle growth in response to the normal IGF1 signaling present
in young growing lambs. DLK1 and PARK7 expression were both up-regulated in
hypertrophied muscle. Since DLK1 is one of the causative genes for the callipyge
phenotype due to the inheritance of the mutation, PARK7 could be considered a
downstream response to DLK1 signaling. These results support the hypothesis that
elevated expression of PARK7 is part of the physiological mechanism for the induced
muscle hypertrophy in callipyge lambs. In addition to the callipyge animals, the upregulation of PARK7 in double muscled cattle also suggests the essential role of PARK7
in regulating muscle mass. These combined results indicated that PARK7 is a key
modulator of PI3K/AKT pathway controlling muscle growth and protein accretion.
Identifying methods to increase the expression of PARK7 in muscle could provide a
mechanism to increase livestock muscle growth and production efficiency or prevent the
loss of muscle mass due to disease or aging.
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Figure 4.1 PARK7 Protein
rotein Expression Level in Sheep Skeletal Muscles.
A: There were higher levels of PARK7 and DLK1 proteins in the semimembranosus (SM)
of callipyge lambs (+/C)) relative to normal lambs (+/+), but no difference in PARK7 or
DLK1 protein levels in the supraspinatus (SS). B: Quantitative analysis of PARK7
protein expression
ssion was significantly higher in the SM of callipyge lambs. α
α-Tubulin was
the control for protein loading. Data shown are mean signal intensity ± SE. The pp-value
for comparisons between genotypes for each muscle is given.

Figure 4.2 PARK7 Protein
rotein Expression in Vastus Lateralis.
PARK7 protein expression was not detectable in vastus lateralis in Park7 ((-/-) mice. αTubulin was used as a control to show equal protein loading.
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Figure 4.3 Comparison of Myotube Size Between
B
Park7 (+/+) and Park7 (-/-) Genotypes.
A: Primary myoblasts were induced to differentiate for 72 hours and stained with an
antibody for total myosin heavy chain (red: MF20) and DNA (blue:
(blue: DAPI). B: No
significant differences were detected between the two genotypes for fusion index. C: The
distribution of myotube diameters were significantly larger (P<.0001) for Park7 (+/+;
1.70±0.24) than Park7 (-//-; 1.05±0.025) myotubes.
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Figure 4.4 Detection of Total Sarcomere Myosin Expression in Myotubes by ELISA.
There were significant effects for genotype and IGF1 treatment, but no significant
interaction. The Park7 (+/+) myotubes had significantly more total sarcomere myosin
expression than Park7 (-/-) myotubes and IGF1 induced significant higher sarcomere
myosin expression at all concentrations.
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Figure 4.5 Detection of Myosin Heavy Chain Isoform mRNA Levels in Myotubes by
Quantitative PCR.
Primary myoblasts were isolated from 2 animals for each genotype. IGF1 was added to
the culture 24hours after differentiation at the indicated concentration. A: Myh4 (Myosin
Heavy Chain, Type IIB) expression; B: Myh7 (Myosin Heavy Chain, Type I) expression;
C: Myh8 (Myosin Heavy Chain, perinatal) expression; D: Myh3 expression (Myosin
Heavy Chain, embryonic). Myh4, Myh7 and Myh8 had significantly higher expression in
Park7 (+/+) myotubes, however, no significant differences were detected for Myh3. The
mean fold change value was calculated using the 2 –ΔΔCt method with Rplp38 as the
control gene and IGF1 concentration of 0 as the control treatment.

115

Figure 4.6 Ph
hosphorylatio
on of AKT (S473)
(
Proteein in Park7 (+/+) and Paark7 (-/-)
Myotubes.
M
Myoblasts
M
weere induced to
t differentiaation for 72 hours. Matuure myotubes were treateed
with
w IGF1 forr 15 minutess. There was increased pphosphorylattion of AKT (P-AKT) inn
Park7
P
(+/+) myotubes
m
rellative to totaal AKT (AKT
T) in myotubbes in fusionn medium (55%
horse serum).. There was a substantiall increase inn AKT phospphorylation iin Park7 (+/+
+)
myotubes
m
relaative to Parkk7(-/-) myotu
ubes at all IG
GF1 concenttrations. α-T
Tubulin was the
co
ontrol for prrotein loadin
ng.

116

ARK7 Inhibiits PTEN Fu
unction, But N
Not PTEN E
Expression.
Figure 4.7 PA
A:
A Western blot analysis of phosphorrylated AKT
T (S473) in P
Park7 (+/+) aand Park7 (--/-)
myotubes
m
in the
t presencee of differentt concentrations of PTEN
N inhibitor (VO-OHpic) after
IG
GF1 stimulation. Differeential phosph
horylation off AKT due tto Park7 gennotype was
elliminated by
y the PTEN inhibitor
i
VO
O-Ohpic at 800 nM. No ddifferences w
were detecteed in
PTEN expresssion. α-Tubu
ulin was the control for pprotein loadding B: Detecction of Ptenn
mRNA
m
level in myotubess by quantitaative PCR. N
No significannt differences were deteccted
between the two
t genotypees or IGF1 trreatment. Thhe mean foldd change waas calculatedd
using the 2 –ΔΔΔCt method with
w Rplp38
8 as the houseekeeping geene and no addded IGF1 aas the
ontrol treatm
ment.
co

117

Figure 4.8 Sustained Activity of AKT Phosphorylation (S473) in Park7 (+/+) and Park7
(-/-) Myotubes After IGF1 Stimulation.
Mature myotubes were stimulated with IGF1 (12.5 ng / mL) for 15 minutes. Total protein
was extracted at the indicated time after removal of IGF1. A: Western blot analysis
showed a higher level of AKT phosphorylation in Park7 (+/+) relative to Park7 (-/-)
myotubes. B: Analysis of the signal intensity for the P-AKT/total AKT showed the Park7
(+/+) myotubes had higher AKT phosphorylation without added IGF1 and had a 3.4 fold
higher level of P-AKT than Park7 (-/-) myotubes at 45 minutes after IGF1 treatment. The
decline in AKT phosphorylation was similar between the genotypes after 90 minutes with
Park7 (+/+) myotubes generally maintaining approximately 20% higher signal intensity.
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CHAPTER 5. IMPLICATION AND FUTURE DIRECTIONS

In the meat animal industry, there is always a need to identify genes that can increase
meat production. The callipyge sheep is an ideal model to screen these genes due to its
muscle hypertrophy phenotype. Functional genomics experiments, such as microarrays,
facilitate to narrow the candidate genes from a pool of genes to a certain number. The
follow-up experiments after functional genomics are essentially required to validate the
expression of candidate genes in multiple muscles, and to determine the true molecular
mechanisms on how these candidate genes regulate protein accretion and muscle growth.
The work presented in this dissertation contains two themes. One is to identify the
potential downstream effector genes that respond to the up-regulation of DLK1 and / or
RTL1 in hypertrophied muscles, and the other one is to explore the functional role of
PARK7, one of the candidate genes from the first study, in muscle growth and
development. These two studies provide insights on the potential genes network in
callipyge sheep and demonstrate how PARK7 could alter myotube size and myosin gene
expression. However, there are other working hypotheses developed from this work and
these should be tested in the future. This chapter covers these hypotheses from the two
studies in this thesis.

119
5.1 Possible Physiological Roles of Effector Genes in Callipyge Sheep
The first study (Chapter 3) identified PARK7, DNTTIP1, SLC22A3, METTL21E and
PDE4D as the potential secondary effector genes in responding to DLK1 (primary
inducer) signaling and also indicated PARK7 and DNTTIP1 could be the components in
the signaling of DLK1 induced up-regulation of Myh4 (see Chapter 3). Though the
current thesis only explores the function of PARK7 in muscle growth (see Chapter 4),
specific studies on the regulations of other genes should be performed in the future in
order to understand the gene regulation in callipyge muscles. Here are some clues that
may facilitate future studies.
DNTTIP1 encodes TdT interacting factor 1 (TdIF1), which was first identified as a
protein that directly binds to terminal deoxynucleotidyltransferase (TdT), and negatively
regulates TdT activity. There are few studies on DNTTIP1 in muscle growth. A recent
study revealed that DNTTIP1 preferentially binds to the sequence 5′-GNTGCATG-3′
following an AT-tract, through its helix-turn-helix and AT-hook motifs (Kubota et al.
2013). Since the increased MYH4 luciferase activity was reported in Chapter 3, the
sequence analysis on MYH4 promoter region was conducted. However, no positive
results were found. Nevertheless, the three DNA-binding regions of DNTTIP1 [within
residues 1–75, an AT-hook domain between residues 159–173, and a predicted helixturn-helix (HTH) region between residues 184–243] (Kubota et al. 2007) makes it with
strong DNA-binding capacity. Herein, we cannot exclude the possibility that DNTTIP1
may bind to other DNA sequence to regulate MYH4 transcriptional activity. Identification
of the binding sequences of DNTTIP1 may be the first step to study its regulatory
function. Moreover, DNTTIP1 is reported to interact with HDAC1 and HDAC2 during
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the M phase (Bantscheff et al. 2011). The HDACs usually repress transcriptional activity
by deacetylating histones (Segre & Chiocca 2011). HDAC1 and HDAC2 interact with
many transcriptional factors, including Rb binding protein-1, Sp1, and ZEB1(Kao et al.
2000; Aghdassi et al. 2012) in order to regulate gene transcription. They are subjected to
various post-translational modifications, such as phosphorylation, ubiquitination, and
SUMOylation (Segre & Chiocca 2011). Based on the multiple function of the HDAC
complex, the other option for future studies is to start with the interaction with HDACs
and examine the regulatory role of this complex on gene expression during myogenisis.
SLC22A3 / OCT3 (Solute carrier 22A3 / Organic cation transporter 3) mediates the
uptake of many important endogenous amines and basic drugs in a variety of tissues
(Chen et al. 2013). Transported endogenous substrates of human OCTs include:
monoamine neurotransmitters, neuromodulators, and other compounds such as choline,
creatinine, and guanidine [for reviews, see (Nies et al. 2011)]. Therefore, the studies on
SLC22A3 could start with the examination of the substrates of SLC22A3 in muscles, and
the inhibitors of SLC22A3 can be used here. Furthermore, it is postulated that SLC22A3
has a role in the overall regulation of neurotransmission and maintenance of homeostasis
within the central nervous system (Wu et al. 1998; Zwart et al. 2001). Since the muscle
activity is controlled by the motor neuron, the other study could be conducted on the
regulation of SLC22A3 in neuron function in muscle.
The functions of METTL21E and PDE4D in muscles have not been characterized.
METTL21E, also known as protein-lysine methyltransferase METTL21E in Bos taurus,
shares 51 % similarity to human METTL21C whose protein family is consisted of other 9
proteins (Cloutier et al. 2013). Methyltransferases catalyze the transfer of a methyl group
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(CH3) from a donor, generally S-adenosyl-L-methionine (AdoMet), to various acceptor
molecules, such as proteins, DNA, RNA, lipids, and small metabolites (Martin &
McMillan 2002; Schubert et al. 2003). The function of METTL21E can be determined by
identifying its acceptors in muscles. Furthermore, a recent study has shown that human
METTL22 family of proteins could interact with molecular chaperones to regulate their
activities. This study also determined the modification sites of these chaperones (Cloutier
et al. 2013). Notably, PARK7 has been suggested to have the chaperone activity due to
the structural similarities to Hsp31 (see Chapter 1). Therefore, the other starting point of
the future study is to examine whether METTL21E could modify the activity of PARK7,
and in turn to regulate other genes expression. The affinity purification coupled to mass
spectrometry method could be used in this study. The phosphodiesterases (PDEs) are
enzymes that catalyze the hydrolysis of cyclic nucleotides (cAMP and cGMP). Using
isoform-specific PDE inhibitors, the function of PDE4D has been proved to be essential
for signaling of β2-adrenergic receptor (β2-AR), which is responsible for both the skeletal
muscle hypertrophy and anti-atrophy effects of the β-adrenergic agonist (Hinkle et al.
2002; Xiang et al. 2005; Bruss et al. 2008). Therefore, future studies could be conducted
to determine the effects of PDE4D in response of β-adrenergic agonist stimulation in
muscles. Since most of PDE4D knockout mice died within four weeks of age, the
muscle-specific knockout model could be helpful here (Jin et al. 1999).
5.2 PARK7 as a Muscle Growth Regulator
The second study (Chapter 4) characterized a positive role of PARK7 in regulating
muscle growth. PARK7 is a molecule that occupies a pivotal position in cellular biology,
because a loss or gain of its function drives abnormal cellular responses. This loss or gain
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may lead either to cell death (loss of function in neurodegenerative disease) or
unregulated cell survival (gain of function in cancer), respectively (see Chapter1). In the
present thesis, we used the loss-of-function model to determine that the presence of
PARK7 alters the myotube size and myosin gene expression in vitro. However, there is no
obvious phenotype observed in vivo, which could be a result of the multiple hormone
stimulation, such as IGF1, androgens and β-adrenergic agonists. These different hormone
stimulations initiate multiple signaling pathways to regulate growth. Therefore, the loss
of Park7 functions in Park7 (-/-) mice may be compensated by other hormones and
signaling pathways in vivo. Since the gain-of-function and loss-of-function in PARK7
leads to different cellular responses, the over-expression model will be needed to further
determine the role of PARK7 in muscle growth. Furthermore, the expression of PARK7
was highly elevated in hypertrophied muscles. Thus the gain-of-function model is more
appropriate to mimic the effects of PARK7 in muscle hypertrophy.
Opposite from muscle hypertrophy, which defines as the increase in muscle mass due
to overall rates of protein synthesis exceed rates of protein degradation, the muscle
atrophy means the decrease in muscle mass and fiber size when protein degradation rates
exceed protein synthesis. Muscle atrophy results from aging, starvation, cancer, diabetes,
bed rest, loss of neural input (denervation, motor neuron disease), or catabolic hormonal
stimulation (corticosteroids). To better understand the role of PARK7 in muscle growth
and development, characterization its function in muscle atrophy will be necessary.
Increased levels of Park7 were identified in sporadic inclusion-body myositis (sIBM), which is a progressive muscle disease associated with aging and is manifested by
pronounced muscle weakness and wasting (Terracciano et al. 2008). PARK7 is highly

123
oxidized and increased in the mitochondria in s-IBM muscle fibers (Terracciano et al.
2008). A detailed description on the effects of PARK7 on maintaining mitochondrial
homeostasis was given in Chapter 1. Though not fully understood, Park7 was reported to
act in parallel with the Pink1 and Parkin to positively control mitochondrial homeostasis
and autophagy (Thomas et al. 2011). The autophagy-lysosome system is one of the major
proteolytic pathways in the cells that are coordinately activated in atrophying, and is
crucial for atrophying [for reviews, see (Sandri 2010)]. For example, myofiber atrophy
induced in vivo by over-expression of constitutively active FoxO3 requires autophagy.
Conversely, knocking down the critical autophagy gene, LC3, by RNAi partially prevents
FoxO3-mediated muscle loss (Mammucari et al. 2007). Therefore, future studies should
address underlying molecular mechanisms on how PARK7 affects atrophy through
modulating autophagy. In addition to the cell autophagy, the positive regulation of
PARK7 in NF-κB signaling (see Chapter 1) also implies its role in muscle atrophy, since
NF-κB signaling is known to induce muscle atrophy [for review, see (Peterson et al.
2011)]. The identification of Cezanne, a known deubiquitination enzyme that inhibits
NF-κB activity, as one of the PARK7 binding partners provides a clue to how PARK7 is
involved in the NF-κB pathway. However, detailed working machinery on how
Cezanne/PARK7 complex exert its effects as well as identification of other NF-κB targets
regulated by PARK7 will be needed in future study.
5.3 Conclusions
The two studies presented in this dissertation provide insights on the genes regulation
in callipyge muscle hypertrophy. This chapter describes a few of the common hypothesis
and possible pathways arising from these two studies that may contribute to understand
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the altered muscle growth in callipyge sheep. The data presented here requires extensive
further studies, and undoubtedly new future technologies will facilitate these studies in
order to be more precise and efforts-saving. Since several of the DLK1 downstream
genes play roles in human cancers, better understanding the signals in DLK1-induced
muscle hypertrophy could not only benefits agriculture but also has implications for
human health.
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APPENDICES

Appendix A

Gene Expression Data for 7-muscle Experiment

Table A. 1 Quantitative PCR Primer Sequences and Amplification Conditions
Gene
Symbol
DLK1

Gene Title
Delta-Like 1 homolog (Drosophila)

RTL1

Retrotransposon-like , Paternally expressed gene 11

APOD

Apolipoprotein D

LPL

Lipoprotein Lipase

PDE7A

cAMP Specific Phosphodiesterase, 7A

PARK7

Parkinson disease (autosomal recessive, early onset) 7

DNTTIP

Deoxynucleotidyltransferase, Terminal, Interacting

BHLHB3

Protein 1
Basic Helix-Loop-Helix domain containing, class B3

METTL21E Similar to SAM dependent methyltransferase family

Primer Sequence
F5’-GGTTACTTCAAATGGCGTCAA-3’
R5’-GGATTCCGCACAAACAACTC-3’
F5'-AGGAACACCGCTGTGGAGGTAGAA-3'
R5'-ACAGCAGAGGCAGCCAAGCA-3'
F5’-TCTTGCTTTGCTTTTCCCCTATACC-3’
R5’-AGCTTGCCTTGGGTTCTTCTCC-3’
F5’-TCACGTATGAAGCCCCACAT-3’
R5’-AAGGAGTGTTCCGGCACCA-3’
F 5'-GGAGGTCGGCCGTGAGAGAT-3'
R 5'-TTCGTCAAAGGGAGGGACGAGAA-3'
F5’-CGAGTCCGCTGCTGTGA-3’
R5’-TGACTTCCGTTCATCATTTTGT-3’
F 5'-ATGGCCTACCTTCTCATTGA-3'
R 5'-TGTACTTCCGCATCTTCTCA-3'
F5’-ATGTAAGGGGTGAGACACAACAGT-3’
R5’-CAAACAGTAGCAACAGCAGCAG-3’
F 5’-GCCCTTGTTCTGTGCTATT-3’
R 5’-CAGGTAAATCTGTGGCAGTC-3’

Anneal
Temp
58˚C
55˚C
55˚C
55˚C
55˚C
51˚C
49˚C
54˚C
50˚C
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Continued
Gene
Symbol
PFKM

Gene Title
Phosphofructokinase, Muscle

RSPRY1

Ring Finger and SPRY Domain Containing 1

PDE4D

cAMP Specific Phosphodiesterase 4D

HDAC9

Histone Deacetylase 9

RPLPO

Ribosomal Protein , Large, P0

CDO1

Cysteine Dioxygenase Type 1

MAPK6

Mitogen Activated Protein Kinase 6

SLC22A3

Similar to Solute Carrier Family 22 member 3

TXNIP

Thioredoxin Interacting Protein

KCNN3

Potassium Intermediate/Small Conductance CalciumActivated Channel, family N3
Calpastatin

CAST

Primer Sequence
F 5’-GAGCCCAACTCCATTTGACA-3’
R 5’-CTTACGCATCCCCAGAACAC-3’
F 5’-CTTCCTTCCCCACCGTTTC-3’
R 5’-AATCCAGCACCCCAACAAGT-3’
F5’-TAAACAGTACAAAGGGGACACT-3’
R5’-CTGTAAGAGAGGCTAAGAAACC-3’
F5'-CCTTTTCACTGGTTCCAGGTAG-3'
R5'-GGCTGAGCAGGCTTTTGTATAAT-3'
F 5’-CAACCCTGAAGTGCTTGACAT-3’
R 5’-AGGCAGATGGATGGATCAGCCA-3’
F5’- AAGGTCCAGCGAAGTTCC-3’
R5’- CAGGGGCTCTAGGCTAACA-3’
F5’-TCAAAGTCAGTAAGCCGAGAA-3’
R5’-AACAGTCCTCCCCACCAC-3’
F5’-TGAACAAAGGGAGAATGTAGGTA-3’
R5’-GCCTTAAAGCACATCAGCAT-3’
F5’-ATGTTGCCATGAGAAACCAGAA-3’
R5’-TAAGGCGGAGAGTGACTGACC-3’
F5’-CGGGAAACGTGGCTAATCTACA-3’
R5’-GTGTTGGCTTGGTCACTCAGCT-3’
F5’- AGAGACCCACCAGGACGTG-3’
R5’- CAGGGGCTCTAGGCTAACA-3’

Anneal
Temp
50˚C
50˚C
50˚C
55˚C
50˚C
52˚C
52˚C
52˚C
52˚C
55˚C
54˚C
153

Continued
Gene
Symbol
COQ10A

Gene Title
Coenzyme Q10 homolog A

IDH2

Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial

FCGRT

Fc Fragment of IgG, Receptor, Transporter, alpha

AKR1C4

Aldo-keto Reductases 1C4

MEG8

Maternal Expressed Gene 3, GTL2 variant D

CABC1
MEG3

Chaperone, ABC1 Activity of bc1 Complex Homolog
(S. pombe)
Maternal Expressed gene 8

MYH7

Myosin, Heavy Chain Type I, Skeletal Muscle, adult

MYH2

Myosin, Heavy Chain Type IIA, Skeletal Muscle,

MYH4

adult
Myosin, Heavy Chain Type IIB, Skeletal Muscle,
adult

Primer Sequence
F 5’-GCTGTGCGGTCATCTCT-3’
R 5’-ATTTCAGGTAGGCAAGGTTA-3’
F5’-CTGGACGCGTGGCCTAGAACA-3’
R5’-TTGCTGAGGCCGTGGATGC-3’
F5’-TCGTCATCGGCTTATTCCT-3’
R5’-GATGATCGGCAGTTGCTG-3’
F5’-GGATCCCAACTATCATCAGA-3’
R5’-GGTTTGCTTGTGCTTTTT-3’
F 5'-CACTGAAAAGCACGTGCCTTCT-3'
R 5'-GATTTAGCATCTGCCATGGACAA-3'
F5’-GAGCTGAGCAGTGCCAACAAGTA-3’
R5’-TAGGAGGCGGCAGTTCTCTG-3’
F5'-GCATAGACGAGGCGGTCAGTAAATG-3'
R5'-CGGAGCGCTGTGGGAGAATAA-3'
F 5'-AAGAACCTGCTGCGGCTG-3'
R 5'-CCAAGATGTGGCACGGCT-3'
F 5'GAGGAACAATCCAATACAAATCTATCT-3'
R 5'-CCCATAGCATCAGGACACGA-3'
F 5'-AAATGCAAGTGCTATCCCAGAG-3'
R 5'-AGTGCGCGTGATGAGTTGA-3'

Anneal
Temp
50˚C
59˚C
52˚C
48˚C
54˚C
57˚C
55˚C
57˚C
51˚C
54˚C
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Continued
Gene
Symbol
MYH1
Myh4
(Mouse)
DNTTIP1
(Mouse)
Park7
(Mouse)
Rplp38
(Mouse)

Gene Title
Myosin, Heavy Chain Type IIX, Skeletal Muscle,
adult
Myosin, Heavy Chain Type IIB, Skeletal Muscle,
adult
Deoxynucleotidyltransferase, Terminal,
Interacting Protein 1
Parkinson disease
(autosomal recessive, early onset) 7
Ribosomal protein large protein 38

Primer Sequence
F 5'-GGAGGAACAATCCAATGTCAAC-3'
R 5'-GTCACTTTTTAGCATTTGGATGAGTTA-3'
F 5'- AGTCCCAGGTCAACAAGCTG-3'
R 5'-TTTCTCCTGTCACCTCTCAACA-3'
F 5'-ATGGCCTACCTTCTCATTGA-3'
R 5'-TGTACTTCCGCATCTTCTCA-3'
F 5'-AGGTCCTACGGCTCTGTTG-3'
R 5'-CACAATGGCTAGTGCAAACTCA-3'
F 5'-GAAGGATGCCAAGTCTGTCAA-3'
R 5'-GAGGGCTGGTTCATTTCAGA-3'

Anneal
Temp
52˚C
55˚C
49˚C
55˚C
55˚C
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Table A. 2 Quantitative Analysis of Gene Expression
Gene
DLK1
RTL1
APOD
LPL
PDE7A
RPLPO(GSP)
PARK7
DNTTIP
DEC2
LOC513822
PFKM
RSPRY1
PDE4A
HDAC9

Genotype
+/C
+/+
+/C
+/+
+/C
+/+
+/C
+/+
+/C
+/+
+/C
+/+
+/C
+/+
+/C
+/+
+/C
+/+
+/C
+/+
+/C
+/+
+/C
+/+
+/C
+/+
+/C
+/+

LD
4.800 ± 0.065
3.695 ± 0.056
5.359 ± 0.167
1.130 ± 0.145
5.994 ± 0.103
5.522 ± 0.089
4.988 ± 0.080
5.312 ± 0.069
5.012 ± 0.126
4.581 ± 0.109
6.999 ± 0.144
6.994 ± 0.125
6.534 ± 0.095
6.047 ± 0.082
5.547 ± 0.095
4.866 ± 0.082
4.772 ± 0.041
4.830 ± 0.036
5.537 ± 0.101
4.708 ± 0.088
6.259 ± 0.039
5.955 ± 0.034
4.489 ± 0.030
4.263 ± 0.026
5.941 ± 0.085
5.454 ± 0.073
3.959 ± 0.076
4.157 ± 0.066

SM
5.002 ± 0.135
3.813 ± 0.117
5.475 ± 0.095
1.000 ± 0.082
6.129 ± 0.070
5.649 ± 0.061
5.080 ± 0.059
5.522 ± 0.051
5.004 ± 0.145
4.700 ± 0.126
6.953 ± 0.094
6.980 ± 0.081
6.671 ± 0.059
6.051 ± 0.051
5.587 ± 0.078
5.027 ± 0.068
4.810 ± 0.047
4.927 ± 0.040
5.706 ± 0.097
4.860 ± 0.084
6.267 ± 0.025
6.024 ± 0.022
4.492 ± 0.040
4.293 ± 0.035
5.998 ± 0.114
5.501 ± 0.098
3.889 ± 0.065
4.269 ± 0.056

ST
4.782 ± 0.261
3.672 ± 0.226
5.215 ± 0.143
1.015 ± 0.124
5.908 ± 0.176
5.312 ± 0.152
5.065 ± 0.234
5.071 ± 0.202
5.052 ± 0.112
4.630 ± 0.097
7.111 ± 0.188
6.742 ± 0.163
6.443 ± 0.084
5.900 ± 0.072
5.473 ± 0.060
4.857 ± 0.052
4.828 ± 0.114
4.758 ± 0.098
5.868 ± 0.106
4.925 ± 0.092
6.182 ± 0.037
5.846 ± 0.032
4.490 ± 0.087
4.083 ± 0.075
5.861 ± 0.076
5.263 ± 0.066
3.704 ± 0.134
3.867 ± 0.116

TB
4.181 ± 0.130
3.528 ± 0.112
4.909 ± 0.059
1.023 ± 0.051
5.806 ± 0.179
5.115 ± 0.155
5.610 ± 0.110
5.718 ± 0.095
5.014 ± 0.147
4.691 ± 0.128
6.997 ± 0.109
6.892 ± 0.095
6.389 ± 0.058
5.992 ± 0.050
5.311 ± 0.127
4.721 ± 0.110
4.908 ± 0.070
4.994 ± 0.061
5.768 ± 0.086
5.022 ± 0.074
6.157 ± 0.096
5.864 ± 0.083
4.477 ± 0.029
4.230 ± 0.025
5.739 ± 0.073
5.272 ± 0.063
4.131 ± 0.069
4.190 ± 0.060

SS
4.086 ± 0.165
3.944 ± 0.143
4.556 ± 0.382
1.403 ± 0.331
5.272 ± 0.132
5.130 ± 0.114
5.643 ± 0.163
5.907 ± 0.141
4.565 ± 0.105
4.527 ± 0.091
6.952 ± 0.095
6.841 ± 0.083
6.145 ± 0.103
5.954 ± 0.089
4.669 ± 0.086
4.456 ± 0.086
5.001 ± 0.065
5.018 ± 0.056
5.196 ± 0.184
4.995 ± 0.159
5.584 ± 0.091
5.322 ± 0.079
4.394 ± 0.083
4.151 ± 0.072
5.611 ± 0.122
5.283 ± 0.106
4.278 ± 0.089
4.228 ± 0.077

IS
3.749 ± 0.182
3.566 ± 0.158
4.390 ± 0.308
1.000 ± 0.267
5.503 ± 0.132
5.234 ± 0.114
5.748 ± 0.145
5.860 ± 0.128
4.876 ± 0.147
4.884 ± 0.127
7.164 ± 0.126
6.965 ± 0.109
6.191 ± 0.056
6.104 ± 0.048
4.837 ± 0.087
4.602 ± 0.076
5.039 ± 0.099
4.994 ± 0.086
5.407 ± 0.093
5.153 ± 0.080
5.725 ± 0.159
5.564 ± 0.138
4.427 ± 0.032
4.300 ± 0.028
5.552 ± 0.120
5.349 ± 0.104
4.327 ± 0.071
4.328 ± 0.062

HT
3.552 ± 0.163
3.416 ± 0.141
2.466 ± 0.133
1.000 ± 0.094
4.442 ± 0.171
4.272 ± 0.148
6.285 ± 0.098
6.182 ± 0.085
4.943 ± 0.093
4.912 ± 0.081
6.868 ± 0.081
6.793 ± 0.071
5.951 ± 0.055
5.877 ± 0.048
4.735 ± 0.037
4.660 ± 0.032
4.853 ± 0.081
4.832 ± 0.070
4.549 ± 0.166
4.442 ± 0.144
5.504 ± 0.085
5.416 ± 0.074
4.421 ± 0.082
4.336 ± 0.071
4.769 ± 0.061
4.785 ± 0.053
4.555 ± 0.060
4.551 ± 0.052
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Continued
Gene
RPLPO(RP)
CDO1
MAPK6
SLC22A3
TXNIP
KCNN3
CAST
COQ10A
IDH2
FCGRT
AKR1C4
MEG8
CABC1
GTL2

Genotype
+/C
+/+
+/C
+/+
+/C
+/+
+/C
+/+
+/C
+/+
+/C
+/+
+/C
+/+
+/C
+/+
+/C
+/+
+/C
+/+
+/C
+/+
+/C
+/+
+/C
+/+
+/C
+/+

LD
6.821 ± 0.048
6.838 ± 0.042
4.024 ± 0.201
4.307 ± 0.174
5.739 ± 0.057
5.453 ± 0.049
3.454 ± 0.152
2.242 ± 0.132
6.054 ± 0.073
5.942 ± 0.064
5.145 ± 0.076
4.400 ± 0.066
5.419 ± 0.028
5.076 ± 0.025
5.891 ± 0.117
5.723 ± 0.102
5.276 ± 0.050
5.483 ± 0.043
5.192 ± 0.080
5.243 ± 0.070
4.586 ± 0.115
5.404 ± 0.099
3.849 ± 0.096
2.708 ± 0.083
6.198 ± 0.081
6.297 ± 0.071
7.039 ± 0.217
5.606 ± 0.188

SM
6.763 ± 0.038
6.809 ± 0.033
3.943 ± 0.175
4.260 ± 0.151
5.884 ± 0.087
5.550 ± 0.075
3.710 ± 0.183
2.459 ± 0.159
6.102 ± 0.078
6.042 ± 0.068
5.207 ± 0.042
4.419 ± 0.036
5.454 ± 0.061
5.152 ± 0.053
5.886 ± 0.098
5.752 ± 0.085
5.392 ± 0.058
5.546 ± 0.050
5.255 ± 0.088
5.284 ± 0.076
4.238 ± 0.127
5.313 ± 0.110
3.851 ± 0.157
2.622 ± 0.136
5.906 ± 0.041
6.055 ± 0.035
6.917 ± 0.189
5.442 ± 0.164

ST
6.740 ± 0.067
6.643 ± 0.058
3.856 ± 0.288
3.723 ± 0.249
5.939 ± 0.134
5.602 ± 0.116
3.320 ± 0.255
2.412 ± 0.211
6.107 ± 0.166
5.803 ± 0.144
5.092 ± 0.131
4.454 ± 0.114
5.388 ± 0.065
5.171 ± 0.056
5.871 ± 0.220
5.539 ± 0.191
5.359 ± 0.134
5.319 ± 0.116
5.461 ± 0.166
5.184 ± 0.144
4.662 ± 0.173
5.181 ± 0.150
3.760 ± 0.188
2.813 ± 0.162
7.466 ± 0.082
7.433 ± 0.071
7.241 ± 0.168
6.078 ± 0.146

TB
6.768 ± 0.048
6.663 ± 0.042
4.111 ± 0.232
4.127 ± 0.201
6.046 ± 0.059
5.730 ± 0.051
3.773 ± 0.189
2.961 ± 0.163
6.339 ± 0.061
6.061 ± 0.053
5.126 ± 0.049
4.459 ± 0.043
5.481 ± 0.072
5.273 ± 0.062
5.699 ± 0.190
5.766 ± 0.164
5.763 ± 0.055
5.710 ± 0.048
5.704 ± 0.032
5.487 ± 0.027
5.011 ± 0.146
5.457 ± 0.127
3.060 ± 0.150
2.382 ± 0.130
7.778 ± 0.024
7.731 ± 0.021
6.626 ± 0.138
5.931 ± 0.120

SS
6.928 ± 0.067
6.779 ± 0.058
4.058 ± 0.156
4.126 ± 0.135
5.413 ± 0.106
5.283 ± 0.092
3.517 ± 0.283
2.906 ± 0.245
6.083 ± 0.098
5.962 ± 0.085
4.637 ± 0.143
4.111 ± 0.123
5.282 ± 0.099
5.158 ± 0.085
5.541 ± 0.134
5.406 ± 0.116
5.681 ± 0.103
5.677 ± 0.189
5.415 ± 0.086
5.282 ± 0.074
4.922 ± 0.165
5.154 ± 0.143
2.798 ± 0.140
2.367 ± 0.121

5.721 ± 0.157
5.109 ± 0.136

IS
6.784 ± 0.040
6.716 ± 0.035
4.211 ± 0.147
4.242 ± 0.128
5.886 ± 0.099
5.738 ± 0.086
3.845 ± 0.165
3.404 ± 0.143
6.328 ± 0.054
6.232 ± 0.047
5.011 ± 0.141
4.523 ± 0.122
5.486 ± 0.053
5.405 ± 0.046
5.823 ± 0.152
5.713 ± 0.131
5.878 ± 0.035
5.823 ± 0.030
5.754 ± 0.095
5.599 ± 0.083
5.230 ± 0.083
5.421 ± 0.072
2.942 ± 0.212
2.562 ± 0.183
5.691 ± 0.134
5.596 ± 0.116
6.472 ± 0.157
6.125 ± 0.136

HT
6.687 ± 0.062
6.660 ± 0.053
4.117 ± 0.097
3.930 ± 0.084
5.365 ± 0.142
5.183 ± 0.123
4.129 ± 0.145
4.065 ± 0.125
6.564 ± 0.056
6.481 ± 0.049
4.020 ± 0.074
3.956 ± 0.064
6.059 ± 0.059
6.025 ± 0.051
5.931 ± 0.166
5.823 ± 0.144
6.170 ± 0.080
6.095 ± 0.069
5.461 ± 0.122
5.320 ± 0.106
3.852 ± 0.156
3.902 ± 0.135
2.626 ± 0.162
2.560 ± 0.140
7.385 ± 0.051
7.375 ± 0.044
6.080 ± 0.147
6.016 ± 0.127
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Continued
Gene
MYH7
MYH2
MYH4
MYH1

Genotype
+/C
+/+
+/C
+/+
+/C
+/+
+/C
+/+

LD
6.703 ± 0.037
6.791 ± 0.032
6.086 ± 0.065
6.891 ± 0.056
4.153 ± 0.294
2.287 ± 0.255
7.661 ± 0.082
7.382 ± 0.071

SM
6.605 ± 0.046
6.765 ± 0.040
6.139 ± 0.082
6.776 ± 0.071
4.825 ± 0.238
2.867 ± 0.206
7.703 ± 0.059
7.459 ± 0.051

ST
6.516 ± 0.188
6.616 ± 0.163
6.335 ± 0.094
6.781 ± 0.081
5.869 ± 0.275
4.162 ± 0.238
7.657 ± 0.116
7.569 ± 0.100

TB
7.079 ± 0.054
7.089 ± 0.047
6.515 ± 0.104
6.766 ± 0.090
4.072 ± 0.132
2.641 ± 0.115
7.662 ± 0.080
7.396 ± 0.069

SS
7.280 ± 0.122
7.242 ± 0.105
6.574 ± 0.082
6.608 ± 0.071
2.856 ± 0.235
2.223 ± 0.203
7.225 ± 0.092
7.079 ± 0.082

IS
7.409 ± 0.101
7.372 ± 0.088
6.903 ± 0.125
6.767 ± 0.108
3.470 ± 0.291
2.546 ± 0.252
7.356 ± 0.302
7.125 ± 0.262

HT
7.435 ± 0.095
7.317 ± 0.082
3.573 ± 0.259
3.011 ± 0.224
1.749 ± 0.115
1.554 ± 0.099
4.411 ± 0.208
3.546 ± 0.180
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Table A. 3 Analysis of Variance of Genotype Effects in qPCR Analysis
Gene

LD

SM

ST

TB

SS

IS

HT

DLK1

0.0001

0.0012

0.0235

0.0125

0.5434

0.4831

0.5571

DNTTIP

0.0028

0.0029

0.0006

0.0169

0.1566

0.0982

0.1847

PARK7

0.0118

0.0005

0.0045

0.0035

0.2206

0.2897

0.3602

METTL21E

0.0016

0.0012

0.0011

0.0012

0.4466

0.0932

0.6473

MEG8

0.0003

0.0020

0.0124

0.0189

0.0678

0.2325

0.7686

SLC22A3

0.0018

0.0036

0.0434

0.0226

0.1639

0.0994

0.7540

PDE4D

0.0074

0.0211

0.0019

0.0048

0.0982

0.2560

0.8451

APOD

0.0178

0.0036

0.0506

0.0328

0.4498

0.1834

0.4861

PFKM

0.0019

0.0008

0.0010

0.0701

0.0818

0.4799

0.4684

AKR1C4

0.0030

0.0014

0.0731

0.0697

0.3350

0.1425

0.8169

CAST

0.0003

0.0137

0.0519

0.0805

0.3872

0.3024

0.6741

MEG3

0.0041

0.0020

0.0034

0.0126

0.0323

0.1546

0.7535

RTL1

0.0000

0.0000

0.0000

0.0000

0.0016

0.0004

0.0009

KCNN3

0.0007

0.0000

0.0144

0.0002

0.0385

0.0480

0.5429

RSPRY1

0.0024

0.0135

0.0167

0.0013

0.0770

0.0302

0.4678

MAPK6

0.0123

0.0330

0.1158

0.0095

0.3987

0.3080

0.3781

IDH2

0.0255

0.1006

0.8324

0.4994

0.9745

0.2903

0.5130

LPL

0.0283

0.0024

0.9841

0.4894

0.2742

0.5850

0.4634

PDE7A

0.0485

0.1745

0.0355

0.1584

0.7970

0.9658

0.8107

HDAC9

0.1051

0.0068

0.3997

0.5484

0.6852

0.9960

0.9624

TXNIP

0.2998

0.5872

0.2247

0.0186

0.3938

0.2387

0.3156

COQ10A

0.3275

0.3465

0.3057

0.8007

0.4794

0.6064

0.6433

CDO1

0.3359

0.2290

0.7413

0.9613

0.7566

0.8806

0.2066

DEC2

0.3383

0.1143

0.6624

0.4019

0.8514

0.7466

0.8565

FCGRT

0.6453

0.8115

0.2612

0.0035

0.2923

0.2756

0.4206

CABC1

0.4002

0.0401

0.7727

0.1930

0.6174

0.9025

MYH7

0.1355

0.0450

0.7061

0.8885

0.8260

0.7920

0.3918

MYH2

0.0002

0.0021

0.0158

0.1293

0.7686

0.4483

0.1617

MYH4

0.0049

0.0016

0.0054

0.0004

0.0971

0.0615

0.2534

MYH1

0.0505

0.0263

0.5915

0.0538

0.2841

0.5889

0.0254

RPLP0(RP)

0.8046

0.3995

0.3222

0.1635

0.1548

0.2511

0.7559

RPLP0(GSP)

0.9811

0.8317

0.1985

0.5024

0.4212

0.2837

0.5159
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Table A. 4 Plasmids Compositions of Effector Luciferase Assay
Effector
Gene
PARK7

Effector
Gene % (µg)
0% (0 µg)

Null Plasmids
(GW-CAT) % (µg)
60% (1.8 µg)

MYH4 or MYH7
Plasmids % (µg)
30% (0.9 µg)

PARK7

30% (0.9 µg)

30% (0.9 µg)

30% (0.9 µg)

PARK7

60% (1.8 µg)

0% (0 µg)

30% (0.9 µg)

METTL21E

0% (0 µg)

60% (1.8 µg)

30% (0.9 µg)

METTL21E

30% (0.9 µg)

30% (0.9 µg)

30% (0.9 µg)

METTL21E

60% (1.8 µg)

0% (0 µg)

30% (0.9 µg)

DLK1

0% (0 µg)

48% (1.44 µg)

50% (1.5 µg)

DLK1

24% (0.72 µg)

24% (0.72 µg)

50% (1.5 µg)

DLK1

48% (1.44 µg)

0% (0 µg)

50% (1.5 µg)

DNTTIP1

0% (0 µg)

48% (1.44 µg)

50% (1.5 µg)

DNTTIP1

12% (0.36 µg)

36% (1.08 µg)

50% (1.5 µg)

DNTTIP1

24% (0.72 µg)

24% (0.72 µg)

50% (1.5 µg)

Transfection
Control
pRL-TK, 10 %,
(0.3 µg)
pRL-TK, 10 %,
(0.3 µg)
pRL-TK, 10 %,
(0.3 µg)
pRL-TK, 10 %,
(0.3 µg)
pRL-TK, 10 %,
(0.3 µg)
pRL-TK, 10 %,
(0.3 µg)
pRL-SV40, 2 %,
(0.06 µg)
pRL-SV40, 2 %,
(0.06 µg)
pRL-SV40, 2 %,
(0.06 µg)
pRL-SV40, 2 %,
(0.06 µg)
pRL-SV40, 2 %,
(0.06 µg)
pRL-SV40, 2 %,
(0.06 µg)
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Figure A. 1 Cellular
C
Locaalization of DNTTIP1.
D
C2C12
C
cells were
w transfected with pD
DNTTIP1-pccDNA3.2 /V
V5 construct and stained with
an
nti-DNTTIP
P1 antibody (red),
(
anti-V
V5 epitope tagg antibody ((green) and D
DAPI (nucleei,
blue). The meerged cells (o
orange) show
wed the deteection of the same cells bby antiDNTTIP1
D
and
d anti-V5 an
ntibodies. DN
NTTIP1 locaalized exclussively in nuccleus in C2C
C12
ceells.
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Figure A. 2 Cellular
C
Locaalization of PARK7.
P
C2C12
C
cells were
w transfected with pP
PARK7-pcD
DNA3.2 /V5 construct annd stained wiith
an
nti-PARK7 (green),
(
antii-V5 epitopee tag (red) annd DAPI (nuuclei, blue). T
The merged cells
(o
orange) show
wed the detection of the same cells bby anti-PARK
K7 and anti--V5 antibodiies.
PARK7 locallized both in
n the cytoplassm and nucl eus in C2C112 cells.
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Figure A. 3 Cellular
C
Locaalization of METTL21E
M
and GW-CA
AT.
C2C12
C
cells were
w transfected with pM
METTL21E--pcDNA3.2 /V5 construuct (A to C) oor
pGWCAT- pccDNA3.2/V
V5 (D to F) an
nd stained w
with anti-ME
ETTL21E or anti-GW-CA
AT
an
ntibody (greeen), and DA
API (nuclei, blue).
b
METT
TL21E (A too C) localizeed both in thee
cy
ytoplasm and nucleus bu
ut mostly acccumulated inn cytoplasm in C2C12 cells. GW-CA
AT
(D
D to F) locallized mostly in nucleus.
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Appendix B

Park7 (-/-) Mice Phenotypic Analysis

Live Body Weight

Live weight & age analysis (female)
20.00
18.00
16.00
14.00
12.00
10.00
8.00
6.00
4.00
2.00

(-/-) y = 3.43x - 3.13
(+/-) y = 2.88x + 0.82
(+/+) y = 2.97x + 0.15

Park7 (+/+)
Park7 (+/-)
2

3

4

5

6

Park7 (-/-)

7

Age

Live Body Weight

Live weight & age analysis (male)
26.00
24.00
22.00
20.00
18.00
16.00
14.00
12.00
10.00
8.00
6.00
4.00
2.00

(-/-) y = 4.18x - 2.96
(+/-) y = 4.06x - 2.13
(+/+) y = 4.44x - 3.57
Park7 (-/-)
Park7 (+/-)
Park7 (+/+)
2

4

6

8

Age

Figure B. 1 Analysis on Live Body Weight by Age in Park7 (+/+), (+/-) and (-/-) Mice.
Twenty females with 4 Park7 (+/+), 12 (+/-) and 4 (-/-) animals and twenty-five males
with 4 Park7 (+/+), 11 (+/-) and 10 (-/-) were examined to analyze the live animal growth.
Animals live body weights were collected from 3 weeks to 6 weeks old. Live body
weights were regressed on age. Equations were given for each genotype. There were no
genotype effect on the slopes and intercepts of any regression lines in both male and
female.

165
Table B. 1 Analysis on Carcass Weights and Internal Organs Weights in Park7 (+/+), (+/-)
and (-/-) Mice

Organs

Equation

Organs

Carcass

+/+ y=0.6396lw-4.2095

+/- y=0.0191lw+7.0533

-/- y=0.3022lw+0.3916

+/+ y=0.0042lw+0.0195

+/+ y=0.0025lw+0.0504

+/- y=0.0017lw+0.0722

Liver

+/- y=-0.0094lw+1.0736

y=0.0025lw+0.0465

+/+ y=0.0737lw-0.4577
+/- y=0.0744lw-0.5963

-/- y=-0.0733lw+2.4782

-/-

+/+ y=0.0127lw-0.0277

+/+ y=0.0144lw-0.0370

+/- y=0.0176lw-0.1177
-/- y=0.0116lw+0.0265

Kidney

Kidney

Liver

+/+ y=0.0637lw-0.5389

+/- y=0.005lw+0.00550
-/-

Female

-/- y=0.0087lw-0.0750
Male

+/- y=0.6389lw-4.7451

-/- y=0.8254lw-9.8533

Heart

Heart

Carcass

+/+ y=0.6009lw-5.3759

Equation

y=-0.026lw+0.2008

+/-

y=0.0159lw-0.0749

-/-

y=0.0137lw-0.0373

166
Table B. 2 Quantitative PCR Primers.
Gene
name

Forward primer (5’-3’)

Reverse primer (5’-3’)

Myh7

AGTCCCAGGTCAACAAGCTG

TTCCACCTAAAGGGCTGTTG

Myh3

CGCAGAATCGCAAGTCAATA

ATATCTTCTGCCCTGCACCA

Myh8

AGTCCCAGGTCAACAAGCTG

CCTCCTGTGCTTTCCTTCAG

Myh4

AGTCCCAGGTCAACAAGCTG

TTTCTCCTGTCACCTCTCAACA

Pten

CCTTTTGAAGACCATAACCCACC

GAATTGCTGCAACATGATTGTCA

Rplp38
(control)

GAAGGATGCCAAGTCTGTCAA

GAGGGCTGGTTCATTTCAGA
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Appendix C

Lab Protocols

C1. 1 Primary Myoblast Isolation



Collagen-Coated Plates
Product: Collage (rat tail), 10 mg/ bottle, 3 bottles/box. Cat#: 11179179001
1. Mix collagen in the bottle from the manufacturer with the filtered 0.2 % acetic
acid. 1 bottle of collagen (10 mg) is good for 100 mL 0.2 % acetic acid.
2. Add 4-5 mL collagen to a 10cm plate and let it sit for 1 hour to 2 hour in
incubator.
3. Aspirate off liquid or collect the collagen to reuse and allow drying in laminar
flow hood for 8 hours (overnight) (or O/N). Plates can be stored indefinitely at
4 Ԩ.



Collagenase / Dispase Solution
Product: Collagenas / Dispase Mix (Roche) 500 mg. Cat#: 11097113001
1. Add 10 mL H2O (cell culture) to make a final concentration of 50 mg/mL, filter
and divide into 10 tubes.
2. For each tube, add 9 mL DPBS to make the working concentration of 5 mg/mL.



Ham’s Complete Medium
1. Growth Medium
Ham’s F-10 medium (500 mL / bottle) with 20 % FBS, 1X PSG and 4 ng/mL
bFGF
2. Differentiation Medium
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DMEM (500mL / bottle) with 5 % Horse Serum and 1X PSG.


Procedure
1. Limb muscle collection. Before removing the skin and fascia, liberally spray the
entire mouse with 70 % ethanol.
2. Peel the skin and fascia from abdomen to the leg to expose the underlying
muscles. Dissect both hind limbs and place in a sterile 60 mm plate with DPBS.
(Remove all the fat from muscle).

The following work should be done in the hood.
3. Transfer all the muscles to a clean 60 mm plate and wash with DPBS twice.
4. Transfer all the muscles to an empty 60 mm plate and suck off DPBS left on the
muscles.
5. Mulch the tissue into smooth pulp using scissors.
6. Add 5 mL Collagenase / Dispase solution and mix well.
7. Incubate at 37 oC for 15min, then pipet up and down to homogenize the pulp and
incubate for another 15 min and mix well to get smooth pulp.
8. Add 5 mL Ham’s complete medium to stop the digestion and transfer all the pulp
into a 15 mL sterile tube.
9. Wash the plate with 5 mL DPBS and transfer the DPBS into the same tube.
10. Briefly spin down the tube (150 g*30s) and filter the supernatant through 100
µM filter (Partec Cell Trics cat.log: 04-004-2328) into another 15 mL tube. Add
10 mL Ham’s complete medium to the debris, mix and put them into a non-coated
plate labeled as “Debris”.
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11. Spin down the filtered supernatant at 450 g*5 min, aspirate the supernatant, add
10 mL Ham’s complete medium, mix the pellet and transfer all the medium into
a 10 cm coated plate labeled as “Pellets”.
12. Add 5 ml Ham’s complete medium every day.
In 3 days
13. Collect both the debris and pellet into different tubes and spin down all the tubes
at 450 g * 5min.
14. Aspirate off the supernatants and wash with 5 mL DPBS. Spin down at 450 g *
5min again and aspirate the supernatant.
15. Dilute trypsin with DPBS (1:7) and add 5 mL diluted trypsin into each tube.
16. Incubate all the tubes in the 37 Ԩ water bath for 10 mins. (Gently mix the tube
every 2 mins).
17. Add 5 mL Ham’s complete medium to stop digestion. Pipet up and down for
several times to make sure the cells is mixed well.
18. Filter the cell mix through 100 uM filters into a new 15 mL tube. Spin down at
450 g * 5min, aspirate off the supernatants, put 10 mL Ham’s medium and put
them into 10 cm non-coated plate. (Fibroblasts will adhere to the plate and
myoblasts will remain in suspension).
19. After 45 min to 1 hour, transfer the medium into the coated plates. Pre-plate
procedure is critical to get rid of the fibroblast. And this procedure should be
repeated 3-4 times until the myoblasts are relatively clean. Extension of the preplating time does help but keep an eye on the plate in case myoblasts attach to
the plates.
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C1. 2 Cell Transfection (Neon System)



Preparation:
1. Make the desired amount of growth medium without antibiotics.
For MyhIIB and MyhI luciferase assay, 400 µL (4 replicates) of the growth
medium for each treatment is aliquoted into 1.5mL tubes.
2. Thaw the plasmids that are needed to be transfected.
3. Calculate the number of cells, amount of plasmids and resuspension buffer as
needed. Usually, 2-3 µg plasmids is enough for 2 × 105 cells in one 10 µL tip and
keep in mind that the volume of plasmids should not exceed 10 % of the total
volume.
For MyhIIB and MyhI luciferase assay, 3 µg of plasmids complex is transfected
into 2 × 105 cells and the transfected cells are plated into 4 wells of 96-well plate
(4 replates).



Plasmids Composition (For MyhIIB and MyhI luciferase assay)
Make sure that the concentration of each plasmid is around 2 µg / µL, so that the
volume of 3 µg of total plasmids does not exceed 10 % of the entire transfection
system (10 µL).
The plasmid compositions are indicated in Table A3.5



Cell Preparation and Transfection Procedures
1. Resuspend cells with DPBS and count the cells.
2. Put desired number of cells into 1.5 mL tubes and spin down at 450 g * 5 min.
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3. Resuspend the cells in resuspension buffer R and put the plasmids complex into
the cells.
For MyhIIB and MyhI luciferase assay, ~12 µL resuspension buffer R is added to
2 × 105 suspended cells in each tube and the calculated amount of plasmids
complex are then added into the cell system.
4. Take the cells, growth medium tubes, transfection tips, Neon Tube and
Electrolytic Buffer to Dr.Kuang’s lab.
For MyhIIB and MyhI luciferase assay, the prepared 400 µL medium (without
antibiotics) tubes will be needed to take along.
5. Turn on the Neon device and fill the Neon Tube with 3 mL Electrolytic Buffer.
6. Insert the Neon Tube into the Neon Pipette Station until you hear a click sound.
7. Press the push-button on the Neon Pipette to the first stop and immerse the Neon
Tip into the cell-DNA mixture. Slowly release the push-button on the pipette to
aspirate the cell-DNA mixture into the Neon Tip.
8. Insert the Neon Pipette with the sample vertically into the Neon Tube placed in
the Neon Pipette Station until you hear a click sound.
9. Select the appropriate electroporation protocol and press “Start” on the
touchscreen.
The transfection condition for primary myoblast is at 1500 V, 10 ms and 3 pulses.
For C2C12 cells is at 1650 V, 10 ms and 3 pulse.
10. The touchscreen displays “Complete” to indicate that electroporation is complete.
The tips can be reused for a couple of times if the cell-DNA mixture is the same.
Put the transfected cells in the medium without antibiotics.

172
For MyhIIB and MyhI luciferase assay, put the transfected cells into the prepared
400 µL medium.
11. After finishing all the transfecitons, take off the tip, turn off the Neon device and
clean the hood. Take everything back to the lab and spread the cells into
appropriate plates.
For MyhIIB and MyhI luciferase assay, spread the transfected cells into 96-well
plates with each well 100 µL cell-medium. Usually, 4 or 8 replicates (wells) for
each treatment are used.
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C1. 3 Luciferase Assay



Solutions
Luciferase buffer are made by mixing 1 vial of Dual-Glo luciferase buffer to 1 vial of
luciferase substrate (lyophilized). This reagent usually made when we get the product
and aliquot the mixing buffer into small tubes.
Stop & Glo reagent should be made just before use. Stop & Glo Substrate: Stop &
Glo buffer = 1:100.



Procedure
1. Calculate the luciferase buffer with substrate and Stop & Glow reagent needed in
the experiments (50 µL for each reagent in each well).
Equal amount of DPBS is used to mix the luciferase buffer, therefore the volume
of the mixed luciferase buffer added to each well is 100 µL (50 µL luciferase
buffer : 50 µL DPBS). Turn on the Tecan plate reader and computer in Lilly 3204 at least 20 mins in advance.
2. Thaw the luciferase buffer with substrate and Stop & Glo buffer (Put back the
left reagent into freezer).
3. Take the 96-well plate out of incubator and wash 1*PBS.
4. Put 100 µL mixed luciferase buffer into each well.
5. Gently shake for 2 mins and during this time, prepare the Stop & Glow buffer by
adding 1/50 amount of substrate to the calculated desired amount of Stop &
Glow buffer.
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6. Take the plate along with gloves, repeater and repeater tips to Lilly 3-204 to
measure luminescence in Tecan plate reader. (Software: Magellan; Program
name: Hui luciferase with 100ms measurement and 15ms shake time).
7. After measuring the firefly luciferase luminescence, add 50 uL Stop & Glow
Reagent into each well and measure the renilla luminescence (Program name:
Hui renilla with 100ms measurement, 15ms shake time and 600ms settlement
time).
8. Copy the data into excel file and save it in the flash drive.
Flush and discard the plate.
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C1. 4 Mouse Genotyping



Solutions
Base solution: A 50 X stock is prepared at 1.25 M NaOH, 10 mM EDTA, which
should be around pH=12. The concentration of 1 X working stock should be 25 mM
NaOH, 0.2 mM EDTA.
Neutralization solution: A 50 X stock is prepared at 2 M Tris-HCl, pH=5.0.The
concentration of 1 X working stock should be 40 mM Tris-HCl pH=5.0.



Procedure:
1. After weaning the mouse, put a small piece of ear into 1.5 mL tube.
2. Add 75 µL of base solution (1 X working stock) to each sample.
3. Place tubes at 95 Ԩ in the heating block (In Dr.Lossie’s lab, the heating block
should be powered on 30 mins in advance) for 30 mins.
4. Cool the tubes to room temperature.
5. Add 75 µL neutralization solution (1 X working stock) and vortex.
6. The sample is ready for PCR.
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C1. 5 Moue Genotyping PCR



Master Mix for Park7
5 X Green Flexi Buffer (Promega): 3 µL
MgCl2: 2 µL;
DMSO: 1 µL
F Primer (20 pmol / µL): 0.6 µL;
R Primer (20 pmol / µL): 0.6 µL
R Primer (20 pmol / µL): 0.6 µL
dNTPs (25 mM): 0.4 µL
Go Taq (Promega): 0.08 µL
H2O: 5.62 µL;
DNA: 1 µL



Program is on the White Eppendorf PCR machine: mmuDJ1
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C1. 6 ELISA

1. The amount of protein that can be absorbed by the plate needed to be titrated.
Both the primary and secondary antibody need to be titrated.
2.

Put the equal amount and volume of protein into 96-well Maxisorb plate.
In the present study, 100 µL of protein (20 µg/100 µL) are added into each well.

3. Incubate at 4 Ԩ with rotation for 5 hours.
4. Add 200 µL blocking buffer (3 % BSA) into each well and incubate at 4 Ԩ
overnight.
5. Wash briefly and add 150 µL primary antibody diluted in 0.1 % BSA in each well.
Incubate the plate at room temperature for 2 hours.
6. Wash with PBS / Tween for 3 times and add 150 µL secondary HRP diluted in
0.1 % BSA into each well. Incubate at room temperature for 45 mins.
7. Wash with PBS / Tween 3 times and wash with PBS 3 times.
8. Make OPD tablets. Put 1 gold tablet and 1 silver tablet into 20 mL H2O.
9. Put 200 µL OPD solutions into each well, wait for 30-45 mins and read it in
USDA plate reader.
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C1. 7 In situ ELISA



Solution

4 % formaldehyde in PBS; 0.5 % Triton 100 (Dilute 10 % Triton with H2O); 1 % BSA
solution (Dilute 3 % BSA with PBS); and 0.1 % BSA solution (Dilute 1 % BSA with
PBS)


Procedure:

The concentrations of primary and secondary antibody are needed to be titrated. In the
present study, 1/500 for MF20 and 1/500 for Donkey anti-Mouse 594 are used.
1. Aspirate growth medium from 96-well plate and gently wash with DPBS twice.
2. Put 100 µL of 4 % formaldehyde and incubate for 5 mins.
3. Wash 3 times with DPBS, put 0.5 % Triton100 and incubate for 5 min.
4. Wash 3 times with DPBS, add 150 µL blocking buffer (1 % BSA) and incubate
for 5 hours.
5. Wash briefly with DPBS and add 100 µL primary antibody diluted in 0.1 % BSA
and incubate at 4 Ԩ overnight with rotation.
6. Wash 5 times with DPBS and add secondary antibody diluted in 0.1 % BSA and
incubate at RT for 45 mins.
7.

Wash 5 times with DPBS and take the plate to LiLLY 3-204 (Tecan plate reader)
to measure the fluorescence.
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C1. 8 Protein Extraction



Preparation
RIPA buffer (Working Solution)
50 mM Tris HCl; 150 mM NaCl; 2 mM EDTA; 1 % Triton X 100; 0.5 %
Deoxycholate; 0.1 % SDS; 50 mM NaF, 1X Protease inhibitor and 1X Phosphatase
inhibitor.



Procedure
1. Remove culture medium and rinse the cells with ice-cold DPBS twice.
2. Add the RIPA buffer to the plate and incubate the plate on ice for 10 mins with
rotation.
3. Scrape cells from the plate and collect cell lysate into 1.5mL tubes.
4. Votex tubes and rotate the protein tubes in cold-box for 45 mins to 1 hour.
5. Centrifuge tubes at 12000 X g for 15 mins at 4 ℃.
6. Transfer supernatant to a new tube for further analysis.
7. The cell lysate can be frozen at this point for long-term storage at -80 ℃.
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